Oxamide IMPDH Inhibitors

Background of the Invention

The present invention relates to novel oxamide derivatives, a process for their manufacture, pharmaceutical preparations containing these derivatives, and the use of these derivatives as medicaments. In particular, the present invention relates to novel oxamide derivatives which are inhibitors of inosine monophosphate dehydrogenase (IMPDH).

Inosine monophosphate dehydrogenase (IMPDH) is an enzyme involved in the de novo synthesis of guanine nucleotides. The enzyme catalyses the NAD-dependent oxidation of inosine-5'-monophosphate (IMP) to xanthosine-5'-monophosphate which is the rate limiting step in the synthesis of guanine nucleotides. As a result of the key role of the enzyme in guanine nucleotide biosynthesis, the enzyme represents an important target for the development of inhibitors which would have utility as therapeutic agents in the treatment of IMPDH related processes.

The de novo synthesis of guanine nucleotides is particularly important in B- and T-lymphocytes to provide sufficient levels of nucleotides to support a proliferative response to mitogen or antigen [Wu, J.C., Persp. in Drug Discovery and Design., 2, 185-204, (1994)]. IMPDH inhibition is thus an attractive target for selectively inhibiting the immune system. Inhibitors of IMPDH are known [Pankiewicz, K.W., Exp. Opin. Ther. Patents., 9, 55-65, (1999)], and the uncompetitive inhibitor mycophenolic acid (MPA) has been demonstrated to inhibit the response of B-and T-cells to mitogen or antigen [Allison, A.C. and Eugui, E.M., Transplant. Proc., 25, 8-18, (1993)]. MPA has therefore been utilised as an immunosuppressant.

It is also recognised that IMPDH plays a role in other rapidly proliferating cells such as tumour cell lines, indicating that IMPDH inhibition is a target for anti-cancer chemotherapy [Nagai, M. et al., 51, 3886-3890, (1990)].

IMPDH inhibition has also been shown to play a role in viral replication in some cell lines which support virus replication [Pankiewicz, K.W., Exp. Opin. Ther. Patents., 9, 55-65, (1999)]. Ribavirin, for example, is a broad spectrum antiviral agent which has been approved by the U.S. Food and Drug Administration for use as an aerosol for infants with serious

30

10

15

20

25

respiratory infections due to respiratory syncytial virus and is also in use as an agent for the treatment of patients infected with Hepatitis C virus when used in combination with interferon [Patterson, J.L. and Fernandez-Larsson, R., Rev. Infect. Dis., 12, 1139-1146, (1990); McHutchison, J.G. et al., New. Engl. J.Med., 339, 1549-1550, (1998)]. Ribavirin is converted in cells to ribavirin 5' monophosphate which is an inhibitor of IMPDH.

Additionally, the IMPDH inhibitors ribavirin and MPA have been shown to inhibit the replication of yellow fever virus (a RNA virus) whilst MPA has been demonstrated to inhibit Hepatitis B virus replication (a DNA virus) in vitro supporting the broad range antiviral activity of these inhibitors [Neyts, J. et al., Antiviral Res., 30, 125-132, (1996); Gong, Z.J. et al., J. Viral Hepatitis., 6, 229-236, (1999)]. Furthermore, MPA has also been shown to potentiate the antiviral effects of nucleoside analogues both in vitro and in animal models [Neyts, J. and De Clercq, E., Inter. Antiviral News., 7, 134-136, (1999)]. Together these observations indicate that IMPDH inhibitors have utility as broad spectrum antiviral agents.

IMPDH inhibitors would therefore have therapeutic potential as immunosuppressants, anticancer agents and anti-viral agents. Specifically, such compounds may be used in the treatment of transplant rejection, the treatment of cancer and as antiviral agents in the treatment of viral diseases such as retroviral infections and hepatitis C virus infections (either alone or in combination with other antiviral agents such as interferon or derivatives thereof, such as conjugates with polyethylene glycol).

Summary of the Invention

10

15

25

The novel oxamide derivatives provided by the present invention are compounds of the general formula (I):

wherein

15

20

25

30

- 5 R¹ represents heterocyclyl;
 - R² represents hydrogen, unsubstituted lower alkyl, lower alkoxy, halo, hydroxy or cyano;
 - R³ represents hydrogen, unsubstituted lower alkyl, lower alkoxy, halo, or cyano;
 - R⁴ represents hydrogen, or unsubstituted lower alkyl;
- 10 R⁵ represents hydrogen, unsubstituted lower alkyl, lower alkoxy, halo, or cyano;
 - R⁶ represents hydrogen, unsubstituted lower alkyl, lower alkoxy, halo, or cyano;
 - R⁷ represents hydrogen, or unsubstituted lower alkyl;
 - R^8 represents hydrogen, lower alkyl, lower cycloalkyl, aryl, or heterocyclyl; or R^4 and R^8 together with the nitrogen atom to which they are attached represent heterocyclyl;

and pharmaceutically acceptable salts thereof.

The oxamide derivatives provided by the present invention are inhibitors of the enzyme inosine monophosphate dehydrogenase (IMPDH). They can be used as medicaments, especially for treating immune mediated conditions or diseases, viral diseases, bacterial diseases, parasitic diseases, inflammation, inflammatory diseases, hyperproliferative vascular diseases, tumours, and cancer. They can be used alone, or in combination with other therapeutically active agents, for example, an immunosuppressant, a chemotherapeutic agent, an anti-viral agent, an anti-barasitic agent, an anti-inflammatory agent, an anti-fungal agent and/or an anti-vascular hyperproliferation agent.

In particular, compounds of the present invention and compositions containing the same are useful as chemotherapeutic agents, inhibitors of viral replication and modulators of the immune system, and can be used for the treatment of viral diseases such as retroviral infections and hepatitis C virus infections (either alone or in combination with other antiviral agents such as interferon or derivatives thereof, such as conjugates with polyethylene glycol), inflammatory diseases such as osteoarthritis, acute pancreatitis, chronic pancreatitis, asthma, and adult respiratory distress syndrome, hyperproliferative vascular diseases such as restenosis,

stenosis and artherosclerosis, cancer, for example lymphoma and leukaemia, and as immunosupressants in the treatment of autoimmune diseases, graft versus host diseases and transplant rejection

5 Compounds of the present invention which have antiviral effects and/or immuno-supressive properties are particularly useful for treating HCV infection.

Detailed Description of the Invention

If not otherwise specified, an unmodified term includes both substituted and unsubstited forms if that term has been defined as substituted or unsubstituted. For example" lower alkyl" includes substituted and unsubstituted lower alkyl. Similarly, "optionally substituted" includes substituted or unsubstituted. The term "saturated" applied to ring structures includes fully and partially saturated rings.

- As used herein, the term "lower alkyl", means a straight-chain or branched-chain alkyl group containing up to 10 carbon atoms, preferably from 1 to 8 carbon atoms, more preferably from 1 to 6 carbon atoms, e.g.methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.butyl, tert-butyl, n-pentyl, n-hexyl and 1,1-dimethylethyl; and which is unsubstituted or substituted by e.g. one or more of cyano, halo, carboxyl, hydroxyl, lower alkoxy, lower cyclo alkoxy, aryloxy,
- heterocyclyloxy, heterocyclyl -(lower alkoxy)-aryl-amino-oxalyl-oxy, lower alkoxy-carbonyl, aryl, aryl-carbonyl-amino-aryl, lower alkyl-carbonyl-amino-aryl, heterocyclyl, lower alkyl-heterocyclyl,

lower cycloalkyl, lower alkenyl, lower alkynyl,

- amino, mono- or di-(lower alkyl) amino, lower cycloalkyl amino, aryl amino, heterocyclylamino, lower alkyl-aryl-lower alkyl-amino, lower alkoxy-carbonyl-amino, lower alkenylcarbonyl-amino, lower alkyl-carbonyl-amino, di-(aryl)-lower alkyl-carbonyl-amino, lower
 alkyl-sulphonyl-lower alkyl-carbonyl-amino, lower cycloalkyl-lower alkyl-carbonyl-amino,
 heterocyclyl-lower alkyl-carbonyl-amino, lower alkoxy-lower alkyl-carbonyl-amino, di-aryllower alkyl-carbonyl-amino, aryl-carbonyl-amino, lower alkyl-aryl-carbonyl-amino, tri-(lower
- alkyl)-aryl-carbonyl-amino, aryl-carbonyl-amino, lower alkyl-aryl-carbonyl-amino, di-(lower alkyl)-aryl-carbonyl-amino, mono- or di-(lower alkoxy)-aryl-carbonyl-amino, di-(lower alkyl)-amino-aryl-carbonyl-amino, lower alkyl-carbonyl-amino-aryl-carbonyl-amino, heterocyclyl-aryl-carbonyl-amino, lower cycloalkyl-carbonyl-amino, mono- or tetra-(lower

alkyl)-lower cycloalkyl-carbonyl-amino, heterocyclyl-carbonyl-amino, mono- or di-(lower alkyl)-heterocyclyl-carbonyl-amino, tri-(lower alkyl)-aryl-oxalyl-amino, lower alkyl-carbamoyl, or aryl-carbamoyl,

thio, lower alkyl thio, lower cycloalkyl thio, aryl thio, heterocyclyl thio, lower alkyl sulphonyl, lower cycloalkyl sulphonyl, aryl sulphonyl, heterocyclyl sulphonyl.

Where there is more than one substituent, each substituent may be the same or different, for example tri-fluoromethyl, triphenylmethyl, 1-[1-methyl-1-[methylformyl]-2-phenyl] ethyl, or 2-[1-hydroxyl-3-cyclohexyl].

The term "unsubstituted lower alkyl" means an alkyl group as defined above where no substituents are present.

The term "lower alkenyl" means an alkenyl group containing from 2 to 7 carbon atoms, e.g. allyl, vinyl and butenyl.

The term "lower alkynyl" means an alkynyl group containing from 2 to 7 carbon atoms, e.g. propargyl or butynyl.

The term "lower cycloalkyl", alone or in combination as in "lower cycloalkyl-lower alkyl", means a cycloalkyl group containing 3 to 10 carbon atoms, preferably 3 to 7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and adamantyl, and which may be unsubstituted or substituted by e.g. one or more of lower alkyl, carboxyl, hydroxyl or aryl or optionally be benz-fused e.g. to aryl. Where there is more than one substituent, each substituent may be the same or different. Cyclopropylmethyl, 2-cyclobutyl-ethyl and 3-cyclohexyl-propyl are examples of lower cycloalkyl-lower alkyl groups.

The term "halo" denotes fluorine, chlorine, bromine or iodine.

15

20

25

The term "lower alkoxy" denotes an unsubstituted or substituted lower alkyl group as defined hereinbefore, which is bonded via an oxygen atom, e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert.-butoxy and the like. Suitable substituents are those applicable for "lower alkyl".

The term "aryl", alone or in combination as in "aryl-lower alkyl", means phenyl or naphthyl, optionally benz-fused, for example benz-fused to a lower cycloalkyl ring. "Aryl" denotes unsubstituted or substituted by e.g. one or more of halo, cyano, carboxyl,

- lower alkyl-thio, nitro,
 oxo, hydroxyl, lower alkoxy, lower cycloalkyloxy, aryloxy, heterocyclyl oxy
 lower alkyl-heterocyclyl, heterocyclyl,
 lower alkoxy-carbonyl, lower alkyl-carbonyl, heterocyclyl-carbonyl, lower alkyl-heterocyclyl-carbonyl,
- sulphamoyl, lower alkyl- sulphamoyl,
 thio, lower alkyl thio, lower cycloalkyl thio, aryl thio, heterocyclyl thio,
 lower alkyl-sulphonyl, lower cycloalkyl sulphonyl, aryl sulphonyl, heterocyclyl-sulphonyl,
 amino, mono- or di-(lower alkyl) amino, lower alkyl-sulphonyl-amino, di-(lower alkyl)heterocyclyl-amino, lower alkyl-carbonyl-amino, (lower alkyl-carbonyl)(lower alkyl)-amino,
 lower alkoxy-carbonyl-amino, aryl-carbonyl-amino,
 - mono- or di-(lower alkyl)-carbamoyl, aryl-carbamoyl, lower alkyl, aryl-lower alkyl, amino-lower alkyl, heterocyclyl-lower alkyl, lower alkoxy-carbonyl-lower alkyl, lower alkyl-sulphamoyl-lower alkyl, aryl-sulphonyl-amino-lower alkyl, lower alkyl, lower alkyl, lower alkyl, aryl-sulphonyl-amino-lower alkyl, lower alkyl, lowe
- heterocyclyl-oxy-carbonyl-amino-lower alkyl, aryloxy-carbonyl-amino-lower alkyl, lower alkyl-carbonyl-amino-lower alkyl, lower alkyl-carbonyl-lower alkyl, lower alkyl-aryl-carbonyl-amino-lower alkyl, aryl-carbamoyl-lower alkyl, lower cycloalkyl-carbonyl-amino-lower alkyl, heterocyclyl-carbonyl-amino-lower alkyl, or aryl-carbonyl-amino-lower alkyl. Where there is more than one substituent, each substituent may be the same or different, for example 1-(3-methoxy-4-oxazolyl)phenyl, 1-(3-chloro-4-methoxy)phenyl, 1-(3-chloro-4-methyl) phenyl and 1-(3-fluoro-4-methyl)phenyl.

The same substituents as listed above apply for all terms containing the phrase "phenyl" i.e. substituted or unsubstituted) phenyl.

The term "aryloxy" denotes an aryl group as defined hereinbefore, which is bonded via an oxygen atom, e.g. phenoxy, and the like.

As used herein, the term "heterocyclyl", alone or in combination as in "heterocyclyl-lower alkyl", means a saturated, unsaturated or partially saturated monocyclic or bicyclic ring system which contains one or more hetero atoms selected from nitrogen, sulphur and oxygen; and which is attached to the rest of the molecule via a carbon atom (C-linked), or a nitrogen atom (N-linked) in the ring system, and which is unsubstituted or substituted in the same manner as the aryl group defined hereinbefore and/or by oxido. Where there is more than one substituent, each substituent may be the same or different.

Examples of heterocyclyl groups are oxazolyl, isoxazolyl, furyl, tetrahydrofuryl, 1,3-dioxolanyl, dihydropyranyl, thienyl, pyrazinyl, isothiazolyl, isoquinolinyl, indolyl, indazolyl, quinolinyl, dihydrooxazolyl, pyrimidinyl, benzofuranyl, tetrazolyl, pyrrolidinonyl, (N-oxide)-pyridinyl, pyrrolyl, triazolyl e.g. 1,2,4-triazolyl, pyrazolyl, benzotriazolyl, piperidinyl, morpholinyl, thiazolyl, pyridinyl, dihydrothiazolyl, imidazolidinyl, pyrazolinyl, benzothienyl, piperazinyl, imidazolyl, thiadiazolyl e.g. 1,2,3-thiadiazolyl, and benzothiazolyl.

15

20

25

30

10

Any functional (i.e. reactive) group present in a side-chain may be protected, with the protecting group being a group which is known per se, for example, as described in "Protective Groups in Organic Synthesis", 2nd Ed., T.W. Greene and P.G.M. Wuts, John Wiley & Sons, New York, NY, 1991. For example, an amino group can be protected by a tert-butoxycarbonyl, formyl, trityl, benzyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (Fmoc), trifluoroacetyl, 2-(biphenylyl)isopropoxy-carbonyl or isobornyloxycarbonyl group or in the form of a phthalimido group; or a hydroxyl group can be protected by a tert-butyldimethylsilyl, tetrahydropyranyl, 4-methoxybenzyl, or benzyl; or a carboxyl group can be protected in the form of an ester, for example as a methyl or tert.butyl ester. The protecting group may be retained in the final compound or optionally removed by techniques known in the art.

The compounds of this invention may contain one or more asymmetric carbon atoms and may therefore occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Furthermore, where a compound of the invention contains an olefinic double bond, this can have the (E) or (Z) configuration. Also, each chiral centre may be of the R or S configuration. All such isomeric forms of these compounds are embraced by the present invention.

Examples of compounds of formula (I) are shown below in Table 1a and 1b:

Table 1a

Table 1a			
1			
		N T T N ON	
	F		
	F. O S. O		
HO CH,	OH, Chra		
	H.C. N.		
H.C. TH. O. OH,		Ho Ho	
	N O O O O O O O O O O O O O O O O O O O		
	HC N N N N N N N N N N N N N N N N N N N	N CH.	
	CH,		
FF F	or or or or	dr' h''c or' or'	

24 (H.C. OH,) H.C. OH,	n ha	NO COH. NO COH	
H	M	OH,	
	N OH,	No. 1	
N 3 OF F			
H. TH. N. TH.	H,C N P P P P P P P P P P P P P P P P P P	The second secon	
HI N O N O N	HC NO HC OH		
C 34, 104, 104, 104, 104, 104, 104, 104, 10	NA OFF		
	H _C C T T T N N	N O O O	

	0 0-N 0 N N	
	0 N S	C
Xoin Orgin	0 N	
		N O N O
		N P N N N N N N N N N N N N N N N N N N
N		O. N.
		0 N N N N N N N N N N N N N N N N N N N
		0
S-11 N N N N N N N N N N N N N N N N N N		

	į N	
	N N N N N N N N N N N N N N N N N N N	
N N N N N N N N N N N N N N N N N N N	O N CI	O N N N N N N N N N N N N N N N N N N N
	N-	
	N-11	
+ 1 N N N N N N N N N N N N N N N N N N	O N N CI	
	0 × 0 × 0 × 0 × 0 × 0 × 0 × 0 × 0 × 0 ×	
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		
	P F F	

	N Ö	0 N S
N O O O		
, o o o	O N N N N N N N N N N N N N N N N N N N	0
	2 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	

C N N		
0 N O N O N O N O N O N O N O N O N O N	0,, N N N N N N N N N N N N N N N N N	0 N
o		
0 . N - N O		
0, , , , , , , , , , , , , , , , , , ,	o y y y y	0
N - N - N		
		0 N N N N N N N N N N N N N N N N N N N
0 S N N N N N N N N N N N N N N N N N N		

0 N - N - N		
N O N O N O N O N O N O N O N O N O N O		0
0		
O N F F	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
0 N 1		
N C N N N N N N N N N N N N N N N N N N		
	P F F F F	0
		c
		O N O N O N O N O N O N O N O N O N O N

0 N N N N N N N N N N N N N N N N N N N	0 N N N N N N N N N N N N N N N N N N N	
0 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	of July of Lu o	
0 N T N O		
N-1 0 5 N		
0		
0 N N N N N N N N N N N N N N N N N N N	I IN	
		N- O O
0	N	
		G . N . N . N . N . N . N . N . N . N .
N S N		0

0 N 0 N		.O.,
	OT NOT NOT NOT NOT NOT NOT NOT NOT NOT N	
		O N O O
N N N N N N N N N N N N N N N N N N N		
0 N N N N N N N N N N N N N N N N N N N		

0 N		
0	O	0/7
0	N N N N N N N N N N N N N N N N N N N	CI CI
0, 1, 0		
0 1 N 1 N 1 N 1 N 1 N 1 N 1 N 1 N 1 N 1		
O N N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N N	
0 N. 7 N. 7 . 0		0
		0
N N N N N N N N N N N N N N N N N N N		
0 N	0 N	
N N N N N N N N N N N N N N N N N N N	0 N N N N	

Compounds of formula (I), and formula (IX) below where R² is methoxy, R⁴, R⁷, and R⁸ are as in formula (I) or formula (IX), and R³, R⁵, R⁶, R⁹, and R¹⁰ are hydrogen are shown in table 1b below.

table 1b

Name	Structure	MS(ES) $(M+H)^+$	Ex No
Benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]a mino]-2-methylpropyl}-1-piperidinecarboxylate		535	421
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2- (phenylthio)ethyl]oxalamide	6 0 0 M	426	422
N-[2-(1-Acetyl-4-piperidinyl)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide	Section 1997 And 1997	443	423
N-(2-Cyclohexyl-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	400	424

N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(N-methylanilino)ethyl]oxalamide	0 0/CH3	423	425
N-[2-(1,2,3,4-Tetrahydro-1-quinolyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		449	426
N-[2-(4-Hydroxyphenylthio)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide		442	427
N-[3-(4-Hydroxyphenyl)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	он, он он, он	424	598
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[(1-oxido-4-pyridyl)carboxamido] ethyl]oxalamide		454	599
N-[2-(4-Acetylbenzamido)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	CM OHICH H	479.1	600
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-[(4-methylbenzamido)methyl]pheny l]oxalamide		485.1	601
N-[3-[(2-Methoxybenzamido) methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	CALL OF THE STATE	501.1	602
N-[3-[(4-Chlorobenzmido) methyl]phenyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	Col	505.1	603
N-[3-[[(1,3-Benzodioxol-5-yl)carboxamido]methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		515.2	604
N-[2-(2,3-Dihydro-1-indolyl)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide	o. N. T. N.	435	605

N-[2-(3,4-Dihydro-6-methyl- 2H-quinol-1-yl)-1,1- dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	01, 0 H,C 01, 0	463	606
N-[1-(3-Benzofuranyl)-1- methylethyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	N HC CH	420	607
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- phenoxypiperidino)propyl]oxala mide	N	507	608
N-[2-(1-Butyryl-4-piperidinyl)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide	8-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	471	609
N-[2-[1-(Methanesulfonyl)-4- piperidinyl]-1,1-dimethylethyl]- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide	1	479	610
N-[2-[1-(Benzenesulfonyl)-4- piperidinyl]-1,1-dimethylethyl]- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide		541	611
N-[2-(1-Isobutyryl-4- piperidinyl)-1,1-dimethylethyl]- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide	64 No. 100 No.	471	612
tert-Butyl 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino] oxalyl] amino]-3-methylbutyl]-1-piperidinecarboxylate	01, 11, 11, 11, 11, 11, 11, 11, 11, 11,	515	613
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- piperidinyl)propyl]oxalamide	CH, C OH ₃	415	614

Preferred compounds of formula (I) and any of the compounds of formula (I) described below are those where at least one of R^2 , R^3 , R^5 and R^6 is not hydrogen especially where R^2 represents lower alkoxy, preferably methoxy.

In preferred compounds of formula (I) and any of the compounds of formula (I) described below, R¹ represents a five-membered heterocycle with one to three heteroatoms selected from nitrogen, oxygen, and sulfur. Furthermore, preferred compounds of formula (I) are those where R¹ represents an unsubstituted or substituted oxazole ring or triazole ring. When substituted, the preferred substituents are methyl, ethyl, or benzyl.

Also preferred are compounds of formula (I) and any of the compounds of formula (I) described below as follows: where R^4 represents hydrogen or branched lower alkyl, and where R^3 , R^6 , and R^7 represent hydrogen. Most preferably, R^1 represents oxazolyl (especially unsubstituted), R^2 represents lower alkoxy (especially methoxy) and R^3 , R^4 , R^6 and R^7 represent hydrogen.

Also preferred are compounds of formula (I) and any of the compounds of formula (I) described below where R⁸ represents branched lower alkyl, aryl, a 3 to 7 membered cycloalkyl ring, or a 5 or 6 membered monocyclic or 9 or 10 membered bicyclic saturated or unsaturated heterocyclic ring with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur. These compounds may be substituted or unsubstituted as defined above. It is additionally preferred for these compounds that R¹ represents oxazolyl (especially unsubstituted), R² represents lower alkoxy (especially methoxy) and R³, R⁴, R⁶ and R⁷ represent hydrogen.

In formula (I) and any of the compounds of formula (I) described below, R⁸ may be branched lower alkyl, aryl, and/or cycloalkyl,and/ or a heterocyclic ring as defined immediately above.

In particular, preferred compounds of formula (I) are those of the general formula:

$$R^{10}$$
 R^{9}
 R^{2}
 R^{3}
 R^{6}
 R^{5}
 R^{7}
 R^{7}
 R^{7}
 R^{8}
 R^{10}
 R

wherein

10

15

20

25

 R^2 to R^8 are defined as above; and,

 R° is hydrogen, lower alkyl, aryl-lower alkyl; R^{10} is hydrogen.

In some compounds of formula (IX), R⁹ represents methyl, ethyl, or benzyl, and R¹⁰ preferably is hydrogen. In others, R⁹ and R¹⁰ both represent hydrogen. It is preferred that R⁸ represents branched lower alkyl, aryl, a 3 to 7 membered cycloalkyl ring, or a 5 or 6 membered monocyclic or 9 or 10 membered bicyclic saturated or unsaturated heterocyclic ring with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur, and in addition is preferred that R² represent lower alkoxy, R³, R⁴, R⁶, and R⁷ represent hydrogen.

10

More particularly, preferred compounds of formula (I) are those of the general formula (IX), wherein R^2 is methoxy or chloro; R^3 , R^4 , R^5 , R^6 , R^7 , R^9 , and R^{10} are hydrogen, and R^8 is heterocyclyl, aryl, or branched chain lower alkyl;

15 Examples of such compounds are:

	tert-Butyl[3-[[[3-methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]benzyl]carbamate
H.S. N. J. N. OH.S. N	N-tert-Butyl-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide
Chwal	[3-[[[3-Methoxy-4-(5-oxazolyl)anilino] oxalyl]amino]benzyl]carbamic acid tetrahydro-3(S)-furyl ester
	N-[3-(Benzamidomethyl)phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide
	Isopropyl [3-[[[3-methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]benzyl]carbamate
CH, CH, CH,	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- (1-methyl-1-phenylethyl)oxalamide
H,C 1, C 1	N-(1,1-Dimethylpropyl)-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide

	137 (23 (13))
HCHCCH I	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- (1,1,3,3-tetramethyl-butyl)oxalamide
N N N OH	N-(1,1-Dimethylpropargyl)-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide
	N-(2-Hydroxy-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide
	N-(1,1-Dimethyl-2-phenylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide
	Phenyl [3-[[4-(5-oxazolyl)anilino] oxalyl]amino]benzyl]carbamate
	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [3-[(phenylcarbamoyl)methyl] phenyl]oxalamide
ЭН, ОН, СОН, ОСН, ОСН, ОСН, ОСН, ОСН, ОСН	tert-Butyl [2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]carbamate
HO F	N-(2-Amino-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate (1:1)
	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-(4-nitrophenyl) ethyl]oxalamide
The state of the s	N-[3-(Aminomethyl)phenyl]-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide trifluoroacetate (1:1)
	Methyl [3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate
N ON N	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- (3-pyridyl)oxalamide
	N-[3- [(Benzenesulfonamido)methyl]phenyl]- N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide

CIH CH3 OH3	N-(2-Dimethylamino-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide hydrochloride (1:1)
H ₂ C N N CH ₃	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1-methyl-1- (methylcarbamoyl)ethyl]oxalamide
H,C CH CI	N-tert-Butyl-N'-[3-chloro-4-(5-oxazolyl)phenyl]oxalamide
H ₃ C CH ₃ O	N-tert-Butyl-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide

or their pharmaceutically acceptable salts.

In particular, preferred compounds of formula (I) and (IX) are also those of the general formulas:

$$R^{10}$$
 R^{9}
 R^{2}
 R^{10}
 R^{10}

$$R^{10}$$
 R^{9}
 R^{2}
 R^{10}
 R^{10}

wherein R², R³, R⁵, R⁶, R⁷, R⁹ and R¹⁰ are defined as above

 R^{11} and R^{13} is H or lower alkyl, m=1 to 5 and

5

10

 R^{12} is heterocyclyl, or aryl (substituted or unsubstited) other than 4-fluorophenyl.

Particularly preferred compounds of formula (XIa or XIb) are those wherein

R² is methoxy, R³, R⁵, R⁶, R⁹, R¹⁰,R¹¹ and R¹³ are hydrogen and wherein R¹² is (unsubstituted or substituted) phenyl other than 4-fluorophenyl and (unsubstituted or substituted heteroaryl). Also preferred are those compounds where R¹² represents a 5 or 6 membered monocyclic or a 9 or 10 membered bicyclic saturated or unsaturated heteroaromatic ring with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur.

Examples of such compounds are listed in table 1c

table 1c

	table ic	·	
Name	Structure	MS(ES) $(M+H)^+$	Ex No
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-methylphenyl)ethyl]oxalamide	N 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	408	302
N-[1,1-Dimethyl-2-(2- methylphenyl)ethyl]-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide	N (C) (C) (F) (F) (F) (F) (F) (F) (F) (F) (F) (408	303
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(3-pyridyl)ethyl]oxalamide	N A CHA	395	304
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(3-methylphenyl)ethyl]oxalamide	N CO CH CHS	408	305
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(2-thienyl)ethyl]oxalamide	N 1	400	306
N-[2-(4-Benzyloxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	N	500	307
N-[2-(4-Hydroxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	N 1 2 N 2 N 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	410	308
N-(3-Methoxy-4-oxazol-5-yl-phenyl)-N'-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethyl]-oxalamide	N. S.	424	309

N-[2-(2-Hydroxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	N O OH	410	310
N-(1,1-Dimethyl-2-phenyl- propyl)-N'-(3-methoxy-4-oxazol- 5-yl-phenyl)-oxalamide	OH OH OH OH OH	408	311
N-[2-(3-Hydroxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	N 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	410	312
N-(3-Methoxy-4-oxazol-5-yl-phenyl)-N'-[2-(3-methoxy-phenyl)-1,1-dimethyl-ethyl]-oxalamide		424	313
N-[2-[4-(Cyanomethoxy)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	N	449	314
2-[4-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetic acid	N	468	315
2-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetic acid		468	438
2-[3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetic acid		468	439
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-oxido-4-pyridyl)ethyl]oxalamide	N N	411	440
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-oxido-3-pyridyl)ethyl]oxalamide	O G GE NO	411	441
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-oxido-2-pyridyl)ethyl]oxalamide	N 2 O	411	442
2-[3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl)]amino]-2-methylpropyl]phenoxy]acetic acid	N ONE ON	468	443
L		· · · · · · · · · · · · · · · · · · ·	

N-[2-(2-Benzofuranyl)-1,1- dimethylethyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	04,0 CH.	434	444
N-[3-Methoxy-4-(5- oxazolyl)phenyl]-N'-[1,1-dimethyl- 2-(3-methyl-2- benzofuranyl)ethyl]oxalamide	one in	448	445
N-[2-(7-Methoxy-2-benzofuranyl)- 1,1-dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	N 24,0 -	464	446
N-[2-(5-Methoxy-2-benzofuranyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	No. 1	464	447
N-[2-(6-Methoxy-2-benzofuranyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	HE CH	464	448
Benzyl 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoate	N. S.	528	449
4-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoic acid	N Jacobs	438	450
Benzyl 3-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoate	Survey of the su	528	451
3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoic acid	M. THE OH	438	452
N-[2-(3-Benzofuranyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N N N N N N N N N N N N N N N N N N N	434	453
Benzyl 2-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylate	M. Line On C.	568	454
2-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylic acid	No. 18 Sept Only 10 Sept Only 1	477.9	455

N-[3-Methoxy-4-(5- oxazolylphenyl]-N'-[1-[(4- pyridyl)methyl]-1- cyclopentyl]oxalamide	N	421	456
N-[3-Methoxy-4-(5- oxazolyl)phenyl]-N'-[1-[(1-oxido- 4-pyridyl)methyl]-1- cyclopentyl]oxalamide	N O SCH	437	457
N-[2-(4-Methoxy-2-benzofuranyl)- 1,1-dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	March and a service and a serv	464	458
N'-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[2-(2,6-dimethyl-4- pyridyl)-1,1-dimethylethyl] oxalamide	он, с с ч	423.22	653
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(2,6-dimethyl-1-oxido-4-pyridyl)ethyl]oxalamide	N N N N N N N N N N N N N N N N N N N	439.3	654
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(4-pyridyl)methyl]- 1-cyclopropyl]oxalamide		393	655
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(1-oxido-4- pyridyl)methyl]-1- cyclopropyl]oxalamide		409	656
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(4-pyridyl)methyl]- 1-cyclobutyl]oxalamide		407	657
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(1-oxido-4- pyridyl)methyl]-1-cyclobutyl] oxalamide		421	658
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(4-pyridyl)methyl]- 1-cyclohexyl]oxalamide		435	659
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(1-oxido-4- pyridyl)methyl]-1- cyclohexyl]oxalamide		451	660

N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(2- methyl-4-pyridyl)ethyl]oxalamide		409	661
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(2- methyl-1-oxido-4- pyridyl)ethyl]oxalamide		425	662
2-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzothiophenecarboxylic acid	N N N S OH	494	663

Particularly preferred compounds of formula (I) and (IX) are also those of the general formula

$$R^{10}$$
 R^{9}
 R^{2}
 R^{14}
 R^{15}
 R^{18}
 R^{18}
 R^{16}
 R^{16}
 R^{10}
 $R^{$

wherein R^2 , R^3 , R^5 , R^6 , R^7 , R^9 and R^{10} are defined as above, R^{11} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} and R^{18} are H or lower alkyl and R^{19} is alkyl, cycloalkylalkyl, heterocyclyl alkyl or aryl alkyl.

Particularly preferred compounds of formula (XII) are those wherein R² is methoxy and R³, R⁵, R⁶, R⁹, R¹⁰,R¹¹ and R¹³ are hydrogen. Also preferred are compounds wherein R¹⁹ represents arylalkyl, branched lower alkyl, a 3 to 7 membered cycloalkyl alkyl, or a 5 or 6 membered monocyclic or 9 or 10 membered bicyclic saturated or unsaturated heterocyclyl alkyl with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur.

Examples of such compounds are listed in table 1d below

Name	Structure	MS(ES) (M+H)'	Ex No
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(2- pyridinyl)methylamino]phenyl]ethyl]oxala	CH O HIC ON ()	500.1	316
mide	N-		

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(3- pyridyl)methylamino]phenyl]ethyl]oxalam ide	CH, CH , ~ , N , S / N	500.1	317
N-[2-[4-(2-Furfurylamino)phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	0m	489.1	318
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-Dimethyl-2-[4-(2-thenylamino)phenyl]ethyl]oxalamide	\$100 mm m	505.1	319
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-(2,2-dimethylpropylamino)phenyl]ethyl]oxalam ide	18 24 34 34 34 34 34 34 34 34 34 34 34 34 34	479.2	320
N-[2-[4-[(1H-Imidazol-2-yl)methylamino]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	On the second se	489.1	321
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(4- pyridyl)methylamino]phenyl]ethyl]oxalam ide	0	500.1	322
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(2- thiazolyl)methylamino]phenyl]ethyl]oxala mide	ON THE STATE OF TH	506.1	323
N-[2-[4-(3-Furfurylamino)phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		489.1	324
N-[2-[4-[5-(Hydroxymethyl)-2-furfurylamino]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		519.1	325
N-[2-(4-Benzylaminophenyl)-1,1- dimethylethyl]-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	0. The case of the	499.1	326
N-[2-[4-(2-Hydroxybenzylamino)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	CHILD TO THE CONTROL OF THE CONTROL	515.1	327
N-[2-[4-(3-Cyanobenzylamino)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		524.1	328

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[4-(3- pyridyl)benzylamino]phenyl]ethyl]oxalami de		576.2	329
N-[2-[4-(2-Fluorobenzylamino)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	SHIP OR SHIP	517.1	33()

Particularly preferred compounds of formula (I) and (IX) are also those of general formula

$$R^{10}$$
 R^{10}
 R

wherein R², R³, R⁵, R⁶, R⁷, R⁹ and R¹⁰ are defined as above, R¹¹, R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷ and R¹⁸ are H or lower alkyl and R²⁰ is alkyl, cycloalkyl, aryl, heterocyclyl.

Particularly preferred compounds of formula (XIII) are those wherein R^2 is methoxy and R^3 , R^5 , R^6 , R^9 , R^{10} , R^{11} and R^{13} are hydrogen. Also preferred are compounds where R^{20} represents aryl, branched lower alkyl, a 3 to 7 membered cycloalkyl ring, or a 5 or 6 membered or 9 or 10 membered bicyclic saturated or unsaturated heterocyclic ring with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur.

Examples of such compounds are listed in table 1e below

10

Table 1e

Name	Structure	MS(ES) (M+H) †	Ex No
N-[2-[4- (Cyclopropylcarboxamido)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	сн 9 нс он, 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	477.1	331
N-[2-[4-(Cyclobutylcarboxamido) phenyl]-1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl oxalamide	CH OHC OH	491.1	332
N-{3-Methoxy-4-(5-oxazolyl)phenyl} -N'-[1,1-dimethyl-2-(4- pivalamidophenyl)-1,1- dimethylethyl]oxalamide	CH OHGOH	493.1	333

			,
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	N .		
-N'-[1,1-dimethyl-2-[4-[(1H-pyrrol-	CH, CH, CH.	502.1	334
2-yl)carboxamido]phenyl]ethyl]	July No. of the state of the st		
oxalamide	N ·		
N-[2-[4-[(2-Furyl)			
carboxamido]phenyl]-1,1-	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	503.1	335
dimethylethyl]-N'-[3-methoxy-4-(5-	1 · N · N	505.1	1 2/2/2/
	N.		
oxazolyl)phenyl]oxalamide			
N-[2-[4-[(3-Furyl)	N. A.	500.1	225
carboxamido]phenyl]-1,1-		503.1	336
dimethylethyl]-N'-[3-methoxy-4-(5-	.0		
oxazolyl)phenyl]oxalamide	À-		
N-[2-[4-[(1H-Imidazol-4-yl)	N == N		,
carboxamido]phenyl]-1,1-		503.1	337
dimethylethyl]-N'-[3-methoxy-4-(5-	,o.,		İ
oxazolyl)phenyl]oxalamide	N-		1
N-[2-[4-[(Tetrahydro-2(RS)-furyl)	0		
carboxamido]phenyl]-1,1-	on the state of th	507.2	338
dimethylethyl]-N'-[3-methoxy-4-(5-	, , N	207.2	336
	0 · . ·		
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)	, N.		220
phenyl]-N'-[1,1-dimethyl-2-[4-[(2-	HC N > N	514.1	339
pyridyl)carboxamido]phenyl]ethyl]ox	0		
alamide	Ň		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	<i>*</i> >.		
-N'-[1,1-dimethyl-2-[4-[(4-pyridyl)	" - "" - "" - "" - "" - "" - "" - "" -	514.1	340
carboxamido]phenyl]ethyl]oxalamide	0.		İ
	N		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	0 N N N N N N N N N N N N N N N N N N N		
-N'-[1,1-dimethyl-2-[4-[(2-thienyl)	N. H. H.	519.1	341
carboxamido]phenyl]ethyl]oxalamide	0.1		
	\		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	~ M ~ ?		
-N-[1,1-dimethyl-2-[4-[(3-thienyl)	14	519.1	342
carboxamido]phenyl]ethyl]oxalamide	0.		
**	N-		
N-[2-[4-(2-Cyclopentylacetamido)	л эңсэн У <mark>М</mark>		
phenyl]-1,1-dimethylethyl]-N'-[3-	A	519.2	343
methoxy-4-(5-oxazolyl)phenyl]	N		
oxalamide			ĺ
N-[3-Methoxy-4-(5-oxazolyl) phenyl]			
-N'-[1,1-dimethyl-2-[4-(2-	n nc n vn	527.2	344
methylbenzamido)phenyl]ethyl]oxala	O		!
mide	N -		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	СИ		
-N'-[1,1-dimethyl-2-[4-(4-		527.2	345
		ت./ندر	343
methylbenzamido)phenyl]ethyl]oxala	()		
mide			

N-[2-[4-(Cycloheptylcarboxamido)			
phenyl]-1,1-dimethylethyl]-N'-[3-	on the on the on	533.2	346
methoxy-4-(5-oxazolyl)phenyl])- ~ 3		
oxalamide	\$		
N-[2-[4-[(5-Isoxazolyl) carboxamido]	N /		
phenyl]-1,1-dimethylethyl]-N'-[3-		504.1	347
methoxy-4-(5-oxazolyl)phenyl]			
oxalamide	1		
N-[2-[4-(Cyclopentylcarboxamido)	C-14 2 ME 24 2 C		
phenyl -1,1-dimethylethyl]-N'-[3-	CA DHC DH,	505.2	348
methoxy-4-(5-oxazolyl)phenyl]	1		
oxalamide	الله الله الله الله الله الله الله الله		
N-[2-{4-[(Tetrahydro-3(RS)-furyl)	-0,		
carboxamido]phenyl]-1,1-	CH, THE MY	507.1	349
dimethylethyl]-N'-[3-methoxy-4-(5-	CH. 1ME 31, N. 20		
oxazolyl)phenyl]oxalamide	A.F		1
N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N'-[1,1-dimethyl-2-[4-[(1-methyl-	CH. OHE H	516.1	350
1H-pyrrol-2-yl)carboxamido[phenyl]	02	2.5.1	
ethyl]oxalamide	5)		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	0) HS H ₁		
-N'-(1,1-dimethyl-2-[4-[(1,2,3-	он энс н, ✓м →	521.1	351
thiadiazol-4-yl)carboxamido]phenyl]		021.1	
ethyl]oxalamide			
ctifyijoxalaimde			
N-[2-[4-(3-Fluorobenzamido)phenyl]			
-1,1-dimethylethyl]-N'-[3-methoxy-	O1 H2 H	531.1	352
4-(5-oxazolyl)phenyl]oxalamide	01 - W - W		
N [2 [4 (4 E] 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	N		ļi
N-[2-[4-(4-Fluorobenzamido)phenyl]	N. N. N.	501.1	252
-1,1-dimethylethyl]-N'-[3-methoxy-	on the the	531.1	353
4-(5-oxazolyl)phenyl]oxalamide			
N-[2-[4-(2-	N-		+
Methoxybenzamido)phenyl]-1,1-	O1 145 31 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	543.2	354
dimethylethyl]-N'-[3-methoxy-4-(5-	0	J 1J.Z	
oxazolyl)phenyl]oxalamide	N-2		
N-[2-[4-(2-Chlorobenzamido)			+
phenyl]-1,1-dimethylethyl]-N'-[3-	ç. Hır an . N	547.1	355
methoxy-4-(5-oxazolyl)phenyl]	0 , , N, - , N O	J 1/ . 1	
oxalamide	N-J		
N-[2-[4-(3-Chlorobenzamido)	*		
phenyl]-1,1-dimethylethyl]-N'-[3-	on HC h	547.1	356
methoxy-4-(5-oxazolyl)phenyl]	o I . w	J 1 /.1	550
oxalamide	N-		
N-[2-[4-(4-Chlorobenzamido)	, Ja		
	оц энс т	547.1	357
phenyl]-1,1-dimethylethyl]-N'-[3-	0 - N - LN 0	J4/.1	1001
methoxy-4-(5-oxazolyl)phenyl			
oxalamide	<u> </u>		<u> </u>

N-[2-[4-[(1H-Indol-2-yl)			
carboxamido]phenyl]-1,1-	or :- : ` ` ` ` \	552.1	358
dimethylethyl]-N'-[3-methoxy-4-(5-	2 1		
oxazolyl)phenyl]oxalamide	N .		Ġ
N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N'-[1,1-dimethyl-2-[4-[4-		556.1	359
		230.1	337
(dimethylamino)benzamido]phenyl]e	67		
thyl]oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	H. (10, 1) (20)		
-N'-[1,1-dimethyl-2-[4-(3,3-		507.1	360
dimethylbutyramido)]phenyl]ethyl]o	N-		
xalamide			1
N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N'-[1,1-dimethyl-2-[4-[2-(1-		519.1	361
tetrazolyl)acetamido]phenyl]ethyl]ox	July 1. U	· ·	
alamide	·		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	Chrai		
	1- 0-11 × Sale (* 5	520.1	2.60
-N'-[1,1-dimethyl-2-[4-[(5-oxo-2(S)-		520.1	362
pyrrolidinyl)carboxamido]phenyl]eth			
yl]oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	Chral		
$-N'-(1,1-dimethyl-2-\{4-[(5-oxo-2(R)-$	6	520.1	363
pyrrolidinyl)carboxamido]phenyl]eth	, a		
yl]oxalamide	,		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	×1.8		
-N'-[1,1-dimethyl-2-[4-[(2-		563.1	364
naphthyl)carboxamido]phenyl]ethyl]	0. 100	300.1	5/0/1
oxalamide	, O		
	, N		
N-[2-{4-[(6-Cyano-3-pyridyl)		500 I	2.15
carboxamido]phenyl}-1,1-	N. N. N.	580.1	365
dimethylethyl]-N'-[3-methoxy-4-(5-		(M+H+	
oxazolyl)phenyl]oxalamide	4-	ACN)	
N-[2-[4-(3-Methoxybenzamido)	No. 19 194 194		
phenyl]-1,1-dimethylethyl]-N'-[3-	(543.1	366
methoxy-4-(5-oxazolyl)phenyl]			
oxalamide	`		
N-[2-[4-(3,5-Difluorobenzamido)			
phenyl]-1,1-dimethylethyl]-N'-[3-		549.1	367
methoxy-4-(5-oxazolyl)phenyl]		/	2 ./ ,
oxalamide	J. Harring		
N-[2-[4-[(1H-Indol-5-yl)	N	EEO 1	2.50
carboxamido]phenyl]-1,1-	N. N.	552.1	368
dimethylethyl]-N'-[3-methoxy-4-(5-	N- C		
oxazolyl)phenyl]oxalamide	N-		
(E)-N-[2-[4-(2-Butenamido)phenyl]-	Co. 1. ~ ~ ~ ~		
1,1-dimethylethyl]-N'-[3-methoxy-4-	,o o	477.1	369
(5-oxazolyl)phenyl]oxalamide	N		
Library 1	<u>. </u>		·

N-[2-[4-(2-Methoxyacetamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	OI, ONE OIL TO THE	481.2	370
N-[3-methoxy-4-(5-oxazolyl)phenyl]- N'-[1,1-dimethyl-2-[4-[(2-methyl-3- furyl)carboxamido]phenyl]ethyl]oxal amide	CH OHC MAN TO	517.1	371
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(5-methyl-4-isoxazolyl)carboxamido]phenyl]ethyl] oxalamide	0 HC	518.1	372
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(3-methyl-4- isoxazolyl)carboxamido]phenyl]ethyl] oxalamide		518.1	373
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(5-methyl-3-isoxazolyl)carboxamido]phenyl]ethyl] oxalamide		518.1	374
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N-[1,1-dimethyl-2-[4-[(1-oxido-3-pyridyl)carboxamido]phenyl]ethyl]ox alamide	6	530.1	375
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(1-oxido-4-pyridyl)carboxamido]phenyl]ethyl]ox alamide		530.1	376
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4,5-dimethyl-2-furyl)carboxamido] phenyl]ethyl]oxalamide	on of the state of	531.1	377
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(2,5-dimethyl-2H-pyrazol-3-yl) carboxamido]phenyl]-1,1- dimethylethyl]oxalamide		531.1	378
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(3-methyl-2-thienyl)carboxamido]phenyl]ethyl]ox alamide		533.1	379
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[2-(3-thienyl)acetamido]phenyl]ethyl]oxala mide	0 N N N N N N N N N N N N N N N N N N N	533.1	380

N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4-methyl-2-thienyl)carboxamido]phenyl]ethyl]ox alamide		533.1	381
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4-methyl-1,2,3-thiadiazol-5-yl)carboxamido]phenyl]ethyl]oxalamide		535	382
N-[2-[4-(4-Acetamidobenzamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		570.1	383
N-[2-[4-(3,4-Dimethoxybenzamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		573.1	384
N-[2-[4-(4-Chloro-2-methoxybenzamido)phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	(A) C (A) C	578.2	385
N-[2-[4-(2,6-Dichlorobenzamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	0 C	581	386
N-[2-[4-[(Bicyclo[4.2.0]octa-1(6),2,4-triene-7(RS)-yl)carboxamido] phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	or the man (T)	539.1	387
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-(2-oxo-2-phenylacetamido)phenyl]ethyl]oxala mide		541.1	388
N-[2-{4-[2-(2-Fluorophenyl) acetamido]phenyl}-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	OF CHE 11 CHE 12	545	389
N-[2-{4-[2-(4-Fluorophenyl) acetamido]phenyl}-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		545	390
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N-[2-{4-[(4-methoxy-3-thienyl) carboxamido]phenyl}-1,1- dimethylethyl]oxalamide	O O O O	549	391

		-	
N-[2-[4-(4-Acetylbenzamido)			
phenyl]-1,1-dimethylethyl]-N'-[3-	31 - 3 - 3 - 3 - 3 - 3 - 3	555.1	392
methoxy-4-(5-oxazolyl)phenyl]			
oxalamide	~		ų.
N-[2-[4-[(1,3-Benzodioxol-5-yl)	<i>3</i> ′-∨-		
	on one on the total	557 1	393
carboxamido]phenyl]-1,1-		557.1	393
dimethylethyl]-N'-[3-methoxy-4-(5-	(3)		
oxazolyl)phenyl]oxalamide			<u> </u>
N-[2-[4-[2-(2-Chlorophenyl)	OHCON ~~		1
acetamido]phenyl]-1,1-		561.1	394
dimethylethyl]-N'-[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	~		
N-[2-[4-[2-(4-Chlorophenyl)			
acetamido]phenyl]-1,1-		561.1	395
dimethylethyl]-N'-[3-methoxy-4-(5-	المناسبة الم		
oxazolyl)phenyl]oxalamide			
tert-Butyl 4-[[4-[2-[[[3-methoxy-4-	بالمريكي والمساورة		
(5-oxazolyl)anilino]oxalyl]amino]-2-		613	596
methylpropyl phenyl carbamoyl)benz			
oate	~-		
4-[[4-[2-[[[3-Methoxy-4-(5-oxazolyl)	~~~~		
anilino oxalyl amino -2-	en on a part of	557	597
methylpropyl]phenyl]carbamoyl]benz			
oic acid	w I		
	J		L

Particularly preferred compounds of formula (I) and formula (IX) are also those of general formula

$$R^{10}$$
 R^{9}
 R^{2}
 R^{3}
 R^{3}
 R^{4}
 R^{5}
 R^{12}
 R^{12}
 R^{12}
 R^{12}
 R^{12}

5

10

wherein R^2 , R^3 , R^5 , R^6 , R^7 , R^9 and R^{10} are defined as above, R^{11} and R^{13} are H or lower alkyl, n=0 or 1, R^a , R^b are lower alkyl or R^a and R^b taken together with the carbon atom to which they are attached form a 3 to 7 member carbocycle, and R^{12} is heterocyclyl, aryl or lower cycloalkyl and Z is O, S or NR^{28} , wherein R^{28} is H or lower alkyl.

Further preferred compounds of formula XVIII are those of general formulas:

$$R^{10}$$
 R^{9}
 R^{2}
 R^{3}
 R^{10}
 $$R^{10}$$
 R^{9}
 R^{2}
 R^{3}
 R^{10}
 R^{1

wherein R^2 , R^3 , R^5 , R^6 , R^7 , R^9 and R^{10} are defined as above; R^{11} and R^{13} is H or lower alkyl, n=0 or 1, m=1 to 5 and, R^{12} is heterocyclyl, aryl or lower cycloalkyl.

Particularly preferred compounds of formulae (XVIII), and (XIVa and XIVb) are those wherein R² is methoxy and R³, R⁵, R⁶, R⁹, R¹⁰, R¹¹ and R¹³ are hydrogen.

Also preferred are compounds of formulae (XVIII), and (XIVa and XIVb) where R¹² represents aryl, , a 3 to 7 membered cycloalkyl ring, or a 5 or 6 membered monocyclic or 9 or 10 membered bicyclic saturated or unsaturated heterocyclic ring with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur.

Examples of such compounds are listed in table 1f1 below

table 1f^l

5

Name	Structure	MS(ES) $(M+H)^+$	Ex No
N-[3-(4-Hydroxy-phenoxy)-1,1-dimethyl-propyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	N ○ 0 0 CH₁	440	396
		1	

N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-(4-methoxyphenoxy)-1,1-dimethylpropyl]oxalamide	0 0t 0t	454	397
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- nitrophenoxy)propyl]oxalamide	N ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	469	398
N-[3-(2-Hydroxyphenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N 2 3 CH3	440	399
N-[3-(4-Amino-phenoxy)-1,1-dimethyl-propyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	0 0H ₁ 0 0 NH ₂	439	400
N-[3-(4-Acetylamino-phenoxy)- 1,1-dimethyl-propyl]-N'-(3- methoxy-4-oxazol-5-yl-phenyl)- oxalamide	0 CH, 0 CH,	481	401
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(3- pyridyloxy)propyl]oxalamide		425	402
N-[3-(3-Hydroxyphenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		440	403
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-(3- methoxyphenoxy)-1,1- dimethylpropyl]oxalamide	N CONTRACTOR	454	404
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(3- nitrophenoxy)propyl]oxalamide	N N N N N N N N N N N N N N N N N N N	469	405
N-[3-(3-Aminophenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		439	406
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		468	433
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		468	434

3-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		468	435
2-[4-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenoxy]acetic acid		498	436
2-[2-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenoxy]acetic acid		498	437
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-(1,1-dimethyl-3-phenoxypropyl)oxalamide	N O O CH	424	542
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(1-oxido-3-pyridyloxy)propyl] oxalamide		441	543
N-[3-(3,4-Dihydroxyphenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N 10 10 10 10 10 10 10 10 10 10 10 10 10	456	544
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-[4- (methylcarbamoyl)phenoxy]propyl]oxalamide	N 1 2 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2	481	545
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-(3,4- dimethoxyphenoxy)-1,1- dimethylpropyl]oxalamide	M 2 4 6 4 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	484	546
N-[3-[4-[(2-Hydroxyethyl) carbamoyl]phenoxy]-1,1-dimethyl-propyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		511	547
N-[3-(3-Chlorophenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N 5 0 H	458	548
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(3- pyridyloxy)propyl]oxalamide		425	549
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2- pyridyloxy)propyl]oxalamide	N O O'H,	425	550

2-[4-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenyl]acetic acid	WO OF THE SHAPE SH	482	551
2-[3-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenyl]acetic acid	No. 19th	482	552
4-[2-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-2-methylpropoxy]benzoic acid		454	553
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-methylbenzoic acid	N 1 C	482	554
3-[3-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenyl]propionic acid		496	555
3-[4-[3-[[[3-Methoxy-4- (5oxazolyl)anilino]oxalyl]amino]- 3-methylbutoxy]phenyl]propionic acid		496	556
3-[2-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenyl]propionic acid	n to on you	496	557
2-[3-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenoxy]acetic acid	N TO THE TOTAL TOT	498	558
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-3-methylbenzoic acid	N 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	482	559
N-[3-(4-Cyano-2- methoxyphenoxy)-1,1- dimethylpropyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	CA CHALCH	479	560
N-[3-(3-Cyanophenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	C4 2 HC O.	449.6	561
N-[3-[4-(4-Acetyl-1-piperazinyl) phenoxy]-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	J. Y. S. I.	550.4	562

N. (2.) (.)		T	
N-[3-Methoxy-4-(5-	on, one on,	521.4	- Na
oxazolyl)phenyl]-N'-[1,1-dimethyl-	0, 0	531.4	563
[3-(2-morpholinophenoxy)propyl]	N	(M + Na)'	
oxalamide	0		
N-[3-Methoxy-4-(5-oxazolyl)	on one on		
phenyl]-N'-[1,1-dimethyl-3-[3-	De	489.6	564
(dimethylamino)phenoxy]	W.	$ (M + Na)^{\dagger} $	
propyl]oxalamide			
N-[3-(1,3-Benzodioxol-5-yloxy)-	о мс онс он		
1,1-dimethylpropyl]-N'-[3-	0 N N N N N N N N N N N N N N N N N N N	468.4	565
methoxy-4-(5-oxazolyl)phenyl]	No.		
oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)	. "		
phenyl]-N'-[3-(3,4,5-	.મ. ડનલ્ડામ્	514.4	566
trimethoxyphenoxy)-1,1-	N		
dimethylpropyl]oxalamide	THE ONE SHE		
N-[3-Methoxy-4-(5-oxazolyl)			
phenyl]-N'-[3-(3,5-	H _ HO OH.	506	567
dimethoxyphenoxy)-1,1-	H. H. TAN	$(M + Na)^{\dagger}$	207
		(NI + Na)	
dimethylpropyl]oxalamide	c		
N-[3-(5,6,7,8-Tetrahydro-5-oxo-2-	29 2 HC 28	102.1	F.: 0
naphthyloxy)-1,1-dimethylpropyl]-	on a last on I I	492.4	568
N'-[3-methoxy-4-(5-	· ·		
oxazolyl)phenyl]oxalamide	N- 24		
N-[3-(2-Acetamido-5-			
methylphenoxy)-1,1-	SH SHOOM S	517.6	569
dimethylpropyl]-N'-[3-methoxy-4-	N 6	$(M + Na)^{\dagger}$	
(5-oxazolyl)phenyl]oxalamide	N		
N-[3-(3-Acetamidophenoxy)-1,1-	(N) (N) (N) (N) (N) (N) (N) (N) (N) (N)		
dimethylpropyl]-N'-[3-methoxy-4-	0	503.6	570
(5-oxazolyl)phenyl]oxalamide	N=	$(M + Na)^{\dagger}$	
N-[3-(1H-Indol-4-yloxy)-1,1-	04 О НО СН / ² С		
dimethylpropyl]-N'-[3-methoxy-4-	о. они н от N	485.2	571
(5-oxazolyl)phenyl]oxalamide). 're'	$(M + Na)^{\dagger}$	
N-[3-(2-Fluoro-6-	Он. Он. Сен.		
methoxyphenoxy)-1,1-	0. Jh 1	472.2	572
dimethylpropyl]-N'-[3-methoxy-4-	South Control of Control		
(5-oxazolyl)phenyl]oxalamide	N- II		
N-[3-Methoxy-4-(5-oxazolyl)			
phenyl]-N'-[1,1-dimethyl-3-(2-	3 N - N - N - C - C - C - C - C - C - C -	492.4	573
oxo-2H-1-benzopyran-7-)	1,2	5,5
yloxy)propyl]oxalamide	N-		
	Эн		
N-{3-(4-Acetyl-3-methylphenoxy)-	çн <u>с</u> нс, ъ ~ [~] ~°о	1902	574
1,1-dimethylpropyl]-N'-[3-	S. N. SHO, H	480.2	574
methoxy-4-(5-oxazolyl)phenyl]			
oxalamide			

(E)-N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-[4-(3-oxo-1-butenyl)phenoxy]propyl] oxalamide		492.4	575
N-[3-(3-Acetylphenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	CH OHLCH	466.4	576
N-[3-(4-Acetylphenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	OH : HC >	466.2	577
N-[3-(4-Acetamido-2-chlorophenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	CH 11/C 11 12/C 13/C 13/C 13/C 13/C 13/C 13/C 13/C 13	515.6	578
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-pyridyloxy)propyl]oxalamide		425	579
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(1- oxido-4-pyridyloxy)propyl] oxalamide	No. 10 No.	441	580
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2,6- dimethyl-4-pyridyloxy)propyl] oxalamide	1	453	581
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2,6- dimethyl-1-oxido-4-pyridyloxy) propyl]oxalamide	No. 201 N. 201	469	582
N-[2-(4-Cyanophenoxy)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		435	583
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-(2-methoxy-4- pyridyloxy)-1,1-dimethylpropyl] oxalamide	N → 10 × 10 × 10 × 10 × 10 × 10 × 10 × 10	455	584
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[4- (1H-tetrazol-5-yl)phenoxy]ethyl] oxalamide	0 - N Od Od N N N N N N N N N N N N N N N N	478	585
N-[3-(4-Cyanophenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		449	586

N-[2-(3-Cyanophenoxy)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	0 N N N N N N N N N N N N N N N N N N N	476	587
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[3- (1H-tetrazol-5-yl)phenoxy]ethyl] oxalamide	2 C CH N N N N N N N N N N N N N N N N N	478	588
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-[4- (1H-tetrazol-5-yl)phenoxy]propyl] oxalamide	HOUSE TO THE SERVICE	492	589
Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclobutyl]ethoxy]benzoate		570.2	590
Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopentyl]ethoxy]benzoate		584.3	591
Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclohexyl]ethoxy]benzoate	The state of the s	598.3	592
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopentyl]ethoxy]benzoic acid	#	494.2	593
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclohexyl]ethoxy]benzoic acid	.H	508.2	594
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl)amino]-1-cyclobutyl]ethoxy]benzoic acid	dk	480.2	595
Benzyl 2-methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate		588	635
3-Chloro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	# (m	502	636
2-Methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	1 No. 20	498	637

3-Methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	NOTE OF THE STATE	498	638
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopropyl]ethoxy]benzoic acid		466	639
2-Chloro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N → 0 → 0 → 0 → 0 → 0 → 0 → 0 → 0 → 0 →	502	640
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-quinolinecarboxylic acid		519	641
(cis/trans)-4-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]-1-cyclohexanecarboxylic acid	NS OF NOT NOT ON	474	642
(cis/trans)-4-[2-[[[3-Methoxy-4- (5-oxazolyl)anilino]oxalyl]amino]- 2-methylpropoxy]-1- cyclohexanecarboxylic acid	O TO NOT NOT NOT NOT NOT NOT NOT NOT NOT	460	643
3-Fluoro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N N N N N N N N N N N N N N N N N N N	486	644
3-Acetamido-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N O N N O O O O O O O O	525	645
3-(Methanesulfonamido)-4-[3- [[[3-methoxy-4-(5- oxazolyl)anilino]oxalyl]amino]-3- methylbutoxy]benzoic acid	N O O O O O O O O O O O O O O O O O O O	561	646
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-3,5-dimethylbenzoic acid	PO NO	496	647
3-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-pyridinecarboxylic acid	N N N O N N O O O O O O O O O O O O O O	469	648
8-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-quinolinecarboxylic acid	N O O O O O O O O O O O O O O O O O O O	519	649

5-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-indolecarboxylic acid	N OH OH	507	650	
--	---------	-----	-----	--

Further preferred compounds of formula XVIII are those of general formula

$$R^{10}$$
 R^{9}
 R^{2}
 R^{3}
 R^{3}
 R^{10}
 R^{10

wherein R², R³, R⁵, R⁶, R⁷, R⁹ and R¹⁰ are defined as above, R¹¹ and R¹³ are H or lower alkyl, n= 0 or 1, R^a, R^b are lower alkyl or R^a and R^b taken together with the carbon atom to which they are attached form a 3 to 7 member carbocycle, and R¹² is heterocyclyl, aryl or lower cycloalkyl, especially aryl, a 3 to 7 membered cycloalkyl ring, or a 5 to 6 membered monocyclic or 9 to 10 membered bicyclic saturated or unsaturated heterocyclic ring with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur.

Particularly preferred compounds of formula (XIX) are those wherein R^2 is methoxy and R^3 , R^5 , R^6 , R^9 , R^{10} , R^{11} and R^{13} are hydrogen.

Examples of such compounds are listed in table 1f2 below:

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2- (phenylthio)ethyl]oxalamide	N O S O S	426	615
N-[2-(4-Hydroxyphenylthio)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N N N N S N S N S N S N S N S N S N S N	442	616
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2- (phenylthio)ethyl]oxalamide	N O O OH,	440	617
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(2- pyridylthio)ethyl]oxalamide	о о о о о о о о о о о о о о о о о о о	427	618

N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2- pyridylthio)propyl]oxalamide	N 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	441	619
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2- thienylthio)propyl]oxalamide	C CH ₃	446	620
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2-pyrimidylthio)propyl]oxalamide	N O O OH, OH, OH, OH, OH, OH, OH, OH, OH,	442	621
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- pyridylthio)propyl]oxalamide	N C OH SN	441	h22
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2- thiazolylthio)propyl]oxalamide	N 0 0 0 CH S N C	447	623
N-[3-(4-Hydroxyphenylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N O O OL	456	624
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(5-methyl-1,3,4-thiadiazol-2-ylthio) propyl]oxalamide	N	462	625
N-[3-(2-Benzooxazolylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	HE ON STAN	481	626
N-[3-(2-Benzothiazolylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	No. 1 September 1997	497	627
Methyl 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropylthio]benzoate	THE CONTRACTOR OF THE CONTRACT	484	628
tert-Butyl 6-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutylthio]-3-pyridinecarboxylate		541	629
6-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-3-pyridinecarboxylic acid trifluoroacetate (1:1)	N N S N OH	485	630
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]benzoic acid	N STATE OF STATE OF THE	484	631

N-[2-(4-Benzyloxyphenylthio)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	NºO O NO	532	664
N-[2-(4-Benzyloxyphenylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	NºO O'NONTO	546	665
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-5-benzoxazolecarboxylic acid	N OTC OF S	525	666
N-[3-(1H-Imidazol-2-ylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		430	667
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-3-pyridinecarboxylic acid trifluoroacetate (1:1)	N N N N N N N N N N N N N N N N N N N	485	668
4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropylthio]benzoic acid	NZ C NZ NZ	470	669
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-6-benzoxazolecarboxylic acid		525	670

Further preferred compounds of formula (XVIII) are those of general formula

$$R^{10}$$
 R^{9}
 R^{2}
 R^{3}
 R^{3}
 R^{4}
 R^{5}
 R^{13}
 R^{11}
 R^{12}
 R^{28}

wherein R^2 , R^3 , R^5 , R^6 , R^7 , R^9 and R^{10} are defined as above, R^{11} , R^{13} and R^{28} are H or lower alkyl, n=0 or 1, R^a , R^b are lower alkyl or R^a and R^b taken together with the carbon atom to which they are attached form a 3 to 7 number carbocycle, and R^{12} is heterocyclyl, aryl or lower cycloalkyl preferably aryl such as phenyl.

Particularly preferred compounds of formula (XX) are those wherein R^2 is methoxy and R^3 , R^5 , R^6 , R^9 , R^{10} , R^{11} and R^{13} are hydrogen and R^{28} is hydrogen or methyl.

Examples of such compounds are listed in table 1f3 below.

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(N-methylanilino) ethyl] oxalamide	N O HC N	423	632
N-(3-Anilino-1,1-dimethylpropyl)- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide hydrochloride (1:1)	N C O CH _O CH _O N CH _O N	423	633
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylamino]benzoic acid	ont ch	467	634

Particularly preferred compounds of formula (1) or formula (IX) are also those of general formula

$$R^{10}$$
 R^{9}
 R^{2}
 R^{3}
 R^{10}
 R^{1

wherein R², R³, R⁵, R⁶, R⁷, R⁹ and R¹⁰ are defined as above, R¹¹ and R¹³ is H or lower alkyl, n = 0 or 1; R²¹ is alkyl, cycloalkyl, phenyl, heterocyclyl, cycloalkyl alkyl, phenyl alkyl or heterocyclyl alkyl, alkyl carbonyl, cycloalkyl carbonyl, phenyl carbonyl, heterocyclyl carbonyl, alkyl sulphonyl, cycloalkyl sulphonyl, phenyl sulphonyl, heterocyclyl sulphonyl. Preferably R²¹ is phenyl, phenyl alkyl, phenyl carbonyl, or phenyl sulfonyl.

Particularly preferred compounds of formula (XV) are also those wherein R^2 is methoxy, R^3 , R^5 , R^6 , R^9 , R^{10} , R^{11} and R^{13} are hydrogen.

Examples of such compounds are listed in table 1g below

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-phenyl-1-piperazinyl)ethyl]oxalamide		478	407
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	408
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(3-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	409
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-phenyl-1-piperazinyl)propyl]oxalamide		492	410
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(2-methoxy-phenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	411
N-[2-(4-Benzyl-1-piperazinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		492	412
N-[2-[4-(Benzenesulfonyl)-1- piperazinyl]-1,1-dimethylethyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		452	413
N-[2-(4-Benzoyl-1-piperazinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		506	414
N-[2-[4-[4- (Trifluoromethyl)phenyl]-1- piperazinyl]-1,1-dimethylethyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	an o an o	546	459
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]oxalamide		492	460
N-[2-[4-(2-Fluorophenyl)-1- piperazinyl]-1,1-dimethylethyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		496	461

	7°. 1		
N-[2-[4-(4-Fluorophenyl)-1-		100	4.43
piperazinyl]-1,1-dimethylethyl]-N'-	1. ~ N . ~ N	496	462
[3-methoxy-4-(5-	N		
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-	34		1
oxazolyl)phenyl]-N'-[2-[4-(2-	0 J. J. O. O. O.	508	463
methoxyphenyl)-1-piperazinyl]-1,1-			
dimethylethyl]oxalamide	.>N		
N-[3-Methoxy-4-(5-	C		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	c. one on	548	464
[4-(2-thiophenesulfonyl)-1-			
piperazinyl]ethyl]oxalamide	N		
N-[3-Methoxy-4-(5-	٠,٥ ١,٠ ١,٠ ١		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		584.1	465
[4-(2,4,6-trimethylbenzenesulfonyl)-	6		
1-piperazinyl]ethyl]oxalamide	J		
N-[2-[4-(4-Fluorobenzenesulfonyl)-	<u></u>		
1-piperazinyl]-1,1-dimethylethyl]-N'-		560.1	466
[3-methoxy-4-(5-	C N X N	300.1	400
	0 . 6		
oxazolyl)phenyl]oxalamide			
N-[2-[4-(Trifluoromethanesulfonyl)-	, *\$	E24	167
1-piperazinyl]-1,1-dimethylethyl]-N'-	C NY N C N	534	467
[3-methoxy-4-(5-	5		
oxazolyl)phenyl)]oxalamide	No.		
N-[2-[4-(Isopropylsulfonyl)-1-	н. сн _ы н. сн _ы		
piperazinyl]-1,1-dimethylethyl]-N'-		508.1	468
[3-methoxy-4-(5-	0.		
oxazolyl)phenyl)]oxalamide			
(E)-N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	OL MAN THE STATE OF THE STATE O	568.1	469
[4-(styrylsulfonyl)-1-	0 1 0 0		
piperazinyl]ethyl]oxalamide	Name of the second		
N-[2-[4-(Ethanesulfonyl)-1-	сн. м.н. ун.		
piperazinyl]-1,1-dimethylethyl]-N'-	CH. WHY HIS WAY	494.1	4 70
[3-methoxy-4-(5-	,O · >		
oxazolyl)phenyl]oxalamide	N-i		
N-[3-Methoxy-4-(5-	эоң		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	Ch. (0 H) 04 (0 O	508.1	471
[4-(propanesulfonyl)-1-	0		
piperazinyl]ethyl]oxalamide	N		
N-[2-[4-(3-Chloropropanesulfonyl)-	1. \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
1-piperazinyl]-1,1-dimethylethyl]-N'-	(H. N. 14, N. N.)	542.1	472
[3-methoxy-4-(5-	N	3-1-1	3/2
oxazolyl)phenyl]oxalamide	N-		
N-[3-Methoxy-4-(5-	, ş. ~	554 1	.172
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	OH	556.1	473
[4-(o-toluenesulfonyl)-1-	0		
piperazinyl]ethyl]oxalamide	N°		<u> </u>

N (2 [4 (2 F) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			,
N-[2-[4-(2-Fluorobenzenesulfonyl)-			
1-piperazinyl]-1,1-dimethylethyl]-N'-	on one on the	560.1	474
[3-methoxy-4-(5-	,		
oxazolyl)phenyl]oxalamide	N		ļi
N-[2-[4-(2-Cyanobenzenesulfonyl)-			i i
1-piperazinyl]-1,1-dimethylethyl]-N'-	in unicida	567.1	475
[3-methoxy-4-(5-	con support		1
oxazolyl)phenyl]oxalamide	N-3		<u> </u>
N-[3-Methoxy-4-(5-	0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		
oxazolyl)phenyl]-N'-[2-[4-(3,5-	O- 040 04 1 5 34	561.1	476
dimethyl-4-isoxazolylsulfonyl)-1-	o		
piperazinyl]-1,1-dimethyl-	الس- الس		
ethyl]oxalamide			
N-[2-[4-(5-Fluoro-2-			
methylbenzenesulfonyl)-1-		574.1	477
piperazinyl]-1,1-dimethylethyl]-N'-			
[3-methoxy-4-(5-			i
oxazolyl)phenyl]oxalamide			
N-[2-[4-(2,5-			
Difluorobenzenesulfonyl)-1-		578.1	478
piperazinyl]-1,1-dimethylethyl]-N'-		370.1	1,0
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-	CH. WHILLIAM CH.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	CH OHE H (N)	546.1	479
[4-(1-methyl-1H-imidazole-4-	N	340.1	473
	0		
sulfonyl)-1-	, "		
piperazinyl]ethyl]oxalamide	7.		
N-[2-[4-(2,6-		578.1	190
Difluorobenzenesulfonyl)-1-	e. N. Sak. a. N. O.	5/8.1	480
piperazinyl]-1,1-dimethylethyl]-N'-	(0)		
[3-methoxy-4-(5-	Ner:		
oxazolyl)phenyl]oxalamide	. ,		ļi
N-[2-[4-(3,4-		5 00 -	461
Difluorobenzenesulfonyl)-1-	On Chicar No	578.1	481
piperazinyl]-1,1-dimethylethyl]-N'-	a) Temeral No.		ĺ
[3-methoxy-4-(5-	وسيم		
oxazolyl)phenyl]oxalamide			
N-[2-[4-	3. F. W. W.		
(Cyclohexylmethanesulfonyl)-1-	2.	562.2	482
piperazinyl]-1,1-dimethylethyl]-N'-	0_ 1 0		
[3-methoxy-4-(5-	,		
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		570.1	483
[4-(2-phenylethanesulfonyl)-1-	0.) N		
piperazinyl]ethyl]oxalamide			
	<u> </u>	L	

N. [2. N. d.] 4. (5.	20.		
N-[3-Methoxy-4-(5-	- > .	520	404
oxazolyl)phenyl]-N'-[2-[4-(2,4-		538	484
dimethoxyphenyl)-1-piperazinyl]-	N .		
1,1-dimethylethyl]oxalamide			-
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		492	485
[4-(4-methylphenyl)-1-	0.		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	~ ~ .CH,		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	() () () () () () () () () (506	486
[4-(2,4-dimethylphenyl)-1-	32 C N 134		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	~ 5		
oxazolyl)phenyl]-N'-[2-[4-(3,4-		538	487
dimethoxyphenyl)-1-piperazinyl]-			
1,1-dimethylethyl]oxalamide	22		
N-[2-(4-Cyclohexyl-1-piperazinyl)-			
1,1-dimethylethyl]-N'-[3-methoxy-4-	9.00	484.4	488
(5-oxazolyl)phenyl]oxalamide	in N		
	~		
N-[2-[4-(Cyclohexylmethyl)-1-	., <		
piperazinyl]-1,1-dimethylethyl]-N'-	No. No. No.	498.2	489
[3-methoxy-4-(5-	0.1		
oxazolyl)phenyl]oxalamide	N×:		
N-[2-[4-(2-Methoxybenzyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-		522.1	490
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[2-[4-(2-Hydroxybenzyl)-1-	1		
piperazinyl]-1,1-dimethylethyl]-N'-		508.1	491
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-	4		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		506.1	492
[4-(2-methylbenzyl)-1-			
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	H, 5 H,C 24,	498.1	493
[4-(2-thenyl)-1-	0 · 1 · 6	11.	
piperazinyl]ethyl]oxalamide	N-		
N-[3-Methoxy-4-(5-	6.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		520.2	494
[4-(2(RS)-phenylpropyl)-1-	**	220.2	
piperazinyl]ethyl]oxalamide			
N-[3-methoxy-4-(5-	2 313		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	: m52n	486.1	495
(4-pivaloyl-1-		100.1	
piperazinyl)ethyl]oxalamide	Q TO		
piperazinyijemyijoxalalilide			<u> </u>

N-[2-[4-(2-Furoyl)-1-piperazinyl]-	٠. ٠. ١		1
1,1-dimethylethyl]-N'-[3-methoxy-4-	180 S. 18531	496.1	496
(5-oxazolyl)phenyl]oxalamide			
	° v		
N-[3-Methoxy-4-(5-	2.2		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	MI CHCPS M	512.1	497
[4-(2-thenoyl)-1-			į
piperazinyl]ethyl]oxalamide	CT .		
N-[3-Methoxy-4-(5-	~ · · · · · ·		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	Mi O HCON	512	498
[4-(3-thenoyl)-1-			
piperazinyl]ethyl]oxalamide			
N-[2-[4-(2-Cyclopentylacetyl)-1-	\ \Q		
piperazinyl]-1,1-dimethyl-ethyl]-N'-		512.1	499
[3-methoxy-4-(5-			
oxazolyl)phenyl)]oxalamide			
N-[2-[4-(Cyclohexylcarbonyl)-1-	<u>_</u> ~		
piperazinyl]-1,1-dimethylethyl]-N'-	Ms CHENTS	512.1	500
[3-methoxy-4-(5-	2		
oxazolyl)phenyl]oxalamide	n n		Ī
N-[3-Methoxy-4-(5-	12		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		520.1	501
[4-(2-methylbenzoyl)-1-			
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	· L, ~	,	
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	Hr. O HCOH,	520.1	502
[4-(4-methylbenzoyl)-1-	,		1
piperazinyl]ethyl]oxalamide			i
N-[2-[4-(Cycloheptylcarbonyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-	o Hickory	526.2	503
[3-methoxy-4-(5-	N. N.		
oxazolyl)phenyl]oxalamide	\$1		ĺ
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-]1,1-dimethyl-2-	Hr. O HCON	496.1	504
[4-[(1H-pyrazol-4-yl)carbonyl]-1-	N. L.N.	1	
piperazinyl]ethyl]oxalamide	·		
N-[2-[4-(Cyclopentylcarbonyl)-1-	1		
piperazinyl]-1,1-dimethylethyl]-N'-	HE SHEPS	498.1	505
[3-methoxy-4-(5-	3 . N. LN		
oxazolyl)phenyl]oxalamide	\$7		
N-[3-Methoxy-4-(5-	3. 24		
oxazolyl)phenyl]-N'-[1,1-Dimethyl-		509.1	506
2-[4-[(1-methyl-1H-pyrrol-2-		507.1	
yl)carbonyl]-1-	\$ 1 ° . '		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	3 N.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	O HEOR	514.1	507
[4-[(1,2,3-thiadiazol-4-yl)carbonyl]	a N N	317.1	307
1-piperazinyl]-ethyl]oxalamide			+
1-piperazinyij-cunyijoxalannuc	<u> </u>	l	

			,
N-[2-[4-(3-Fluorobenzoyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-		524.1	508
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	<u></u>		
N-[2-[4-(4-Fluorobenzoyl)-1-	~		
piperazinyl]-1,1-dimethylethyl]-N'-	HE STATE OF	524.1	509
[3-methoxy-4-(5-		į	
oxazolyl)phenyl]oxalamide			
N-[2-[4-(Cyclopropylcarbonyl)-1-	1		
piperazinyl]-1,1-dimethylethyl]-N'-	He owden	470.1	510
[3-methoxy-4-(5-	o- My -m		
oxazolyl)phenyl]oxalamide			
N-[2-[4-(2-Cyclohexylacetyl)-1-	. ~		
piperazinyl]-1,1-dimethylethyl]-N'-	1	526.2	511
[3-methoxy-4-(5-		320.2	211
oxazolyl)phenyl]oxalamide	* 1.		
N-[3-Methoxy-4-(5-		500.3	C12
oxazolyl)phenyl]-N'-[2-[4-(3,3-		500.2	512
dimethylbutyryl)-1-piperazinyl]-1,1-			
dimethylethyl]oxalamide	No.		[
N-[2-[4-(3-Hydroxy-2,2-	~ C. C. C.		
dimethylpropionyl)-1-piperazinyl]-	The state of the s	502.1	513
1,1-dimethylethyl]-N'-[3-methoxy-4-			
(5-oxazolyl)phenyl]oxalamide	7-3		
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	3	510.1	514
[4-(3-methyl-2-furoyl)-1-			
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	HG GHGPH D IN	510.1	515
[4-(2-methyl-3-furoyl)-1-			
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	1 1 man	<u> </u>	
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	High on some No.	510.1	516
[4-[(5-methyl-1H-pyrazol-3-		510.1	
yl)carbonyl]-1-			
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	La La La La La La La La La La La La La L	511.1	517
[4-[(5-methyl-4-	3	J11.1	517
isoxazolyl)carbonyl]-1-	l J'		
piperazinyl]ethyl]oxalamide	?		
N-[3-Methoxy-4-(5-	Non Non	5111	510
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	O NOTE NO NOTE NO	511.1	518
[4-[(5-methyl-3-			ĺ
isoxazolyl)carbonyl]-1-	N N		
piperazinyl]ethyl]oxalamide			

N-[2-[4-(4-Aminobenzoyl)-1-	No. 10 No.	į	*
piperazinyl]-1,1-dimethylethyl]-N'-	Mis Company of the Co	521.1	519
[3-methoxy-4-(5-	"		
oxazolyl)phenyl]oxalamide	*		
N-[2-[4-(2-Hydroxybenzoyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-		522.1	520
[3-methoxy-4-(5-			1
oxazolyl)phenyl]oxalamide	\		!
N-[2-[4-(4-Hydroxybenzoyl)-1-	\$		
piperazinyl]-1,1-dimethylethyl]-N'-	ns. O HCOS	522.1	521
[3-methoxy-4-(5-	- 1 N		:
oxazolyl)phenyl]oxalamide			į į
N-[3-Methoxy-4-(5-			ı
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	# ##C () The control of the control	524.1	522
[4-[(2,5-dimethyl-2H-pyrazol-3-	, Trans		
yl)carbonyl]-1-	Ç.		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	1 4524	526.1	523
[4-(3-methyl-2-thenoyl)-1-		021	0.20
piperazinyl]ethyl]oxalamide	(T)		
N-[3-Methoxy-4-(5-	i can		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	Hr. OHICH	526.1	524
[4-(4-methyl-2-thenoyl)-1-	N. T.	321	321
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	0 H 2 GH	526.2	525
[4-[(2,2,3,3-tetramethyl-1-		320.2	323
cyclopropyl)carbonyl]-1-			
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	. >		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	The same of the sa	528.1	526
[4-[(4-methyl-1,2,3-thiadiazol-5-		320.1	320
yl)carbonyl]-1-			
piperazinyl]ethyl]oxalamide			j l
N-[2-[4-(3-Cyanobenzoyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-		531.1	527
[3-methoxy-4-(5-		551.1	321
oxazolyl)phenyl]oxalamide			
N-[2-[4-[(Bicyclo[4.2.0]octa-	3 /=	 	
	2.51	532.1	528
1(6),2,4-trien-7-yl)carbonyl]-1- piperazinyl]-1,1-dimethylethyl]-N'-		352.1	320
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	о́ Jaн		
N-[2-[4-(3-Hydroxybenzoyl)-1-	4504	522.1	529
piperazinyl]-1,1-dimethylethyl]-N'-	Hi. O HE OH	322.1	329
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	N-	L	

N-[2-[4-(2-Ethylbutyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-	HC CHECK TH	486.1	530
[3-methoxy-4-(5-	20		
oxazolyl)phenyl]oxalamide	N.		
N-[3-Methoxy-4-(5-	*	_	-
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		506.2	531
[4-(2-phenylethyl)-1-	41,300		Ì
piperazinyl]ethyl]oxalamide	12		
N-[3-Methoxy-4-(5-	. /~s ^{CH} .		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	H. HECH W.	490.1	532
[4-[3-(methylthio)propyl]-1-			!
piperazinyl]ethyl]oxalamide	NT.		Ĩ
N-[2-[4-(2,6-Difluorobenzyl)-1-	- (<u>-</u>	
piperazinyl]-1,1-dimethylethyl]-N'-	, s : 22	528.1	533
[3-methoxy-4-(5-	2,7.	520.1	333
oxazolyl)phenyl]oxalamide			
N-[2-[4-(3-Furfuryl)-1-piperazinyl]-	H. 0 H.O. ()	100.1	E24
1,1-dimethylethyl]-N'-[3-methoxy-4-	N N	482.1	534
(5-oxazolyl)phenyl]oxalamide	0 ' '		
N-[2-[4-[(2-Benzofuranyl)methyl]-	N-		
1-piperazinyl]-1,1-dimethylethyl]-N'-	H, 2 M, 50 /	532.1	535
[3-methoxy-4-(5-	L _N	332.1	333
	0.0		
oxazolyl)phenyl)]oxalamide	,		
N-[2-[4-(2-Cyanobenzyl)-1-		-171	524
piperazinyl]-1,1-dimethylethyl]-N'-	4 - 2 - 2 - 2	517.1	536
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			<u> </u>
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[2-[4-(3,3-	٠	486.2	537
dimethylbutyl)-1-piperazinyl]-1,1-			
dimethylethyl]oxalamide	87		
N-[3-Methoxy-4-(5-	C. N. C.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	HC HCH	543.2	538
[4-[(2-quinolinyl)methyl]-1-			
piperazinyl]ethyl]oxalamide	The second secon		
tert-Butyl 4-[2-[[[3-methoxy-4-(5-	αι, • αι, • - αι,		
oxazolyl)anilino]oxalyl]amino]-2-	ি কর্ ক ক কুনু বুলি	516	539
methylpropyl]-1-piperazineacetate	We want to the second	- • •	
	n		<u> </u>
4-[2-[[[3-Methoxy-4-(5-			
oxazolyl)anilino]oxalyl]amino]-2-		460	540
methylpropyl]-1-piperazineacetic			
acid trifluoroacetate (1:1)	T"		
N-[2-[4-(Cyclopropylmethyl)-1-	>4		
piperazinyl]-1,1-dimethylethyl]-N'-	5 . 0 N N N N N N N N N N N N N N N N N N	456	541
[3-methoxy-4-(5-	() N		
oxazolyl)phenyl]oxalamide	N		
OAUZOIYI/PHEHYIJOAAIAIIIIGC			

tert-Butyl 4-[4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-1-piperazinyl]benzoate	NO NO NO NO NO NO NO NO NO NO NO NO NO N	578	651
4-[4-[2-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-2-methylpropyl]-1-piperazinyl]benzoic acid trifluoroacetate (1:1)	NO FACH	522	652

In particular preferred compounds of formula (I) and formula (IX) \setminus are also those of the general formula

$$R^{10}$$
 R^{9}
 R^{2}
 R^{23}
 R^{24}
 R^{24}
 R^{27}
 wherein R², R³, R⁵, R⁶,R⁷,R⁹,R¹⁰ and R¹³ are defined as above, R²², R²³, R²⁴, R²⁵ and R²⁶ are H or lower alkyl,R²⁷ is alkyl, aryl or heterocyclyl, alkoxy, aryloxy, heterocyclyl oxy, especially aryl or aryloxy.

Particularly preferred compounds of formula (XVI) are those wherein R^2 is methoxy, R^3 , R^5 , R^6 , R^9 , R^{10} , R^{13} , R^{22} , R^{23} , R^{24} , R^{25} and R^{26} are hydrogen.

Examples of such compounds are listed in table 1h below:

Name	Structure	ME(ES) (M+H)	Ex No
Phenyl [3-[[[4-(5-oxazolyl)anilino]oxalyl]amino]benzyl] carbamate	HC 0	487	415
N-[3-[(3-	он, о	489	
Fluorobenzamido)methyl]phenyl]-N'-	5, N = 0 N O		416
[3-methoxy-4-(5-			0
oxazolyl)phenyl]oxalamide	<u> </u>		
N-[3-[(3-	сн, о 🔨 ->>		
Chlorobenzamido)methyl]phenyl]-N'-		505	417
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			

N-[3-[(3- Methoxybenzamido)methyl]phenyl]- N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		501.2	418
N-[3-[(3,4- Dimethoxybenzamido)methyl]phenyl] -N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	OH, O O O O	531.2	419
N-[3-[(3- Cyanobenzamido)methyl]phenyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		496.1	420

In particular preferred compounds of formula (I) or formula (IX) are also those of the general formula

wherein R², R³, R⁵, R⁶, R⁷ and R¹⁰ are defined as above; R¹¹ and R¹³ is H or lower alkyl and R¹² is heterocyclyl, aryl or lower cycloalkyl.

Particularly preferred compounds of formula (XVII) are those wherein R^2 is methoxy, R^3 , R^5 , R^6 , R^9 , R^{10} , R^{11} and R^{13} are hydrogen and wherein R^{12} is phenyl or

10

Examples of such compounds are listed in table 1i below:

Name	Structure	MS(ES) $(M+H)^{\dagger}$	Ex No
N-[3-Methoxy-4-(4-oxazolyl) phenyl]-N'-[1,1-dimethyl -2-(4- phenyl-1-piperazinyl)ethyl] oxalamide		478	428

N-[2-(4-Benzyloxyphenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide		500	429
N-[2-(4-Hydroxyphenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide	C. S. OH	410	43()
N-[3-Methoxy-4-(4-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	431
N-[3-Methoxy-4-(2-methyl-4-oxazolyl)-phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		522.4	432

The compounds of formula (IV) and (VIII) which are intermediates in the foregoing processes are novel and are also provided by the present invention.

5

10

With reference to Reaction Scheme A, the first step comprises the coupling of a compound of formula (II) with an activated oxalyl derivative, such as methyl chlorooxoacetate, to give a compound of formula (III). The reaction may be carried out in a conventional manner, suitably in an organic solvent which is inert under the reaction conditions and in the presence of an organic base at about 0°C to about room temperature. Suitable solvents include halogenated

hydrocarbons, e.g. dichloromethane. Pyridine and tri(lower alkyl)amines, e.g. triethylamine, can be mentioned as examples of suitable organic bases which can be used.

Subsequent hydrolysis of the compound of formula (III) to give the acid compound of formula (IV) may be carried out by treatment with a solution of an alkali metal hydroxide, such as sodium hydroxide, in a suitable solvent system, such as aqueous methanol.

Alternatively, a compound of formula (II) may be coupled with tert.butyl chlorooxoacetate, followed by treatment with acid to remove the tert.butyl group, to give a compound of formula (IV).

The compound of formula (IV) is then coupled with an amine compound of formula (V) using standard peptide coupling reagents, such as hydroxybenzotriazole in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, to give the oxamide compound of formula (I).

After this coupling step, the R groups of the resulting compound may be further modified by techniques known in the art, for example, functional groups may be altered, and/or connected to further groups

20

10

15

Reaction Scheme B

Referring to Reaction Scheme B, the first step comprises the coupling of a compound of formula (VI) with an activated oxalyl derivative, such as methyl chlorooxoacetate, to give a compound of formula (VII). The reaction is carried out in the manner described above for the formation of a compound of formula (III) from a compound of formula (II).

Subsequent hydrolysis of the compound of formula (VII) to give the acid compound of formula (VIII) is then carried out as described above for the hydrolysis of a compound of formula (III).

Alternatively, a compound of formula (VI) may be coupled with tert.butyl chlorooxoacetate, followed by treatment with acid to remove the tert.butyl group, to give a compound of formula (VIII).

10

25

The compound of formula (VIII) is then coupled with an amine compound of formula (V) to give the oxamide compound of formula (IX), under the conditions described above for the coupling of a compound of formula (IV) with a compound of formula (V).

After this coupling step, the R groups of the resulting compound may be further modified by
techniques known in the art, for example, functional groups may be altered, and/or connected to
further groups

Reaction Scheme C

$$R^{1}$$
 R^{2}
 R^{3}
 R^{3}
 R^{4}
 R^{5}
 R^{5}
 R^{5}
 R^{7}
 R^{7

Alternatively, compounds of formula (I) are made by the coupling of a compound of formula (II) with an oxalamic acid compound of formula (X), using standard peptide coupling reagents,

such as hydroxybenzotriazole in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, to give the oxamide compound of formula (I).

After this coupling step, the R groups of the resulting compound may be further modified by techniques known in the art, for example, functional groups may be altered, and/or connected to further groups

As mentioned above, the compounds of formula (I) and salts thereof are inhibitors of IMPDH enzyme both in vitro and in vivo, and can be used in the control or prevention of IMPDH mediated conditions or diseases.

IMPDH activity can be assayed using an adaptation of the method reported by Carr [S. Carr et al., J. Biol. Chem. 268, p.27286 (1993)], the disclosure of which is herein incorporated by reference. IMPDH activity was measured spectrophotometrically, by monitoring the increase in absorbance at 340nm due to the formation of NADH (ε340 is 6220 M-1 cm-1) from the reduction of NAD. The IMPDH reaction mixture contained 0.1M Tris pH8.0, 0.1M KCl, 1mM DTT, 3mM EDTA, 100mM IMP and 100mM NAD. The reaction was initiated by the addition of IMPDH (human type II) to a final concentration in the assay of between 1nM and 5nM with respect to the IMPDH tetramer. The initial rate is measured by following the linear increase in absorbance at 340nm at 37°C for 45 minutes. The reading was conducted using a Spectromax 190 (Molecular Devices) spectrophotometer in a 96 well plate format with a final reaction volume of 200μl.

For inhibitor assay analysis, the compound is dissolved in DMSO to a final concentration of 10mM and added to the initial reaction mixture as 5µl to give final DMSO concentration of 2.5%. The enzyme reaction is initiated by the addition of IMPDH and the initial rates measured as above. IC₅₀ determinations are made by measuring the initial rates in the presence of 10 concentrations of inhibitor and fitting the data using the 4 parameter curve fit from the Softmax pro software (Molecular Devices).

25

30

Preferred compounds of the invention tested in the above assay have an IC₅₀ value up to 500nM i.e. $0.5 \mu M$.

Specific examples of IC_{50} values for preferred compounds of formula (I) are set out below in Table 2:

<u>Table 2</u>

Compound of Formula (I)		IC_{50}
Compound of Formula (1)		
a St. or	tert-Butyl [3-[[[3-methoxy-4-(5-	(μM) 0.036
	oxazolyl)	0.036
	anilino]oxalyl]amino]benzyl]carbamate	
~~~		
H C	N-tert-Butyl-N'-[3-methoxy-4-(5-	0.037
H ₃ C N	oxazolyl)phenyl]oxalamide	
↑ A Sheal	[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]	0.044
	oxalyl]amino]benzyl]carbamic acid	
	tetrahydro-3(S)-furyl ester	
5. "	N-[3-(Benzamidomethyl)phenyl]-N'-[3-	0.013
ハ <b>ル</b> シ * ・	methoxy-4-(5-	0.015
	oxazolyl)phenyl]oxalamide	
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		
7 OH, CH	Isopropyl [3-[[[3-methoxy-4-(5-	0.033
	oxazolyl)	
	anilino]oxalyl]amino]benzyl]carbamate	
эн, о он, / II - г	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-	0.03
	N'-(1-methyl-1-phenylethyl)oxalamide	
;н, _О ;н,	N-(1,1-Dimethylpropyl)-N'-[3-	0.031
H,C N N N	methoxy-4-(5-	0.55.
Ö	oxazolyl)phenyl]oxalamide	
64.0	• • • • • • • • • • • • • • • • • • • •	0.024
H,C,H,C, J,H,	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-	0.034
H³C CH³	N'-(1,1,3,3-tetramethyl-butyl)oxalamide	
,~ Q 3/CH,	N-(1,1-Dimethylpropargyl)-N'-[3-	0.048
" O CH	methoxy-4-(5-	
OH ₃ C CH,	oxazolyl)phenyl]oxalamide	
Tie oray	N-(2-Hydroxy-1,1-dimethylethyl)-N'-	0.072
	[3-methoxy-4-(5-	
	oxazolyl)phenyl]oxalamide	
Ö ÓH,	N-(1,1-Dimethyl-2-phenylethyl)-N'-[3-	0.015
	methoxy-4-(5-	0.013
The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s	oxazolyl)phenyl]oxalamide	
□	onabor, rypricity i johanamiae	

	Phenyl [3-[[[4-(5-oxazolyl)anilino] oxalyl]amino]benzyl]carbamate	0.011
	N-[3-Methoxy-4-(5-oxazolyl)phenyl]- N'-[3-[(phenylcarbamoyl)methyl] phenyl]oxalamide	0.035
OH, OH, OH, OH, OH, OH, OH, OH, OH, OH,	tert-Butyl [2-[[[3-methoxy-4-(5- oxazolyl)anilino]oxalyl]amino]-2- methylpropyl]carbamate	0.075
9 My 5	N-(2-Amino-1,1-dimethylethyl)-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide trifluoroacetate (1:1)	0.097
	N-[3-Methoxy-4-(5-oxazolyl)phenyl]- N'-[1,1-dimethyl-2-(4-nitrophenyl) ethyl]oxalamide	0.010
м — — — — — — — — — — — — — — — — — — —	N-[3-(Aminomethyl)phenyl]-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide trifluoroacetate (1:1)	0.233
	Methyl [3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate	0.121
	N-[3-Methoxy-4-(5-oxazolyl)phenyl]- N'-(3-pyridyl)oxalamide	0.277
	N-[3- [(Benzenesulfonamido)methyl]phenyl]- N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	0.125
H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃ C - H ₃	N-(2-Dimethylamino-1,1- dimethylethyl)-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide hydrochloride (1:1)	0.17
NEW THE	N-[3-Methoxy-4-(5-oxazolyl)phenyl]- N'-[1-methyl-1- (methylcarbamoyl)ethyl]oxalamide	().199
H,C CI	N-tert-Butyl-N'-[3-chloro-4-(5- oxazolyl)phenyl]oxalamide	0.169
H ₃ C N CH ₃	N-tert-Butyl-N'-[3-methoxy-4-(4- oxazolyl)phenyl]oxalamide	0.46

Compounds of formula (I) which are acidic can form pharmaceutically acceptable salts with bases such as alkali metal hydroxides, e.g. sodium hydroxide and potassium hydroxide; alkaline earth metal hydroxides, e.g. calcium hydroxide, barium hydroxide and magnesium hydroxide, and the like; with organic bases e.g. N-ethyl piperidine, dibenzylamine, and the like. Those compounds of formula (I) which are basic can form pharmaceutically acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric acid and hydrobromic acid, sulphuric acid, nitric acid and phosphoric acid, and the like, and with organic acids, e.g. with acetic acid, tartaric acid, succinic acid, fumaric acid, maleic acid, malic acid, salicylic acid, citric acid, methanesulphonic acid and p-toluene sulphonic acid, and the like. The formation and isolation of such salts can be carried out according to methods known in the art.

The oxamide derivatives provided by the present invention (i.e. the compounds of formula (I) and their pharmaceutically acceptable salts, especially as depicted in all the formulae herein), can be used as medicaments, for example in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered enterally, such as orally, in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, or nasally, e.g. in the form of nasal sprays. They can also be administered rectally, e.g. in the form of suppositories, or parenterally, (e.g. intramuscularly, intravenously, or subcutaneously), for example, in the form of injection solutions.

20

25

10

For the manufacture of pharmaceutical preparations the oxamide derivatives can be formulated with therapeutically inert, inorganic or organic carriers. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active ingredient no carriers are, however, generally required in the case of soft gelatine capsules. Suitable carriers for the manufacture of solutions and syrups are, for example, water, polyols, sucrose, saccharose, invert sugar, glucose and the like. Suitable carriers for the manufacture of injection solutions are, for example, water, saline, alcohols, polyols, glycerine, vegetable oils and the like. Natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like are suitable carriers for the manufacture of suppositories. The pharmaceutical preparations of the present invention may also be provided as sustained release formulations or other appropriate formulations.

The pharmaceutical preparations can also contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colourants, flavourants, salts for adjustment of the osmotic pressure, buffers, masking agents or antioxidants. They may also contain other therapeutically active substances, such as an immunosuppressant, a chemotherapeutic agent, an anti-viral agent, an anti-binflammatory agent and/or an anti-vascular hyperproliferation agent. A preferred agent that may be used with the compounds of the present invention is interferon or derivatives thereof, such as conjugates with polyethylene glycol.

10

15

Accordingly part of this invention is a pharmaceutical composition comprising a compound of formula (I) or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, and, optionally, one or more additional therapeutically active substance(s). Such substances may be one or more immunosuppressants, chemotherapeutic agents, antivirals, antibiotic, antiparasitics, antifungals, antiinflammatories, or antivascular antiproliferation agents. Preferably the substance is interferon or an interferon derivative.

Medicaments containing compounds of formula (I) or salts thereof and a therapeutically acceptable carrier, as well as a process for the manufacture of such medicaments are also objects of the present invention. This process comprises bringing a compound of formula (I) or a pharmaceutically acceptable salt thereof into a galenical administration form together with a therapeutically inert carrier material and, if desired, one or more additional therapeutically active substances.

A further object of the invention comprises the use of the oxamide derivatives provided by the invention in the treatment of an immune mediated condition or disease, a viral disease, a bacterial disease, a parasitic disease, inflammation, an inflammatory disease, a hyperproliferative vascular disease, a tumour, or cancer. The dosage can vary within wide limits and will, of course, be adjusted to the individual requirements in each particular case.

Dosage levels of between about 0.01 and about 100 mg/kg body weight per day (preferably 0.5 - 75 mg/kg/day) in monotherapy and/or in combination therapy are preferred, administered from about 1 -5 times per day. The active ingredient may be combined with a carrier material.

A typical preparation will contain from about 5% - 95% active compound (w/w) (preferably

from about 20% - 80% active compound). The daily dosage can be administered as a single dosage or in divided dosages.

Accordingly this invention is also directed to a method for treating an immune mediated condition or disease, a viral, bacterial, parasitic, inflammatory ,hyperproliferative vascular disease, inflammation, a tumor, or cancer in a subject by administering to the subject a therapeutically effective amount of a compound of formula (I) or its pharmaceutically acceptable salts. In addition, this method includes concurrent or sequential administration of one or more therapeutically active substances taken from immunosuppresants, chemotherapeutics, antivirals, antibiotics, antiparasitics, antifungals, antiinflammatories, and anti-vascular hyperproliferation agents. Preferably the substance is interferon or an interferon derivative.

This invention is especially directed to a method for treating IMPDH mediated diseases.

The compounds and compositions of the present invention may be for use in monotherapy and/or combination therapy, i.e. the treatment may be in conjunction with the administration of one or more additional therapeutically active substance(s). When the treatment is combination therapy, such administration may be concurrent or sequential with respect to that of the oxamide derivatives of the present invention. Thus, concurrent administration, as used herein, includes administration of the agents in conjunction or combination, together, or before or after each other.

It will be understood that references herein to treatment extend to prophylaxis as well as to treatment of existing conditions. Treatment of a disease or condition, as used herein, also includes preventing, inhibiting, regressing, reversing, alleviating or relieving the disease or condition, or the clinical symptoms thereof. The term "subject" as used herein refers to animals, including humans and other mammals.

30 The following Examples illustrate the present invention.

10

15

With regard to the starting materials that are known compounds some of these may be purchased from commercial suppliers. Other starting materials that are known and their analogues can be prepared by methods well known in the art. Examples of compounds available from commercial suppliers, and citations to the synthesis of other compounds and their analogues are provided in the following:

Compounds of formula (II) and the compounds of formula (VI) are obtained from commercial suppliers (e.g. 4-(5-oxazolyl)aniline, Maybridge catalogue number DFP 00120), or prepared by adaptation of the methods disclosed in published patent application WO 974002, or prepared by adaptation of the methods provided in Palacz et al., FEBS Lett., 1984, 176(2), 365-370.

10

The compounds of formula (V) are obtained from commercial suppliers (e.g. tert-butylamine, Aldrich catalogue number B8,920-5; Cumylamine, TCl-US catalogue number C1293), or prepared by adaptation of the methods provided in Kazuo Achiwa et al., Chem.Pharm.Bull., 1998, 46(4), 697-670.

15

The compounds of formula (X) are prepared by adaptation of the methods provided in Minisci et al., J. Org. Chem., 1995, 60(17), 5430-5433.

30

Examples of commercially available reagents include those used in Examples 7, 10 and 11, (2methoxy-4-nitrobenzoic acid, Aldrich catalogue number 42,291-6; tert-butylacetic acid, Aldrich catalogue number B8,840-3; and p-tolualdehyde, Aldrich catalogue number T3,560-2, respectively).

25

Where indicated, the NMR spectra were recorded on a Bruker DRX 400 MHz spectrometer with the probe temperature set at 300 K.

Where indicated by "(M+;EI)", mass spectra were recorded under electron impact conditions (EI), on a THERMOQUEST MAT95 S with a source temperature of 200°C. Other mass spectra were recorded under electrospray ionisation spectra (ESI) conditions, on one of the following machines:

a) THERMOQUEST SSQ 7000 [Solvent 0.085% TFA in 90% Acetonitrile/water; flow rate 100 microliters/minute; capillary 250°C; spray voltage 5KV; sheath gas 80 psi], or

- b) LC-MS system (liquid chromatograph coupled to mass spectrum) THERMOQUEST TSQ 7000 ELECTROSPRAY or MICROMASS PLATFORM ELECTROSPRAY [Solvent 0.1% TFA in water or 0.085% TFA in 90% acetonitrile/ water or 0.085% TFA in acetonitrile].
- Unless otherwise indicated, the mass spectroscopy values recorded in the MS(ES) column refer to (M+H) values, apart from the ones shown as (M';EI).

### Example 1

15

10 N-Tert-butyl-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide

A solution of 26 mg (0.1 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 15 mg (0.2 mmol) of tertiary butylamine, 28 mg (0.15 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 15 mg (0.11 mmol) of 1-hydroxy-7-azabenzotriazole in 1 ml of dimethylformamide was stirred at room temperature for 4 hours then diluted with ethyl acetate and washed with 2M hydrochloric acid, saturated sodium bicarbonate and water. The resulting solution was dried over magnesium sulphate and evaporated to dryness. The residue was triturated with diethyl ether/petrol (1:1) and collected by filtration to give 11 mg of

N-tert-butyl-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide as a white solid. MS: m/e 318.0 [M+H]'.

The starting material was prepared as follows:

5

10

- 1) 5.7 g (30 mmol) of 3-methoxy-4-(5-oxazolyl)aniline and 3.33 g (33 mmol) of triethylamine were dissolved in 50 ml of dichloromethane and the solution was cooled to 0°C. A solution of 3.86 g (31.5 mmol) of methyl oxalyl chloride in 10 ml of dichloromethane was added dropwise and the resulting mixture was stirred for 1 hour then washed with 2M hydrochloric acid. The precipitated solid was collected by filtration and washed with dichloromethane and give 6.2 methyl N-[3-methoxy-4-(5water oxazolyl)phenyl]oxalamate as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ: 3.88 (3H,s), 3.94 (3H,s), 7.48 (1H,s), 7.58 (1H,dd), 7.65 (1H,d), 7.68 (1H,d)), 8.39 (1H,s), 10.92 (1H,s).
- ii) 6.2 g (22.46 mmol) of methyl N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamate and 1.2 g (30 mmol) of sodium hydroxide were refluxed in 240 ml of methanol/water (1:1) for 2 hours then cooled, filtered and acidified with 2M hydrochloric acid. The precipitated solid was collected by filtration and washed with water, acetone and diethyl ether to give 5.1 g of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid as a pale yellow solid. MS: m/e 262.9 [M+H][†].

20

30

Alternatively N-tert-butyl-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide can be prepared as follows:

A solution of 95 mg (0.5 mmol) of 3-methoxy-4-(5-oxazolyl)aniline, 73 mg (0.5 mmol) of N-tert-butyloxalamic acid, 134 mg (0.7 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 75 mg (0.55 mmol) of 1-hydroxy-7-azabenzotriazole in 4 ml of dichloromethane was stirred a room temperature for 18 hours. The resulting mixture was washed with 2M hydrochloric acid and saturated sodium bicarbonate, dried over magnesium sulphate and evaporated to dryness. The residue was triturated with petrol and

collected by filtration to give 128 mg of N-tert-butyl-N'-[3-methoxy-4-(5-

oxazolyl)phenyl]oxalamide as a pale yellow solid. MS: 318 [M+H][†].

### Example 2

# Tert-butyl [3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl] amino]benzyl]carbamate

A mixture of 2.04 g (7.79 mmol) of N-(3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, prepared as described above in Example 1 above, 1.9 g (8.56 mmol) of tert-butyl (3-aminobenzyl)carbamate, 1.8 g (9.4 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1.3 g (9.6 mmol) of 1-hydroxy-7-azabenzotriazole in 30 ml of dimethylformamide was stirred for 20 hours at room temperature. The resulting precipitate was collected by filtration and washed with dichloromethane to give 1.8 g of tert-butyl [3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate as a white solid. MS: m/e 466 M[†].

15

5

10

## N-[3-(Aminomethylphenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate

15 mg (0.032 mmol) of tert-butyl [3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]-amino]benzyl]carbamate, prepared as described in Example 2 above, were dissolved in 1 ml of dichloromethane and 1 ml of trifluoroacetic acid at room temperature for 5 minutes. The solution was evaporated to dryness, the residue triturated with diethyl ether and collected by filtration to give 11 mg of N-[3-(aminomethylphenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate as a white solid. MS: m/e 408 [M+H+MeCN][†].

5

### N-[3-(Benzamidomethyl)phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide

29 mg (0.21 mmol) of benzoyl chloride were added to a solution of 100 mg (0.21 mmol) of N-[3-(aminomethyl)phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide trifluoroacetate, prepared as described in Example 3 above, and 46 mg (0.46 mmol) of triethylamine in a mixture of 2 ml of dimethylformamide and 5 ml of dichloromethane, and stirred at room temperature for 18 hours. The solution was washed with 2M hydrochloric acid and saturated sodium bicarbonate then dried over magnesium sulphate and evaporated to dryness. The residue was chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. After trituration with diethyl ether there was obtained 45 mg of N-[3-(benzamidomethyl)phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as a white solid. MS: m/e 471.0 [M+H]⁺.

5

 $\frac{N-[3-[(Benzenesulphonamido)methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide}{phenyl]oxalamide}$ 

$$\begin{array}{c} \text{NH}_2 \\ \text{NHOCCONH} \end{array}$$

$$\begin{array}{c} \text{PhSO}_2\text{Cl} \\ \text{Et}_3\text{N} \end{array}$$

$$. \text{TFA}$$

In an analogous manner to that described in Example 4 but replacing benzoyl chloride with phenylsulphonyl chloride there was obtained N-[3-[(benzenesulphonamido)methyl]-phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as a white solid. MS: m/e 507  $[M+H]^{+}$ .

## Example 6

10

## 15 Methyl [3-[[[3-methoxy-4-(5-oxazolyl]anilino]oxazolyl]aminobenzyl]carbamate

In an analogous manner to that described in Example 4 but replacing benzoyl chloride with methyl chloroformate there was obtained methyl [3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate as a white solid. MS: m/e 425 [M+H]⁺.

## 5 Example 7

10

## N-Tert-butyl-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide

A mixture of 371 mg (1 mmol) of N-[4-(bromoacetyl)-3-methoxyphenyl]-N'-tert-butyloxalamide and 315 mg (5 mmol) of ammonium formate was refluxed in 10 ml of formic acid for 4 hours then cooled and evaporated to dryness. The residue was dissolved in ethyl

acetate, washed with 2M sodium hydroxide and dried over magnesium sulphate. The solution was evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (7:18) for the elution. There was obtained after trituration with diethyl ether/petrol (1:1) 65 mg of N-tert-butyl-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide as a white solid. MS: m/e 318 [M+H][†].

### The starting material was prepared as follows:

- A mixture of 3.94 g (20 mmol) of 2-methoxy-4-nitrobenzoic acid, 3.9 g (40 mmol) of i) N,O-dimethylhydroxylamine hydrochloride, 5.73 g (29.92 mmol) of dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 3.37 g (22 mmol) of 1hydroxybenzotriazole hydrate and 5.06 g (44 mmol) of N-ethylmorpholine in 50 ml of dichloromethane was stirred at room temperature for 3 hours then washed with 2M hydrochloric acid and saturated bicarbonate. The resulting solution was dried over magnesium sulphate, evaporated to dryness and the residue triturated with diethyl ether and collected by filtration to give 3.95 g of N,O-dimethyl 2-methoxy-4-nitrobenzohydroxamate as a white solid. ¹H NMR (400 MHz, CDCl₃) δ: 3.37 (3H,s), 3.48 (3H,s), 3.97 (3H,s), 7.45 (1H,d), 7.80 (1H,d), 7.91 (1H,dd).
- ii) A mixture of 1.2 g (5 mmol) of N,O-dimethyl 2-methoxy-4-nitrobenzohydroxamate and 4.75 g (25 mmol) of tin(II) chloride in 40 ml of ethanol was heated at 80°C for 30 minutes then cooled and evaporated to dryness. The residue was dissolved in dichloromethane, washed with 2M sodium hydroxide and the organic phase dried over magnesium sulphate and evaporated to dryness to give 960 mg of N,O-dimethyl 4-amino-2-methoxybenzohydroxamate as an off-white solid. ¹H NMR (400 MHz, CDCl₃) δ: 3.25 (3H,s), 3.62 (3H,s), 3.79 (3H,s), 6.22 (1H,d), 6.28 (1H,dd), 7.09 (1H,d).
  - iii) A mixture of 700 mg (3.33 mmol) of N,O-dimethyl 4-amino-2-methoxybenzohydroxamate, 483 mg (3.33 mmol) of N-tert-butyloxalamic acid, 600 mg (3.92 mmol) of 1-hydroxybenzotriazole hydrate and 960 mg (5.01 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in 15 ml of dichloromethane was stirred at room temperature for 3 hours then washed with 2M hydrochloric acid and saturated sodium bicarbonate. The organic phase was dried over magnesium sulphate, evaporated to

dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (3:1) for the elution to give 960 mg of N,O-dimethyl 4-[[(tert-butylamino)oxalyl] amino]-2-methoxybenzohydroxamate as a white solid. ¹H NMR (400 MHz, CDCl₃) δ: 1.46 (9H,s), 3.25-3.4 (3H,br.s.), 3.45-3.65 (3H,br.s.), 3.89 (3H,s), 7.08 (1H,dd), 7.29 (1H,d), 7.44 (1H,s), 7.53 (1H,d), 9.40 (1H,s).

iv) 3.1 ml (4.34 mmol) of 1.4M methylmagnesium bromide in tetrahydrofuran were added in portions over 1 hour to a solution of 337 mg (1 mmol) of N,O-dimethyl 4-[[(tert-butylamino)oxalyl]amino]-2-methoxybenzohydroxamate in 10 ml of anhydrous tetrahydrofuran. The resulting solution was diluted with diethyl ether and washed with 2M hydrochloric acid. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (3:7) for the elution to give 255 mg of N-(4-acetyl-3-methoxyphenyl)-N'-tert-butyloxalamide as a white solid. ¹H NMR (400 MHz, CDCl₃) δ: 1.45 (9H,s), 2.61 (3H,s), 3.96 (3H,s), 7.03 (1H,dd), 7.43 (1H,s), 7.64 (1H,d), 7.82 (1H,d), 9.47 (1H,s).

10

15

20

v) 320 mg (0.85 mmol) of phenyltrimethylammonium tribromide were added in portions over 10 minutes to a stirred solution of 247 mg (0.85 mmol) of N-(4-acetyl-3-methoxyphenyl)-N'-tert-butyloxalamide in 5 ml of anhydrous tetrahydrofuran. After 15 minutes a further 100 mg (0.26 mmol) of phenyltrimethylammonium tribromide were added. The resulting suspension was diluted with diethyl ether, washed with water and the organic phase was dried over magnesium sulphate. Evaporation gave a gum which was chromatographed on silica gel using firstly 0.5% methanol in dichloromethane then 1% methanol in dichloromethane for the elution. The product was dissolved in diethyl ether/petrol (2:1) and the resulting crystals were collected by filtration to give 135 mg of N-[4-(bromoacetyl)-3-methoxyphenyl]-N'-tert-butyloxalamide as a white solid. ¹H NMR (400 MHz, CDCl₃) &: 1.44 (9H,s), 3.99 (3H,s), 4.61 (2H,s), 7.06 (1H,dd), 7.42 (1H,s), 7.68 (1H,d), 7.93 (1H,d), 9.51 (1H,s).

## Examples 8-11

#### 5 Example 8

10

### Tert-butyl[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]carbamate

77mg (0.87 mmol) of tert-butyl (2-amino-2-methylpropyl)carbamate , 207 mg (1.05 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 166 mg (1.08 mmol) of 1-hydroxy-7-azabenzotriazole and 200 mg (0.76 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid were dissolved in 5 ml of dichloromethane and 5 ml of dimethylformamide and stirred for 16 hours at room temperature. The mixture was then diluted with 50 ml of dichloromethane and washed with a 10% solution of citric acid and brine. The organic layer was then dried with anhydrous magnesium sulphate, filtered and evaporated to dryness. The residue was chromatographed on silica gel using 30% ethyl acetate in hexane for the elution to give 165 mg of tert-butyl [2-[[[3-methoxy-4-(5-oxazolyl)-

anilino]oxalyl]amino]-2-methylpropyl]carbamate as a yellow solid, ¹H NMR (400MHz, d6 DMSO) δ: 1.35 (s, 6H), 1.45 (s, 9H), 3.25 (d, 2H), 3.95 (s, 3H), 7.25 (t, 1H), 7.55 (s,1H), 7.70 (m, 2H), 7.80 (s,1H), 8.25 (s, 1H), 8.50 (s, 1H), 10.8 (s, 1H).

## 5 <u>Example 9</u>

10

20

25

# N-(2-Amino-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide trifluoroacetate (1:1)

26 mg (0.29 mmol) of tert-butyl [2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]carbamate was dissolved and stirred in 10 ml of a 1:1 mixture of 1,1,1-trifluoroacetic acid and dichloromethane. After 1 hour the solvent mixture was co-evaporated with toluene three times and dichloromethane twice. The resulting gum was then triturated with 40-60 petroleum ether to give 124 mg of N-(2-amino-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate (1:1) as a yellow solid,  1 H NMR (400MHz, d6 DMSO)  $\delta$ : 1.40 (s,6H), 3.20 (m,2H), 3.90 (s, 3H), 7.50 (s,1H), 7.60-7.74 (m, 2H), 7.80 (s, 1H), 7.90 (s(br), 3H), 8.30 (s,1H), 8.40 (s,1H), 10.80(s,1H).

The previously described trifluoroacetic acid salt was partitioned between a saturated sodium hydrogencarbonate solution and ethyl acetate. The organic layer was then dried with magnesium sulphate, filtered and evaporated to give the free base used in Example 10.

#### Example 10

# N-(3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-(3,3-dimethylbutyramido)-1,1-dimethylethyl]oxalamide

30 mg (0.09 mmol) of N-(2-amino-1,1-dimethyl-ethyl)-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide, 52 mg (0.45 mmol) of tert-butylacetic acid, 86 mg (0.45 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 69 mg of HOAt were dissolved and stirred in 2 ml of dimethylformamide. After stirring for 16 hours the mixture was diluted with 10 ml of dichloromethane and washed with 10% citric acid solution in water, saturated sodium hydrogen carbonate solution and brine. The organic solution was then dried with solid

magnesium sulphate, filtered and evaporated to give N-(3-methoxy-4-(5-oxazolyl)phenyl]-N'-[2-(3,3-dimethylbutyramido)-1,1-dimethylethyl] oxalamide as a pale yellow solid, MS: m/e 431.3 [M+H]+

### 5 Example 11

10

15

20

25

30

# N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-(4-methylbenzylamino)-1,1-dimethylethyl]oxalamide

30 mg (0.09 mmol) of N-(2-amino-1,1-dimethyl-ethyl)-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide, 11.3 mg (0.095 mmol) of 4-methylbenzaldehyde and 30 mg (0.14 mmol) of sodium triacetoxyborohydride were dissolved in 2ml of a 5% acetic acid dichloromethane mixture for 16 hours. The reaction mixture was then diluted with 8 ml of dichloromethane and washed with water, saturated sodium hydrogen carbonate and brine. The resulting organic solution was then dried with magnesium sulphate, filtered and evaporated to give N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[2-(4-methylbenzylamino)-1,1-dimethylethyl]oxalamide as a yellow solid MS: m/e 437.3 [M+H]+.

## Example 12

## 2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropionic acid

A mixture of 161 mg (0.446 mmol) of methyl 2-[[3-methoxy-4-(5-oxazolyl)anilinooxalyl]amino]-2-methylpropionate and 56 mg (1.33 mmol) of lithium hydroxide hydrate in 3 ml of methanol and 0.5 ml of water was heated at 50°C for 2 hours then diluted with water and washed with diethyl ether. The aqueous phase was acidified to pH2 with 2M hydrochloric acid and extracted twice with ethyl acetate. The combined organic extracts were dried over magnesium sulphate and evaporated to dryness. The residue was

chromatographed on silica gel using dichloromethane/methanol/acetic acid/water (120:15:3:2) for the elution. After trituration with ether there was obtained 70 mg of 2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropionic acid as a white solid. MS: m/e 247.9 [M+H][†].

## Example 13

5

10

20

## N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1-methyl-1-(phenylcarbamoyl)ethyl]oxalamide

A solution of 30 mg (0.086 mmol) of 2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropionic acid, 16 mg (0.172 mmol) of aniline, 18 mg (0.132 mmol) of 1-hydroxy-7-azabenzotriazole and 25 mg (0.131 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in 2 ml of dimethylformamide was stirred at room temperature for 18 hours then diluted with ethyl acetate and washed with 2M hydrochloric acid and saturated sodium bicarbonate. The organic phase was dried over magnesium sulphate and after evaporation the residue was triturated with diethyl ether and collected by filtration to give 20 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1-methyl-1-(phenylcarbamoyl)ethyl]oxalamide as a white solid. MS: m/e 423.0 [M+H]⁺.

5

10

15

## $\underline{N\text{-}[3\text{-}Methoxy\text{-}4\text{-}(5\text{-}oxazolyl)phenyl]\text{-}N'\text{-}[1\text{-}methyl\text{-}1\text{-}(methylcarbamoyl)ethyl]}oxalamide}$

of (0.086 mmol)of Α mixture 30 mg 2-[[[3-methoxy-4-(5oxazolyl)anilino oxalyl]amino]-2-methylpropionic acid, 12 mg (0.178 mmol) of methylamine hydrochloride, 18 mg (0.132 mmol) of 1-hydroxy-7-azabenzotriazole, 25 mg (0.131 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 22 mg (0.218 mmol) of triethylamine in 2 ml of dimethylformamide was stirred at room temperature for 18 hours then diluted with ethyl acetate and washed with 2M hydrochloric acid and saturated sodium bicarbonate. The organic solution was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using dichloromethane/methanol (24:1) for the After trituration with ether there was obtained 17 mg of N-[3-methoxy-4-(5oxazolyl)phenyl]-N'-[1-methyl-1-(methylcarbamoyl)ethyl]oxalamide as a white solid. MS:  $m/e 361.0 [M+H]^{+}$ .

## 2-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]phenyl]acetic acid

solution 740 mg (1.81 mmol) of methyl of 2-[3-[[[3-methoxy-4-(5oxazolyl)anilino|oxalyl|amino|phenyl|acetate and 152 mg (3.62 mmol) of lithium hydroxide hydrate in 10 ml of methanol, 10 ml of 1,4-dioxane and 5 ml of water was stirred at room temperature for 18 hours. The solvent was removed by evaporation and the residue dissolved in water. The aqueous solution was washed with diethyl ether and acidified with citric acid The solid which precipitated was collected by filtration and washed with water, solution. ethanol and diethyl ether give 414 mg of 2-[3-[[[3-methoxy-4-(5to oxazolyl)anilino]oxalyl]amino]phenyl]acetic acid as a white solid. MS: m/e 396.0 [M+H][†].

5

5

10

15

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[3-[(phenylcarbamoyl)methyl] phenyl]oxalamide

(0.076 mmol) 2-[3-[[[3-methoxy-4-(5-Α solution of 30 mg of oxazolyl)anilino]oxalyl]amino]phenyl]acetic acid and 11 mg (0.096 mmol)ethylmorpholine in 1 ml of dimethylformamide was cooled to 0°C and a solution of 12 mg (0.088 mmol) of isobutyl chloroformate in 1 ml of dichloromethane was added. The resulting mixture was stirred for 30 minutes at 0°C then a solution of 7 mg (0.075 mmol) of aniline in 1 ml of dichloromethane was added and stirring was continued for a further hour at 0°C. After 18 hours at room temperature the mixture was evaporated to dryness and the residue chromatographed on silica gel using dichloromethane/methanol (19:1) for the elution. There obtained 3 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[3was [(phenylcarbamoyl)methyl]phenyl]oxalamide as a white solid MS: m/e 471.0 [M+H]⁺.

10

15

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[3-[(methylcarbamoyl)methyl] phenyl]oxalamide

Α mixture of 30 mg (0.076 mmol)of 2-[3-[[[3-methoxy-4-(5-(0.115 mmol)oxazolyl)anilino]oxalyl]amino]phenyl]acetic acid, 22 mg dimethylaminopropyl)-3-ethylacrbodiimide hydrochloride, 14 mg (0.092 mmol) hydroxybenzotriazole hydrate, 26 mg (0.385 mmol) of methylamine hydrochloride and 52 mg (0.452 mmol) of N-ethylmorpholine in 1 ml of dimethylformamide was stirred at room temperature for 18 hours. The solvent was removed by evaporation and the residue chromatographed on silica gel using dichloromethane/methanol (1:19) for the elution. There obtained 15 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[3-[(methyl was carbamoyl)methyl]phenyl]oxalamide as a white solid. MS: m/e 409 [M+H]⁺.

## N-(3-Aminophenyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate

20 mg (0.043 mmol) of tert-butyl [3-[[[3-methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]phenyl]carbamate were dissolved in a mixture of 1 ml of dichloromethane and 1 ml of trifluoroacetic acid at room temperature for 10 minutes. The solvent was removed by evaporation and the residue triturated with diethyl ether. The resulting solid was collected by filtration to give 18 mg of N-(3-aminophenyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate as a white solid. MS: m/e 394.0 [M+H+MeCN]⁺.

### 15 Example 19

5

## N-[3-(Benzamido)phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide

A mixture of 30 mg (0.064 mmol) of N-(3-aminophenyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate, 9 mg (0.074 mmol) of benzoic acid, 15 mg (0.078 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 15 mg (0.096 mmol) of 1-hydroxybenzotriazole hydrate and 22 mg (0.19 mmol) of N-ethylmorpholine in 0.5 ml of dimethylformamide was stirred at room temperature for 18 hours then diluted with ethyl acetate and washed with 10% citric acid solution, saturated sodium bicarbonate and water. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using dichloromethane/methanol (19:1) for the elution. There was obtained after trituration with diethyl ether/petrol (1:1). 12 mg of N-[3-(benzamidophenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as a white solid. MS: m/e 457.0 [M+H]⁺.

### Example 20

10

15

20

25

N-[3-(Methanesulphonamido)phenyl]-N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide

12 mg (0.011 mmol) of methanesulphonyl chloride were added to a solution of 50 mg (0.011 mmol) of N-(3-aminophenyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate and 32 mg (0.317 mmol) of triethylamine in 0.5 ml of dimethylformamide. The resulting solution was left at room temperature for 18 hours then diluted with ethyl acetate and washed with 10% citric acid solution, saturated sodium bicarbonate and water. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (1:1) for the elution. There was obtained 5 mg of N-[3-(methanesulphonamido)phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as a white solid. MS: m/e 431.0 [M+H][†].

5

## N-[2-(4-Aminophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide

A mixture of 44 mg (0.1 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-nitrophenyl)ethyl]oxalamide and 90 mg (0.5 mmol) of tin(II) chloride were stirred and heated at 85°C in 2 ml of ethanol and 1 ml of 1,4-dioxane for 5 hours. The resulting solution was cooled, diluted with ethyl acetate and washed with 2M sodium hydroxide. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. After trituration with petrol there was obtained 31mg of N-[2-(4-aminophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide as a white solid. MS: m/e 409 [M+H]⁺.

5

N-[2-(4-Benzamidophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide

A mixture of 30 mg (0.074 mmol) of N-[2-(4-aminophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide, 10 mg (0.082 mmol) of benzoic acid, 14 mg (0.092 mmol) of 1-hydroxybenzotriazole hydrate, 21 mg (0.11 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 18 mg (0.16 mmol) of N-ethylmorpholine in 2 ml of dichloromethane was stirred at room temperature for 18 hours then diluted with dichloromethane and washed with 2M hydrochloric acid and saturated sodium bicarbonate. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. There was obtained 9 mg of N-[2-(4-benzamidophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as a white solid. MS: m/e 513 [M+H][†].

20

5

N-[2-(4-Acetamidophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide

A mixture of 30 mg (0.074 mmol) of N-[2-(4-aminophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide, 8 mg (0.078 mmol) of acetic anhydride and 17 mg (0.15 mmol) of N-ethylmorpholine in 1 ml of dichloromethane was stirred at room temperature for 2 hours. The solvent was removed by evaporation and the residue triturated with diethyl ether and collected by filtration to give 14 mg of N-[2-(4-acetamidophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide as a white solid. MS: m/e 451  $[M+H]^{+}$ .

### Example 24

15

20

N2-[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]-N1,3-dimethyl-L-valinamide

290 mg (0.75 mmol) of N-[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]-3-methyl-L-valine methyl ester in 3 ml of methanol and 1 ml of 1M aqueous sodium hydroxide were warmed gently and the resulting solution left at room temperature for 18 hours. The mixture was diluted with water, washed with diethyl ether and the aqueous phase acidified with 2M hydrochloric acid. The solution was extracted with ethyl acetate and the organic phase dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/acetic acid (99:1) for the elution. After trituration with diethyl ether there was obtained 110 mg of N2-[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]-N1,3-dimethyl-L-valinamide as a white solid. MS: m/e 376.0 [M+H]⁺.

## Example 25

10

15

20

### Tert-butyl [3-[[[4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate

In an analogous manner to that described in Example 1 but replacing 3-methoxy-4-(5-oxazolyl)aniline with 4-(5-oxazolyl)aniline and N-tert-butyloxalamic acid with N-[3-[(tert-butoxyformamido)methyl]phenyl]oxamic acid there was obtained tert-butyl [3-[[[4-(5-oxazolyl)anilino] oxalyl]amino]benzyl]carbamate as a white solid. ¹H NMR (400 MHz,

DMSO) δ: 1.4 (9H,s), 4.1 (2H,d), 7.02 (1H,d), 7.32 (1H,t), 7.40 (1H,t), 7.63 (1H,s), 7.69 (1H,d), 7.70-7.79 (3H,m, 7.97 (2H,d), 8.43 (1H,s), 10.82 (1H,s), 10.99 (1H,s).

The starting material was prepared as follows:

- i) 586 mg (4.78 mmol) of methyl oxalyl chloride were added to a solution of 1 g (4.5 mmol) of tert-butyl (3-aminobenzyl)carbamate and 508 mg (5.03 mmol) of triethylamine in 10 ml of dichloromethane. The resulting solution was stirred at room temperature for 30 minutes then washed with 5% citric acid solution and saturated sodium bicarbonate. The organic phase was dried over magnesium sulphate and the solvent removed by evaporation to give 1.5 g of methyl N-[3-[(tert-butoxyformamido)methyl]phenyl]oxamate as a viscous gum. ¹H NMR (400 MHz, CDCl₃) δ: 1.43 (9H,s), 3.96 (3H,s), 4.31 (2H,d) 4.9-5.0 (br.s, 1H), 7.11 (1H,d), 7.33 (1H,t), 7.51 (1H,s), 7.52 (1H,d), 8.86 (br.s. 1H).
- ii) A mixture of 1.232 g (4 mmol) of methyl N-[3-[(tert-butoxy formamido)methyl] phenyl]oxamate and 0.24 g (6 mmol) of sodium hydroxide in 15 ml of methanol/water (2:1) was stirred at room temperature for 2 hours. The solvent was removed by evaporation and the residue dissolved in water and diethyl ether. The aqueous layer was acidified with citric acid and washed twice with ethyl acetate. The combined organic solutions were dried over magnesium sulphate and the solvent removed by evaporation to give 670 mg of N-[3-[(tert-butoxyformamido)methyl] phenyl]oxamic acid as a white solid. ¹H NMR (400 MHz, DMSO) δ: 1.48 (9H,s), 4.17 (2H,d), 7.09 (1H,d), 7.36 (1H,t), 7.49 (1H, t), 7.64 (1H,d), 7.74 (1H,s), 10.75 (1H,s).

5

10

15

### Tert-butyl [2-[[[4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate

In an analogous manner to that described in Example 25 but replacing N-[3-[(tert-butoxyformamido)methyl]phenyl]oxamic acid with N-[2-[tert-butoxyformamido)methyl]phenyl]oxamic acid there was obtained tert-butyl [2-[[[4-(5-oxazolyl)anilino]oxalyl]-amino]benzyl]carbamate as a white solid MS: m/e 437.0  $[M+H]^+$ .

## Example 27

5

10

15

20

### Tert-butyl [4-[[[4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate

In an analogous manner to that described in Example 25 but replacing N-[3-[(tert-butoxyformamido)methyl]phenyl]oxamic acid with N-[4-[tert-butoxyformamido)methyl]phenyl]oxamic acid there was obtained tert-butyl [4-[[[4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate as a white solid. MS: m/e 436.6 [M]⁺.

## N-Tert-butyl-N'-[4-(5-oxazolyl)phenyl]oxalamide

In an analogous manner to that described in Example 1 but replacing 3-methoxy-4-(5-oxazolyl)aniline with 4-(5-oxazolyl)aniline there was obtained N-tert-butyl-N'-[4-(5-oxazolyl)phenyl]oxalamide as a pale yellow solid. MS: m/e 329.0 [M+H+MeCN] '.

#### Example 29

5

10

15

## N-[3-(Aminomethylphenyl]-N'-[4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate

In an analogous manner to that described in Example 3 but replacing tert-butyl [3-[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate with tert-butyl [3-[[4-(5-oxazolyl)oxalyl]amino]benzyl]carbamate there was obtained N-[3-(aminomethylphenyl]-N'-[4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate as a white solid. MS: m/e 336 [M] '.

## **Examples 30-193**

In a manner analogous to that described in Example 1, starting with N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid (prepared as described in Example 1, parts (i) and (ii)) and the appropriate amine the compounds shown in Table 3 were also prepared:

Table 3

Example	Structure	MS(ES)
30.		338.0
31.		362.9
32.		395.0
33.		352.0
34.	X, I, N, I, N, I, N,	466 (M ⁺ ;EI)
35.		352.0
36.		330.0
37.		275.9

	T	
38.		344.0
39.		352.9
40.		261.9
41.		358.9
42.		342.9
43.		341.9
44.		338.9
45.	N-N N N N N N N N N N N N N N N N N N N	327.9
46.		380.0
47.		332.0
48.	+	374.0
49.		362.0

	· · · · · · · · · · · · · · · · · · ·	
50.		317.9
51.		332.0
52.		361.0
53.		389.9
54.		328.0
55.	- North Contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contraction of the contr	346.0
56.		289.9
57.		318.0
58.		304.0
59.	N N N N N N N N N N N N N N N N N N N	333.9
60.	N S O N N N N N N N N N N N N N N N N N	394.0

	<del></del>	
61.		439 (M';EI)
		(101 ,L1)
62.	N N N N N N N N N N N N N N N N N N N	386 (M ⁺ ;EI)
63.		304.0
64.		353.2
65.		360.2
66.		316.2
67.	O. T. N.	412.2
68.		345.8
69.		362.4
70.		334.2
71.	N O O	348.0

72.		340.0
73.	0	345.8
74.		346.0
75.	0 N N N	346.8
76.		395.8
77.	N N N N N N N N N N N N N N N N N N N	332.4
78.		332.4
79.	0,, N, P, N	316.2
80.		344.0
81.	O	317.8
82.		328.2

83.	O N	332.4
84.		334.2
85.	0 0 0	334.2
86.	0 N N N N N N N N N N N N N N N N N N N	339.2
87.		344.8
88.		348.0
89.	O N N N N N N N N N N N N N N N N N N N	359.2
90.		358.2
91.		366.2
92.	0	389.4
93.		306.2

94.		319.8
95.		438.0
96.	0 N	504.2
97.	O O	374.()
98.		299.8
99.	O NOT NOT NOT NOT NOT NOT NOT NOT NOT NO	302.2
100.		316.2
101.		372.0
102.	0 1 0 0	319.8
103.	O	332.4
104.		332.4

105	0.0	
105.	0 . · . N	336.6
106.		342.0
107.	N N N F	308.0
108.		345.8
109.		402.0
110.		405.2
111.		356.0
112.	N N N N N N N N N N N N N N N N N N N	358.2
113.	0 N	358.2
114.		359.2
115.		374.0
116.		372.0

117.		389.2
118.		389.4
119.		276.0
120.	0. N F F	394 (M ⁺ ;EI)
121.	O N	378.4
122.		428 (M ⁺ ;EI)
123.		435.2
124.	0	357.2
125.		358.2
126.	0 N	358.2
127.		360.2
128.		378.4

129.		377.4
130.		378.4
131.	N. O	423
132.		389.4
133.		338.2
134.		363.4
135.	O N N F	356
136.	N N F	370
137.		371.8
138.	O N CI	406.2
139.	N N CI	402.2

140.	0 N N CI	386.2
	N N N CI	
141.	O , ``	406.2
:	N N N N N N N N N N N N N N N N N N N	
142.	N N N N N N N N N N N N N N N N N N N	383.2
143.		384
144.		380.2
145.	O N F F	406.2
146.		366.2
147.		366.2
148.		368.2
149.	N N N N N N N N N N N N N N N N N N N	356
150.	O N N CO	371.8
151.		395

	1	
152.		383.2
153.	N N N N N N N N N N N N N N N N N N N	409.4
154.		380.8
155.		368.2
156.		424.2
157.		354.2
158.		380.2
159.		352.4
160.		377.4
161.		368.2
162.	N N N S	395
163.		457.4

164	
164.	396
165.	424
166.	434.2
167.	395
168.	416.4
169.	417.4
170.	378.4
171.	379.2
172.	405.2
173.	428.8
174.	396

175.	F F F	406.2
176.		406.2
177.		394.2
178.		407
179.		507.2
180.		473.2
181.		451.2
182.		405.2
183.		426
184.		459.2
185.		420.2

186.		409.4
187.	O N N N N N N N N N N N N N N N N N N N	485.4
188.		471.6
189.		487.2
190.		437.2
191.		409.4
192.		445.2
193.		464

### Examples 194-214

In a manner analogous to that described in Example 4, starting with N-[3-(aminomethyl)phenyl]-N'-[3-methoxy-4-(5-(oxazolyl)phenyl]oxalamide trifluoroacetate (prepared as descibed in Example 3) and the appropriate carboxylic acid derivative the compounds shown in Table 5 also were prepared:

7	Гэ	Ь	ما	_
	1 1	. 1. 2	10	

Table 5				
Example	Structure	MS(ES)		
194.		409.1		
	To N			
195.		453.0		
196.		445.0		
197.		481.0		
198.		435.1		
199.		449.1		
200.		451.2		
201.	0	460.0		
202.		461.1		
203.	0, N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N , N ,	461.0		
204.		461.0		

	· · · · · · · · · · · · · · · · · · ·	T
205.		465.1
206.	1	472.1
207.	0 N N	472.0
208.	C N 2 N 1 N 1 N	473.0
209.	0	477.0
210.	0 N N N N N N N N N N N N N N N N N N N	477.0
211.		477.2
212.		477.2
213.		485.1
214.		485.2

### Examples 215 - 301

In a manner analogous to that described in Example 10, starting with N-[2-amino-1,1-dimethylethyl)-N'-(3-methoxy-4-oxazol-5-ylphenyl)oxalamide (prepared as described in Example 9) and the appropriate carboxylic acid the compounds shown in table 4 were also prepared:

<u>Table 4</u>

Example	Structure	MS(ES)
215.	0 N	401.0
216.		415.0
217.	0 N N N N N N N N N N N N N N N N N N N	417.0
218.	O N N N N N N N N N N N N N N N N N N N	426.0
219.		427.0
220.		427.0
221.		431.0
222.		438.0
223.		438.0
224.	N N N N N N N N N N N N N N N N N N N	439.0
225.		443.0
226.		443.0

227.	0	443.1
228.	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	443.1
229.	0 0 N 1 N 1 N 1 N 1 N 1 N 1 N 1 N 1 N 1	451.0
230.	0	451.0
231.		457.1
232.		462.0
233.		482.0
234.	0	428.0
235.	0	429.1
236.		431.0
237.	0 , N , O , N , N , N , N , N , N , N , N	440.0
238.	N N N N N N N N N N N N N N N N N N N	445.0

220		
239.	0 N N N N N N N N.	1550
	F N	455.0
	N 0	
	14	
240.	C , N N	
	C .N N	455.0
	\$4. C	
241.	0	
£41.	0	457.1
	0	437.1
2.12	Ne ^{mil}	
242.	0, ~ N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	0 , ~ , ~ , ~ , ~ , ~ , ~ , ~ , ~ , ~ ,	467.1
	0,, 1,, 2, 0	
	N	
243.	2	
213.	0 N N N N N N N N N N N N N N N N N N N	471.0
		1, 1.0
	•	
214	N	
244.	0 .NN	471.0
	N - 1 - 1 - 1 - 2 - 2 - 2 - 2 - 2 - 2 - 2	471.0
	0	
	n	
245.	0	
	O .N	<b>4</b> 71.0
	0	
	,	
246.		-
	0 · N ·	482.0
	0 0	102.0
247.		
247.	do an Joseph No. Joseph	487.1
		407.1
210	N-	
248.	c .	1761
	6 " N L N N N N N N N N N N N N N N N N N	476.1
	o	
	N°	
249.		
	0 0 N N N.	477.1
	, ,	
	0, 0	
	N -	
250.	0 -	
	6	479.1
	0 N N N N	479.1
250.	e	

251. 479.1  252. 480.1  253. 480.1  254. 480.1  255. 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
252. 480.1  253. 480.1  254. 6
252. 480.1  253. 480.1  254. 6
253. 480.1  254. 431.1  255. 6
253. 480.1  254. 431.1  255. 6
253. 480.1  254. 431.1  255. 6
253. 480.1  254. 6
253. 480.1  254. 6
254.
254.
254.
254.
254.
254.
255.  256.  257.  258.  259.  260.  258.  260.
255.  256.  257.  258.  259.  260.  258.  260.
255.  256.  257.  258.  259.  260.  258.  260.
255.  256.  257.  258.  259.  260.  258.  260.
255.  256.  257.  258.  259.  260.  258.  260.
256.  257.  258.  259.  260.  250.  251.  252.  253.  254.  254.  255.  256.  257.  258.  258.  259.  259.  260.  260.  260.  260.  260.  260.
256.  257.  258.  259.  260.  250.  251.  252.  253.  254.  254.  255.  256.  257.  258.  258.  259.  259.  260.  260.  260.  260.  260.  260.
256.  257.  258.  259.  260.  250.  251.  252.  253.  254.  254.  255.  256.  257.  258.  258.  259.  259.  260.  260.  260.  260.  260.  260.
256.  257.  258.  259.  260.  250.  251.  252.  253.  254.  254.  255.  256.  257.  258.  258.  259.  259.  260.  260.  260.  260.  260.  260.
257.
257.
257.
257.
258. 487.1  259. 505.1
258. 487.1  259. 505.1
258. 487.1  259. 505.1
258. 487.1  259. 505.1
258. 487.1  259. 505.1
259. 505.1  260. N. S. N.
259. 505.1  260. N. S. N.
259. 505.1  260. N. S. N.
259. 505.1  260. N. S. N.
259. 505.1  260. N. S. N.
259. 505.1  260. N. S. N.
260. F 505.1
260. F 505.1
260. 0 1 463.0
260. 0 1 463.0
260. 0 1 463.0
60. N. N. N. N. M.
60. N. N. N. N. M.
O
0 C D
261. O N O N O N O N O N O N O N O N O N O
261. O N O N O N O N O N O N O N O N O N O
261.
467.1
N-
262.
S
$\circ \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad \qquad ^{N} \qquad $
0 0 0

263.	F	
205.	0	473.0
	0 N N N N N N N N N N N N N N N N N N N	
	0 0	
	Ñ-	
264.	N	
	0	391.0
265.	9	
	O	401.0
	0 0	
	N	
266.	N. I. N. L.	
	O O O	405.0
267.	N P	
207.	O N N N N N N N N N N N N N N N N N N N	431.1
	N I	j
268.	N. O	
	N	433.0
	N.J.	
269.		
207.	Land Name of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the	441.0
	0 0	
	N-1	
270.	8 . 5	
		441.0
	N- ^{JJ}	
271.	0 3 N	
		441.0
272.	0 N	-
2,2.	0 N N N N N N N N N N N N N N N N N N N	442.0
	0 0	
	N	
273.	0 N N N.	
		442.0
274.	N-0	
اند / <del>۱</del> ۰		442.0
	o N	112.0
	N-J	
·	· · · · · · · · · · · · · · · · · · ·	

	<u></u>	_
275.	0 N N N N N N N N N N N N N N N N N N N	453.0
276.	0, N,	453.0
277.		453.0
278.		453.0
279.		453.()
280.		454.()
281.		455.()
282.		455.0
283.		455.()
284.	N N S S	457.0
285.	s s	457.0

286.	0	
200.	0 N N N N	457.1
		10,11
207	N-	
287.	0	457.1
		457.1
	0, > 0	·
	N-	
288.	N N N N N N N N N N N N N N N N N N N	
	1 1 1	459.0
	0 0	İ
	N	
289.		
	с .	527.2
	O N N N N	
	0 N. J. N. N. N. N. N. N. N. N. N. N. N. N. N.	
	N-	
290.	8	
		563.0
	· N	
291.	o ~ci	
		487.0
292.		
	-F	494.1
	I I I I I I I I I I I I I I I I I I I	
293.	N O	
293.	i N I N J	494.1
	0 0 0	474.1
294.	N	
221.	ρ . •	497.1
	o	1,,,,
	0	
	Ň-	
295.	9	
	0 N N N N N N N N N N N N N N N N N N N	501.0
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
296.		
	.N.	502.1
	O N N N	
	0 0	
	N-	
L		

297.	505.0
298.	505.0
299.	507.1
300.	462.0
301.	463.1

### Examples 302-315; 438-458 and 653-663

10

15

Typical methods used for the preparation of compounds of table 1c are described below:

### Example 440

## $\underline{N\text{-}[3\text{-}Methoxy\text{-}4\text{-}(5\text{-}oxazolyl)phenyl]\text{-}N'\text{-}[1,1\text{-}dimethyl\text{-}2\text{-}(1\text{-}oxido\text{-}4\text{-}pyridyl)ethyl]}oxalamide}$

30 mg (0.1 mmol) of 60% 3-chloroperoxybenzoic acid were added to a stirred solution of 20 mg (0.051 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-pyridyl)ethyl]oxalamide in 1 ml of dichloromethane. The mixture was stirred for 1 hour then diluted with ethyl acetate, washed with sodium bisulphite solution, sodium bicarbonate solution and brine. The organic solution was dried over magnesium sulphate, evaporated to dryness and the residue triturated with diethyl ether to give 13 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-oxido-4-pyridyl)ethyl]oxalamide as an off-white solid. MS: m/e 411 [M+H][†].

### The starting material was prepared as follows:

- i) A solution of 17.4 g (0.115 mol) of alpha, alpha-dimethyl-4-pyridineethanol in 115 ml of acetic acid was added dropwise to a mixture of 115 ml of acetic acid, 58 ml of concentrated sulphuric acid and 6.8 ml (0.126 mmol) of acetonitrile with cooling in an ice/salt bath. The resulting mixture was stirred for 2 hours at room temperature and the pH raised to 10 by the addition of 6M sodium hydroxide solution with ice cooling. The slurry was filtered, washed with ethyl acetate and the aqueous filtrate extracted twice with ethyl acetate. The combined organic extracts were dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/methanol (1:19), (1:9) and (3:17) for the gradient elution. There was obtained 1.87 g of N-[1,1-dimethyl-2-(4-pyridyl)ethyl]acetamide as an orange oil. ¹H NMR (400 MHz CDCl₃) δ: 1.29 (6H,s), 1.91 (3H,s), 3.11 (2H,s), 5.10 (1H,br.s.), 7.07 (2H,d), 8.50(2H,d).
- 15 ii) A solution of 1.8 g (9.3 mmol) of N-[1,1-dimethyl-2-(4-pyridyl)ethyl]acetamide, 2.66 g (9.3 mmol) of titanium (IV) isopropoxide and 2.56 g (14 mmol) of diphenylsilane in 10 ml of tetrahydrofuran was stirred at room temperature for 20 hours. The resulting mixture was chromatographed on silica gel using dichloromethane/methanol/acetic acid/water (60:18:2:3) for the elution. The product was dissolved in 20 ml of concentrated hydrochloric acid and 50 ml of methanol and evaporated to dryness. The residue was evaporated with toluene five times to give 620 mg of alpha, alpha-dimethyl-4-pyridineethylamine hydrochloride (1:1), as a pale brown solid. ¹H NMR (400 MHz DMSO) δ: 1.31 (6H,s), 3.26 (2H,s), 8.02 (2H,d), 8.4-8.6 (3H,br.s), 8.88 (2H,d).
- iii) A mixture of 100 mg (0.45 mmol) of alpha, alpha-dimethyl-4-pyridineethylamine hydrochloride (1:1), 120 mg (0.45 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 105 mg (0.68 mmol) of 1-hydroxybenzotriazole hydrate, 105 mg (0.54 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 127 mg (1.1 mmol) of N-ethylmorpholine in 4 ml of dichloromethane was stirred for 20 hours at room temperature then diluted with ethyl acetate and washed with water and brine. The organic solution was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/methanol (19:1) for the elution. After trituration with diethyl ether there was obtained 32 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-

pyridyl)ethyl]oxalamide as a white solid. MS: m/e 395 [M+H].

10

15

20

25

### Example 455

2-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylic acid

A solution of 68 mg (0.12 mmol) of benzyl 2-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylate in 10 ml of tetrahydrofuran was hydrogenated with 20 mg of 10% palladium on carbon for 4 hours. The resulting suspension was filtered , evaporated to dryness and the residue triturated with diethyl ether to give 41 mg of 2-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylic acid as a white solid. MS: m/e 477.9 [M+H] † .

The starting material was prepared as follows:

A solution of 1.976 g (22.46 mmol) of isobutyric acid in 8 ml of anhydrous itetrahydrofuran was added to a stirred suspension of 1.078 g (26.95 mmol) of 60% sodium hydride and 2.268 g (22.46 mmol) of diisopropylamine in in 40 ml of anhydrous tetrahydrofuran under a nitrogen atmosphere and the mixture heated to reflux for 15 minutes. After cooling to 0°C a solution of 14.04 ml (22.46 mmol) of 1.6M butyllithium in hexanes was added maintaining the temperature at 0-5°C. After 5 minutes at 0°C the mixture was warmed to 30-35°C for 20 minutes, cooled to 0°C and a solution of 5.3 g (22.46 mmol) of 2-(bromomethyl)-5-benzofurancarbonitrile in 15 ml of anhydrous tetrahydrofuran was added maintaining the temperature at 0°C. The suspension was stirred for 5 minutes at 0°C then warmed to 30-35°C for 20 minutes before being cooled to 15°C and quenched by the careful addition of 50 ml of water and diluted with 50 ml of diethyl ether. The aqueous phase was separated, acidified with concentrated hydrochloric acid and extracted with diethyl ether. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (1:2) for the elution. There was obtained 670 mg of 5-cyano-alpha, alpha-dimethyl-2-benzofuranpropionic acid as a white

solid.  1 H NMR (400 MHz CDCl₃)  $\delta$ : 1.23 (6H,s), 3.01 (2H,s), 6.46 (1H,s), 7.38 (1H,d), 7.42 (1H,d), 7.75 (1H,s).

ii) A mixture of 652 mg (2.68 mmol) of 5-cyano-alpha, alpha-dimethyl-2benzofuranpropionic acid, 732 mg (2.68 mmol) of diphenylphosphoryl azide and 269 mg (2.66 mmol) of triethylamine in 8 ml of tert-butanol was refluxed for 8 hours then evaporated to dryness and the residue dissolved in ethyl acetate and washed with saturated sodium bicarbonate solution. The organic phase was dried over magnesium sulphate, evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (2:3) for the elution to give 225 mg of white solid which was suspended in 10 ml of 2M sodium hydroxide solution and stirred and refluxed for 20 hours. The resulting suspension was cooled, evaporated to dryness and 5 ml of ethylene glycol and 400 mg of potassium hydroxide were added. After heating at 190°C for 20 minutes 2 ml of water were added and after a further 20 minutes another 15 ml of water were added and heating continued for 20 minutes until a thick paste remained which was cooled and dissolved in 20 ml of water. Concentrated hydrochloric acid was added to bring the pH to 2 then 25 ml of dioxan, 3 g (21.74 mmol) of potassium carbonate and 1.5 g (6.88 mmol) of di-tert-butyl dicarbonate were added and the mixture stirred for 24 hours. The solvent was removed by evaporation and the residue dissolved in diethyl ether and water. The aqueous phase was separated, acidified with 2M hydrochloric acid and extracted with diethyl ether. The organic phase was dried over magnesium sulphate and evaporated to dryness to give 106 mg of 2-[2-(tert-butoxyformamido)-2-methylpropyl]-5benzofurancarboxylic acid as a colourless gum.

10

15

iii) A mixture of 105 mg (0.32 mmol) of 2-[2-(tert-butoxyformamido)-2-methylpropyl]5-benzofurancarboxylic acid, 80 mg (0.53 mmol) of benzyl bromide, and 200 mg (1.45 mmol) of potassium carbonate in 4 ml of dimethylformamide was stirred at room temperature for 1 hour then diluted with diethyl ether and water. The organic phase was washed twice with water, dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (1:5) for the elution. There was obtained 104 mg of benzyl 2-[2-(tert-butoxyformamido)-2-methylpropyl]-5-benzofurancarboxylate as a colourless gum. ¹H NMR (400 MHz CDCl₃) δ: 1.39 (6H,s), 1.50 (9H,s), 3.23 (2H,s), 4.49 (1H,s), 5.41 (2H,s), 6.52 (1H,s), 7.34-7.52 (6H,m), 8.02 (1H,d), 8.30 (1H,s).

iv) 103 mg (0.24 mmol) of benzyl 2-[2-(tert-butoxyformamido)-2-methylpropyl]-5-benzofurancarboxylate were dissolved in 5 ml of trifluoroacetic acid/dichloromethane (1:1) for 10 minutes then evaporated to dryness and the residue dissolved in 1 ml of dimethylformamide and added to a stirred solution of 66 mg (0.25 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 115 mg (1 mmol) of N-ethylmorpholine, 45 mg (0.29 mmol) of 1-hydroxybenzotriazole hydrate and 70 mg (0.37 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in 2 ml of dimethylformamide and the resulting mixture stirred at room temperature for 18 hours. After dilution with ethyl acetate the organic solution was washed with 2M hydrochloric acid, saturated sodium bicarbonate solution and water, dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (45:55) for the elution. After trituration with diethyl ether there was obtained 81 mg of benzyl 2-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylate as a white solid. MS m/e 568 [M+H]⁺.

#### Example 443

2-[3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl)]amino]-2-methylpropyl]phenoxy]acetic acid

A solution of 45 mg (0.081 mmol) of benzyl 2-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetate in 5 ml of ethanol/tetrahydrofuran (1:1) was hydrogenated with 4 mg of 10% palladium on carbon catalyst for 5 hours. The resulting suspension was filtered, evaporated to dryness and triturated with diethyl ether to give 29 mg of 2-[3-[2-[[[3-methoxy-4-(5-oxazolyl)amino]-2-methylpropyl]phenoxy]acetic acid as a white solid. MS: m/e 468 [M+H]⁺.

The starting material was prepared as follows:

10

15

20

30

i) 8 mg (0.2 mmol) of 60% sodium hydride were added to a stirred solution of 85 mg (0.2 mmol) of N-[2-(3-hydroxyphenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide in 1 ml of dimethylformamide. After 10 minutes 55 mg (0.24

mmol) of benzyl bromoacetate were added and the mixture stirred at room temperature for 4 hours. The resulting solution was diluted with ethyl acetate, washed twice with water, dried over magnesium sulphate and evaporated to dryness. The residue was chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. There was obtained 51 mg of benzyl 2-[3-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetate as a white solid. MS: m/e 558 [M+H][†].

In a manner analogous to that described in Example 1, starting with N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid, prepared as described in Example 1, parts (i) and (ii), and the appropriate amine, additional compounds shown in table 1c were also prepared.

table 1c

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-Methoxy-4-(5- oxazolyl)phenyl]-N'-[1,1-dimethyl- 2-(4- methylphenyl)ethyl]oxalamide	N = 10 1	408	302
N-[1,1-Dimethyl-2-(2- methylphenyl)ethyl]-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide	N TC : CH3	408	303
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(3-pyridyl)ethyl]oxalamide	N OHC CH	395	304
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(3-methylphenyl)ethyl]oxalamide	N TO STAN	408	305
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(2-thienyl)ethyl]oxalamide	N CHY CH TO	400	306
N-[2-(4-Benzyloxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	Mark Cont.	500	307
N-[2-(4-Hydroxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	My C ON THE ON	410	308

N-(3-Methoxy-4-oxazol-5-yl-phenyl)-N'-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethyl]-oxalamide	0,5H,	424	309
N-[2-(2-Hydroxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	OH OH OH	410	310
N-(1,1-Dimethyl-2-phenyl- propyl)-N'-(3-methoxy-4-oxazol- 5-yl-phenyl)-oxalamide	O H	408	311
N-[2-(3-Hydroxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	713 N	410	312
N-(3-Methoxy-4-oxazol-5-yl-phenyl)-N'-[2-(3-methoxy-phenyl)-1,1-dimethyl-ethyl]-oxalamide	N S O S O S O S O S O S O S O S O S O S	424	313
N-[2-[4-(Cyanomethoxy)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	N Service ON N Service N	449	314
2-[4-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetic acid	N	468	315
2-[2-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetic acid	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	468	438
2-[3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetic acid	No. The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of t	468	439
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-oxido-4-pyridyl)ethyl]oxalamide	N N N N N N N N N N N N N N N N N N N	411	440
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-oxido-3-pyridyl)ethyl]oxalamide	N	411	441
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-oxido-2-pyridyl)ethyl]oxalamide	N O O OHS NO NO O NO O O O O O O O O O O O O O O	411	442

2-[3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl)]amino]-2-methylpropyl]phenoxy]acetic acid	N	468	443
N-[2-(2-Benzofuranyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N	434	-1-14
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(3-methyl-2-benzofuranyl)ethyl]oxalamide	N. S. S. S. S. S. S. S. S. S. S. S. S. S.	448	445
N-[2-(7-Methoxy-2-benzofuranyl)- 1,1-dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	N S N S N S N S N S N S N S N S N S N S	464	446
N-[2-(5-Methoxy-2-benzofuranyl)- 1,1-dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	N. S. C. C. S. C. C. C. C. C. C. C. C. C. C. C. C. C.	464	447
N-[2-(6-Methoxy-2-benzofuranyl)- 1,1-dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	N CH	464	448
Benzyl 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoate		528	449
4-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoic acid	H . A . A . B	438	450
Benzyl 3-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoate	CH, 14	528	451
3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoic acid	N O O'H	438	452
N-[2-(3-Benzofuranyl)-1,1- dimethylethyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	N O O CH N O N O CH CHC CH O	434	453
Benzyl 2-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylate	With an in the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the sam	568	454

2-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylic acid	The contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract o	477.9	455
N-[3-Methoxy-4-(5- oxazolylphenyl]-N'-[1-[(4- pyridyl)methyl]-1- cyclopentyl]oxalamide	1 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 -	421	456
N-[3-Methoxy-4-(5- oxazolyl)phenyl]-N'-[1-[(1-oxido- 4-pyridyl)methyl]-1- cyclopentyl]oxalamide	N	437	457
N-[2-(4-Methoxy-2-benzofuranyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	M	464	458
N'-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[2-(2,6-dimethyl-4- pyridyl)-1,1-dimethylethyl] oxalamide	HC 2	423.22	653
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(2,6-dimethyl-1-oxido-4-pyridyl)ethyl]oxalamide	N-O	439.3	654
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(4-pyridyl)methyl]- 1-cyclopropyl]oxalamide		393	655
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(1-oxido-4- pyridyl)methyl]-1- cyclopropyl]oxalamide		409	656
N-[3-Methoxy-4-(5-oxazolyl) phenyl -N'-[1-[(4-pyridyl)methyl]- 1-cyclobutyl]oxalamide		407	657
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(1-oxido-4- pyridyl)methyl]-1-cyclobutyl] oxalamide		421	658
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(4-pyridyl)methyl]- 1-cyclohexyl]oxalamide		435	659

N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(1-oxido-4- pyridyl)methyl]-1- cyclohexyl]oxalamide		451	660
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(2-methyl-4-pyridyl)ethyl]oxalamide		409	661
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(2-methyl-1-oxido-4- pyridyl)ethyl]oxalamide		425	662
2-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzothiophenecarboxylic acid	N Q N N N S N N OH	494	663

## Examples 316-330:

In a manner analogous to that described in Example 11 starting with N-[2-(4-aminophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide, prepared as described in example 21, and the appropriate aldehyde compounds shown in table 1d were also prepared.

table 1d

Name	Structure	$MS(ES)$ $(M+H)^+$	Ex No
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(2- pyridinyl)methylamino]phenyl]ethyl]oxala mide		500.1	316
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(3- pyridyl)methylamino]phenyl]ethyl]oxalam ide	CH. 24. 1.	500.1	317
N-[2-[4-(2-Furfurylamino)phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	CH	489.1	318
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-Dimethyl-2-[4-(2- thenylamino)phenyl]ethyl]oxalamide		505.1	319
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-(2,2-dimethylpropylamino)phenyl]ethyl]oxalam	0 N	479.2	320

ide			
N-[2-[4-[(1H-Imidazol-2-yl)methylamino]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	CH CHE CH, CHE CH	489.1	321
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(4- pyridyl)methylamino]phenyl]ethyl]oxalam ide	CH O HC 24	500.1	322
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(2- thiazolyl)methylamino]phenyl]ethyl]oxala mide	C. )	506.1	323
N-[2-[4-(3-Furfurylamino)phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	3 h. 3h. 2h. 2h. 2h. 2h. 2h. 2h. 2h. 2h. 2h. 2	489.1	324
N-[2-[4-[5-(Hydroxymethyl)-2- furfurylamino]phenyl]-1,1-dimethylethyl]- N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		519.1	325
N-[2-(4-Benzylaminophenyl)-1,1- dimethylethyl]-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		499.1	326
N-[2-[4-(2-Hydroxybenzylamino)phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	O	515.1	327
N-[2-[4-(3-Cyanobenzylamino)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		524.1	328
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[4-(3-pyridyl)benzylamino]phenyl]ethyl]oxalami de	Sugar Con	576.2	329
N-[2-[4-(2-Fluorobenzylamino)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	H; OH; M; ONL, C; F	517.1	330

### Examples 331-395 and 596-597:

In a manner analogous to that described in Example 22 starting from N-[2-(4-aminophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide, prepared as described in

example 21, and the appropriate carboxylic acid compounds shown in table 1e were also prepared.

Table 1e

Name	Structure	MS(ES) (M+H)	Ex No
N-[2-[4- (Cyclopropylcarboxamido)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	CH CH: H C	477.1	331
N-[2-[4-(Cyclobutylcarboxamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl oxalamide	CH CHC ST	491.1	332
N-{3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-(4- pivalamidophenyl)-1,1- dimethylethyl]oxalamide	CH 2H: 2H: 2H 2H 2H 2H 2H 2H 2H 2H 2H 2H 2H 2H 2H	493.1	333
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(1H-pyrrol- 2-yl)carboxamido]phenyl]ethyl] oxalamide	5 N N N S	502.1	334
N-[2-[4-[(2-Furyl) carboxamido]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	He M. M. A.	503.1	335
N-[2-[4-[(3-Furyl) carboxamido]phenyl]-1,1- dimethylethyl]-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	0 M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M	503.1	336
N-[2-[4-[(1H-Imidazol-4-yl) carboxamido]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	GH. SHE SHE ST.	503.1	337
N-[2-[4-[(Tetrahydro-2(RS)-furyl) carboxamido]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		507.2	338
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[4-[(2- pyridyl)carboxamido]phenyl]ethyl]ox alamide	0 N N C	514.1	339
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4-pyridyl) carboxamido]phenyl]ethyl]oxalamide		514.1	340

	1		
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(2-thienyl)	CH CHC CH	519.1	341
carboxamido phenyl ethyl oxalamide		319.1	341
carooxamidojphenyijetnyijoxaramide	en che si, in che		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N-[1,1-dimethyl-2-[4-[(3-thienyl)		519.1	342
carboxamido]phenyl]ethyl]oxalamide			
N [2 [4 /2 C - 1 1 + 1 - ]	No come		
N-[2-[4-(2-Cyclopentylacetamido) phenyl]-1,1-dimethylethyl]-N'-[3-	ON OH-19	519.2	343
methoxy-4-(5-oxazolyl)phenyl]	<i>→</i> .	319.2	3.43
oxalamide	N-		İ
N-[3-Methoxy-4-(5-oxazolyl) phenyl]			
-N'-[1,1-dimethyl-2-[4-(2-	Gr. H ₁ 3\ 0 N ₁ N ₂ N ₃	527.2	344
methylbenzamido)phenyl]ethyl]oxala	O N	327.2	311
mide	N-		İ
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	- он,		
-N'-[1,1-dimethyl-2-[4-(4-	OF HIGH	527.2	345
methylbenzamido)phenyl]ethyl]oxala			
mide	<i>i⊎</i>		
N-[2-[4-(Cycloheptylcarboxamido)			
phenyl]-1,1-dimethylethyl]-N'-[3-	OL NEW TO TO	533.2	346
methoxy-4-(5-oxazolyl)phenyl]			
oxalamide	٠		
N-[2-[4-[(5-Isoxazolyl) carboxamido]	(h, h, h, s)		
phenyl]-1,1-dimethylethyl]-N'-[3-	N	504.1	347
methoxy-4-(5-oxazolyl)phenyl]	l a i		
oxalamide	-		
N-[2-[4-(Cyclopentylcarboxamido)	Sharp the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of	505.2	2.40
phenyl]-1,1-dimethylethyl]-N'-[3-	N. I.	505.2	348
methoxy-4-(5-oxazolyl)phenyl]			
oxalamide			
N-[2-{4-[(Tetrahydro-3(RS)-furyl)	Con. Che St.	507.1	2 10
carboxamido]phenyl]-1,1-   dimethylethyl]-N'-[3-methoxy-4-(5-	0	507.1	349
oxazolyl)phenyl]oxalamide	,		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N'-[1,1-dimethyl-2-[4-[(1-methyl-	CIL CIL CH . 131	516.1	350
1H-pyrrol-2-yl)carboxamido]phenyl]		310.1	330
ethyl]oxalamide	0		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	N≅N .N		
-N'-(1,1-dimethyl-2-[4-[(1,2,3-	CH, CH, M	521.1	351
thiadiazol-4-yl)carboxamido]phenyl]	0		
ethyl]oxalamide	•		
N [2 [1 (2 Elyapah anganida) hll	~		
N-[2-[4-(3-Fluorobenzamido)phenyl]	or ne	5311	352
-1,1-dimethylethyl]-N'-[3-methoxy-   4-(5-oxazolyl)phenyl]oxalamide	C. M. C. C.	531.1	332
4-(3-0xaz0iyi)pilenyi]0xalamide	0		
L	1		

N-[2-[4-(4-Fluorobenzamido)phenyl]	~ ·		
-1,1-dimethylethyl]-N'-[3-methoxy-	2 ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	531.1	353
4-(5-oxazolyl)phenyl]oxalamide	.0.		
- (2	N=		
N-[2-[4-(2-			
Methoxybenzamido)phenyl]-1,1-	N ON THE STATE OF	543.2	354
dimethylethyl]-N'-[3-methoxy-4-(5-	(a)		
oxazolyl)phenyl]oxalamide	N-		
N-[2-[4-(2-Chlorobenzamido)			
phenyl]-1,1-dimethylethyl]-N'-[3-	H, CH H, M-1-N-1-N-1-N-1-N-1-N-1-N-1-N-1-N-1-N-1-	547.1	355
methoxy-4-(5-oxazolyl)phenyl]	,o.,	J 1, . 1	
oxalamide	N		
N-[2-[4-(3-Chlorobenzamido)			
phenyl]-1,1-dimethylethyl]-N'-[3-	on, say, n	547.1	356
methoxy-4-(5-oxazolyl)phenyl]	On Section 1	J4/.1	550
oxalamide	.0. N=		
N-[2-[4-(4-Chlorobenzamido)		5 1 7 1	257
phenyl]-1,1-dimethylethyl]-N'-[3-	The second second	547.1	357
methoxy-4-(5-oxazolyl)phenyl]	0		
oxalamide	· ·		
N-[2-[4-[(1H-Indol-2-yl)	an men Y		
carboxamido]phenyl]-1,1-	ON HE COLL TO	552.1	358
dimethylethyl]-N'-[3-methoxy-4-(5-	",1"		
oxazolyl)phenyl]oxalamide	N- ^f		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	, a		
-N'-[1,1-dimethyl-2-[4-[4-	2 3 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	556.1	359
(dimethylamino)benzamido]phenyl]e			
thyl]oxalamide	v-		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	0. N 104 H5H		
-N'-[1,1-dimethyl-2-[4-(3,3-		507.1	360
dimethylbutyramido)]phenyl]ethyl]o	N-		
xalamide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	CM District Charles Inch		
-N'-[1,1-dimethyl-2-[4-[2-(1-	O. J.	519.1	361
tetrazolyl)acetamido]phenyl]ethyl]ox	N=		
alamide			!
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	c Chiral		
-N'-[1,1-dimethyl-2-[4-[(5-oxo-2(S)-		520.1	362
pyrrolidinyl)carboxamido]phenyl]eth		220.1	
yl oxalamide	<b>*</b>		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	j* Chiral		
		520.1	363
-N'-(1,1-dimethyl-2-{4-[(5-oxo-2(R)-	a	J20.1	303
pyrrolidinyl)carboxamido]phenyl]eth	· •		
yl]oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	, , , , , , , , , , , , , , , , , , ,	5(2.1	254
-N'-[1,1-dimethyl-2-[4-[(2-	N	563.1	364
naphthyl)carboxamido]phenyl]ethyl]	0. 0		
oxalamide	"		

N-[2-{4-[(6-Cyano-3-pyridyl)	A. 11		
carboxamido]phenyl}-1,1-	ch che	580.1	365
dimethylethyl]-N'-[3-methoxy-4-(5-	,	(M+H+	
oxazolyl)phenyl]oxalamide	N	ACN)	
N-[2-[4-(3-Methoxybenzamido)			
phenyl]-1,1-dimethylethyl]-N'-[3-		543.1	366
methoxy-4-(5-oxazolyl)phenyl]	~ '		:
oxalamide	\$		
N-[2-[4-(3,5-Difluorobenzamido)			
phenyl]-1,1-dimethylethyl]-N'-[3-		549.1	367
methoxy-4-(5-oxazolyl)phenyl]	To Year		
oxalamide			
N-[2-[4-[(1H-Indol-5-yl)	· N		
carboxamido]phenyl]-1,1-	Con the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of th	552.1	368
dimethylethyl]-N'-[3-methoxy-4-(5-	,0		
oxazolyl)phenyl]oxalamide	Dec. 1   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   Dec. 2   D		
(E)-N-[2-[4-(2-Butenamido)phenyl]-	IN THE SECOND STATE SECOND		
1,1-dimethylethyl]-N'-[3-methoxy-4-	N N	477.1	369
(5-oxazolyl)phenyl]oxalamide	N-1		
N-[2-[4-(2-Methoxyacetamido)	Physical State of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the		
phenyl]-1,1-dimethylethyl]-N'-[3-		481.2	370
methoxy-4-(5-oxazolyl)phenyl]			
oxalamide			
N-[3-methoxy-4-(5-oxazolyl)phenyl]-	: 0		
N'-[1,1-dimethyl-2-[4-[(2-methyl-3-	Section 1997	517.1	371
furyl)carboxamido]phenyl]ethyl]oxal			
amide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	N-1		
-N'-[1,1-dimethyl-2-[4-[(5-methyl-4-	, , , , , , , , , , , , , , , , , , ,	518.1	372
isoxazolyl)carboxamido]phenyl]ethyl]			
oxalamide	N-L		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N'-[1,1-dimethyl-2-[4-[(3-methyl-4-	LHI 31	518.1	373
isoxazolyl)carboxamido]phenyl]ethyl]			
oxalamide	N		İ
N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N'-[1,1-dimethyl-2-[4-[(5-methyl-3-	THE CASE AND A SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND S	518.1	374
isoxazolyl)carboxamido phenyl ethyl	\$\frac{1}{2}\cdot \cdot		
oxalamide			 
N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N-[1,1-dimethyl-2-[4-[(1-oxido-3-	G 6- 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	530.1	375
pyridyl)carboxamido]phenyl]ethyl]ox	C	550.1	3/3
alamide	,3		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N'-[1,1-dimethyl-2-[4-[(1-oxido-4-	6 1 N H 1 N 1 1 3	530.1	376
pyridyl)carboxamido]phenyl]ethyl]ox	ا ا		
alamide			
L	1		

N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4,5-dimethyl-2-furyl)carboxamido] phenyl]ethyl]oxalamide		531.1	377
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(2,5-dimethyl-2H-pyrazol-3-yl) carboxamido]phenyl]-1,1- dimethylethyl]oxalamide		531.1	378
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(3-methyl-2-thienyl)carboxamido]phenyl]ethyl]ox alamide	S 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	533.1	379
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[2-(3-thienyl)acetamido]phenyl]ethyl]oxala mide	S S	533.1	380
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4-methyl-2-thienyl)carboxamido]phenyl]ethyl]ox alamide		533.1	381
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4-methyl-1,2,3-thiadiazol-5-yl)carboxamido]phenyl]ethyl]oxalamide	SHI THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF T	535	382
N-[2-[4-(4-Acetamidobenzamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		570.1	383
N-[2-[4-(3,4-Dimethoxybenzamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		573.1	384
N-[2-[4-(4-Chloro-2-methoxybenzamido)phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	ON LINE LINE SON	578.2	385
N-[2-[4-(2,6-Dichlorobenzamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	N N CO	581	386
N-[2-[4-[(Bicyclo[4.2.0]octa-1(6),2,4-triene-7(RS)-yl)carboxamido] phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	n	539.1	387

N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N'-[1,1-dimethyl-2-[4-(2-oxo-2-	OH OH IN TO S	541.1	388
phenylacetamido)phenyl]ethyl]oxala	.0	2 1 1 / 2	• 0 0
mide	N		
N-[2-{4-[2-(2-Fluorophenyl)	• 20. 0		
acetamido]phenyl}-1,1-	0. 3H 4 **********************************	545	389
dimethylethyl]-N'-[3-methoxy-4-(5-	o - •≠		
oxazolyl)phenyl]oxalamide			
N-[2-{4-[2-(4-Fluorophenyl)			
acetamido phenyl}-1,1-	°	545	39()
dimethylethyl)-N'-[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	g. ,	- 40	200
-N-[2-{4-[(4-methoxy-3-thienyl)	0, 2,	549	391
carboxamido]phenyl}-1,1-	, · · · ·		
dimethylethyl]oxalamide			
N-[2-[4-(4-Acetylbenzamido)			200
phenyl]-1,1-dimethylethyl]-N'-[3-	8) 100 A S	555.1	392
methoxy-4-(5-oxazolyl)phenyl]	° 77		
oxalamide			
N-[2-[4-[(1,3-Benzodioxol-5-yl)			
carboxamido]phenyl]-1,1-		557.1	393
dimethylethyl]-N'-[3-methoxy-4-(5-	٠. · · · · · · · · · · · · · · · · · · ·		
oxazolyl)phenyl]oxalamide	GI GI		
N-[2-[4-[2-(2-Chlorophenyl) acetamido]phenyl]-1,1-	9 3 4 4 5 A 5 A 5 A 5 A 5 A 5 A 5 A 5 A 5 A	561.1	394
dimethylethyl]-N'-[3-methoxy-4-(5-		301.1	334
oxazolyl)phenyl]oxalamide	"And"		
N-[2-[4-[2-(4-Chlorophenyl)	Programme and the second		
acetamido phenyl]-1,1-	9 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	561.1	395
dimethylethyl]-N'-[3-methoxy-4-(5-	· N. J.		
oxazolyl)phenyl]oxalamide			
tert-Butyl 4-[[4-[2-[[[3-methoxy-4-			
(5-oxazolyl)anilino]oxalyl]amino]-2-		613	596
methylpropyl]phenyl]carbamoyl)benz			
oate			
4-[[4-[2-[[[3-Methoxy-4-(5-oxazolyl)			
anilino]oxalyl]amino]-2-	Cr. 11, 14, 17, 17	557	597
methylpropyl]phenyl]carbamoyl]benz	3 3		
oic acid	N		

# Examples 396-406; 433-437; 542-595 and 635-650

Typical methods used for the preparation of the compounds of tables 1f⁴, 1f²and 1f³ are described below:

### Example 398.

### N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-nitrophenoxy)propyl]oxalamide

5 (i) A mixture of 0.5g (3.94 mmol) of 2,4,4-trimethyl-5,6-dihydro-1,3(4H)oxazine and 0.5g (3.6 mmol) of 4-nitrophenol were heated at 180C under a nitrogen atmosphere for 6 hours. The resulting mixture was cooled and purified by chromatography on silica gel using ethyl acetate for the elution. There was obtained 524 mg of N-[1,1-dimethyl-3-(4-nitrophenoxy)propyl]acetamide.

10

15

20

(ii) 693 mg (2.61 mmol) of N-[1,1-dimeyhyl-3-(4-nitrophenoxy)propyl]acetamide, 815 mg(2.87 mmol) of titanium isopropoxide and 719 mg (3.91mmol) of diphenylsilane were dissolved in 8 ml of tetrahydrofuran and left at room temperature for 18 hours. The resulting solution was dissolved in ethyl acetate and saturated sodium bicarbonate solution, filtered and the organic phase extracted twice with 2M hydrochloric acid. The combined acid extracts were basified with 2M sodium hydroxide solution, extracted with ethyl acetate and the organic extracts dried over magnesium sulphate, filtered and evaporated to dryness to give 266 mg of 1,1-dimethyl-3-(4-nitrophenoxy)propylamine. The 1,1-dimethyl-3-(4-nitrophenoxy)propylamine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid by a procedure analogous to that described in example 1 to give N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-nitrophenoxy)propyl]oxalamide as a pale yellow solid. MS: m/e 469 [M+H]⁺.

#### Example 433

25

#### 4-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid.

A solution of 650 mg (1.17 mmol) of benzyl 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate in 20 ml of tetrahydrofuran was hydrogenated with 65 mg of 10% palladium on charcoal catalyst for 48 hours, a further 65 mg of catalyst being added after 24 hours and again after 44 hours. The resulting suspension was filtered, evaporated to dryness and the residue triturated with diethyl ether to give 415 mg of 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid as a

white solid. MS: m/e 468  $[M+H]^+$ .

20

25

30

#### The starting material was prepared as follows:

- A mixture of 1.14 g (5 mmol) of benzyl 4-hydroxybenzoate and 800 mg (6.3 mmol) of 2,4,4-trimethyl-5,6-dihydro-1,3(4H)-oxazine was stirred and heated at 180°C for 3 hours. A further 600 mg (4.72 mmol) of oxazine were added and heating was continued for 21 hours. The resulting mixture was cooled and chromatographed on silica gel using ethyl acetate/petrol (3:1) for the elution. There was obtained 1.52 g of benzyl 4-(3-acetamido-3-methylbutoxy) benzoate as a white solid. ¹H NMR (400 MHz CDCl₃) δ: 1.43 (6H,s), 1.94 (3H,s), 2.26 (2H,t), 4.14 (2H,t), 5.36 (2H,s), 5.65 (1H,s), 6.91 (2H,d), 7.35-7.52 (5H,m), 8.05 (2H,d).
  - ii) A solution of 1.5 g (4.23 mmol) of benzyl 4-(3-acetamido-3-methylbutoxy) benzoate, 1.166 g (6.35 mmol) of diphenylsilane and 1.2 g (4.23 mmol) of titanium(IV) isopropoxide in 4 ml of tetrahydrofuran was stirred at room temperature for 6 hours. The resulting mixture was diluted with diethyl ether/2M sodium hydroxide solution, filtered and the organic phase extracted twice with 2M hydrochloric acid. The combined aqueous extracts were basified with 2M sodium hydroxide solution and extracted with ether. The organic extract was dried over magnesium sulphate and evaporated to dryness to give 1.16 g of benzyl 4-(3-amino-3-methylbutoxy) benzoate as a pale coloured gum. ¹H NMR (400 MHz CDCl₃) δ: 1.22 (6H,s), 1.92 (2H,t), 4.08 (2H,t), 5.36 (2H,s), 6.90 (2H,d), 7.33-7.48 (5H,m), 8.05 (2H,d).
  - iii) A solution of 873 mg (3.33 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 500 mg (3.27 mmol) of 1-hydroxybenzotriazole hydrate, 1.2 g (3.83 mmol) of benzyl 4-(3-amino-3-methylbutoxy) benzoate and 1 g (5.22 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in 10 ml of dimethylformamide was stirred at room temperature for 24 hours. The resulting mixture was diluted with ethyl acetate and washed with 2M hydrochloric acid, saturated sodium bicarbonate solution and water then dried over magnesium sulphate, evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. After trituration with diethyl ether there was obtained 765 mg of benzyl 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate as a white solid. MS: m/e 558 [M+H][†].

#### Example 434

2-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid.

In an analogous manner to that described in Example 433 but replacing benzyl 4-[3- $[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate with benzyl 2-[3-<math>[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate there was obtained 2-[3-<math>[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid as a white solid. MS: m/e 468 <math>[M+H]^{+}$ .

### The starting material was prepared as follows:

5

1()

- i) A solution of 917 mg (3.5 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 650 mg (4.66 mmol) of 3-amino-3-methyl-1-butanol hydrochloride (1:1), 612 mg (4 mmol) of 1-hydroxybenzotriazole hydrate, 690 mg (6 mmol) of N-ethylmorpholine and 960 mg (5 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in 10 ml of dimethylformamide was stirred at room temperature for 20 hrs. The resulting mixture was diluted with ethyl acetate and washed with 2M hydrochloric acid, saturated sodium bicarbonate solution and water then dried over magnesium sulphate, evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (3:1) for the elution. There was obtained 410 mg of N-(3-hydroxy-1,1-dimethylpropyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as a pale yellow solid. MS: m/e 348 [M+H]⁺.
- ii) A solution of 48 mg (0.276 mmol) of diethyl azodicarboxylate in 2 ml of tetrahydrofuran was added to a mixture of 72 mg (0.275 mmol) of triphenylphosphine, 57 mg (0.25 mmol) of benzyl salicylate and 87 mg (0.25 mmol) of N-(3-hydroxy-1,1-dimethylpropyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide and left at room temperature for 1 hour. The resulting mixture was chromatographed twice on silica gel using first ethyl acetate/petrol (1:1) then methanol/dichloromethane (1:49) for the elutions. There was obtained 29 mg of benzyl 2-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate as a colourless gum. MS: m/e 558 [M+H][†].

### Example 435

### 3-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid.

In an analogous manner to that described in Example 433 but replacing benzyl 4-hydroxybenzoate with benzyl 3-hydroxybenzoate there was obtained 3-[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid as a white solid. MS: m/e 468 [M+H][†].

#### Example 553

### 4-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropoxy]benzoic acid.

In an analogous manner to that described in Example 433 but replacing benzyl 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate with benzyl 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropoxy]benzoate there was obtained 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropoxy]benzoic acid as a white solid. MS: m/e 454 [M+H]⁺.

#### The starting material was prepared as follows:

5

10

15

- (i) A solution of 0.280 g (4 mmol) of 2,2-dimethylaziridine (Cairns, J. Am. Chem. Soc. 1941, 63, 871) and 9 g (40 mmol) of benzyl 4-hydroxybenzoate in 30 ml of chloroform was heated under refluxed for 3 hr. The reaction mixture was allowed to cool and diluted with dichloromethane. The solution was washed with 2M sodium hydroxide solution, dried over anhydrous magnesium sulphate, and concentrated *in vacuo*. Column chromatography of the residue using(dichloromethane:methanol:acetic acid:water (240:12:3:2) afforded benzyl 4-(2-amino-2-methylpropoxy)benzoate (0.300g, 1 mmol, 25%).
  - (ii) The benzyl 4-(2-amino-2-methylpropoxy)benzoate was coupled to N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid in a manner analogous to that described for example 433,

part (iii) to give benzyl 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropoxy]benzoate as a white solid.

Example 561 was prepared in a manner analogous to that described for example 433, parts (i) and (ii) where the benzyl 4-hydroxybenzoate was replaced with 3-cyanophenol.

Examples 585, 588 and 589 were prepared from the compounds of examples 583, 587 and 586 respectively, by reacting the nitrile substituent with trimethylsilyl azide and dibutyl tin oxide according to the method of S.J. Wittenberger and B.G.J. Donner, J. Org. Chem., 1993, <u>58</u>, 4139-4141.

For examples in table 1f¹ containing unprotected hydroxyl or amino groups suitable protecting groups were used, such as benzyl for hydroxyl and benzyloxycarbonyl for amino or similar groups, hereinbefore mentioned and well known in the art.

15

table 1f

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-(4-Hydroxy-phenoxy)-1,1-dimethyl-propyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	0 CH	440	396
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-(4- methoxyphenoxy)-1,1- dimethylpropyl]oxalamide		454	397
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- nitrophenoxy)propyl]oxalamide	N 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	469	398
N-[3-(2-Hydroxyphenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N C C C C C C C C C C C C C C C C C C C	440	399
N-[3-(4-Amino-phenoxy)-1,1-dimethyl-propyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	N CH, OCH, OCH,	439	400

N-[3-(4-Acetylamino-phenoxy)-			
1,1-dimethyl-propyl]-N'-(3-	NE TO COM	481	401
methoxy-4-oxazol-5-yl-phenyl)-	==-		
oxalamide	N N N N N N N N N N N N N N N N N N N		
N-[3-Methoxy-4-(5-oxazolyl)	0 OH > NO OH	<del></del>	
		425	402
phenyl]-N'-[1,1-dimethyl-3-(3-		423	402
pyridyloxy)propyl]oxalamide			
)	N N		
N-[3-(3-Hydroxyphenoxy)-1,1-	N 9 9		40.5
dimethylpropyl]-N'-[3-methoxy-4-		440	403
(5-oxazolyl)phenyl]oxalamide			
27 (2.2)			
N-[3-Methoxy-4-(5-oxazolyl)	N. 0 0		40.4
phenyl]-N'-[3-(3-	[] I.N. ~ .O. ~ .O.	454	404
methoxyphenoxy)-1,1-	ON LIX OF LIX		
dimethylpropyl]oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)	N^Q O′		
phenyl]-N'-[1,1-dimethyl-3-(3-	N N N N N N N N N N N N N N N N N N N	469	405
nitrophenoxy)propyl]oxalamide	N N N N O N N O -		
, , , , , , , , , , , , , , , , , , ,	0 '		
N-[3-(3-Aminophenoxy)-1,1-	NºO O		
dimethylpropyl]-N'-[3-methoxy-4-		439	406
(5-oxazolyl)phenyl]oxalamide	N N N N N N N N N N N N N N N N N N N	100	100
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	ö		
4-[3-[[[3-Methoxy-4-(5-oxazolyl)	N P P		
anilino]oxalyl]amino]-3-		468	433
methylbutoxy]benzoic acid			
2-[3-[[[3-Methoxy-4-(5-oxazolyl])	N C O CH,		
anilino oxalyl]amino]-3-		468	434
methylbutoxy]benzoic acid	N OH,		
,, , , , , , , , , , , , , , , ,	₿ 6H₃		
3-[3-[[[3-Methoxy-4-(5-oxazolyl)	N=C 5-34		
anilino]oxalyl]amino]-3-	N OU	468	435
methylbutoxy benzoic acid			
,, <b>,                    </b>	офон		
2-[4-[3-[[[3-Methoxy-4-(5-	N O CH		
oxazolyl)anilino]oxalyl]amino]-3-	9, 94	498	436
methylbutoxy phenoxy acetic acid	OH, OH		
	. 2 ° L		
2-[2-[3-[[[3-Methoxy-4-(5-			
oxazolyl)anilino]oxalyl]amino]-3-		498	437
methylbutoxy phenoxy acetic acid	: b. j.		
memyloutoxy phenoxy facetic acid	Į.		
N-[3-Methoxy-4-(5-	N°O COH,	<del></del>	
oxazolyl)phenyl]-N'-(1,1-dimethyl-		424	542
3-phenoxypropyl)oxalamide	· · · · · · · · · · · · · · · · · · ·	- <del></del>	
o phenoxypropynyoxuumide	0 оң		
	i		J

N-[3-Methoxy-4-(5-oxazolyl)	N T CHI		
phenyl -N'-[1,1-dimethyl-3-(1-	о сн	441	543
oxido-3-pyridyloxy)propyl]	· N - N - N - N - N - N - N - N - N - N		
oxalamide	O CH,		
	N 2HL		1
N-[3-(3,4-Dihydroxyphenoxy)-1,1-			Ť
dimethylpropyl]-N'-[3-methoxy-4-	1 1 N 2 C S	456	544
(5-oxazolyl)phenyl]oxalamide	Wind the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of t		
	3-		1
N-[3-Methoxy-4-(5-oxazolyl)	M _e to the M		
phenyl]-N'-[1,1-dimethyl-3-[4-		481	545
(methylcarbamoyl)phenoxy]propyl	1 0	101	313
loxalamide	Mark of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the seco		
			<del>                                     </del>
N-[3-Methoxy-4-(5-oxazolyl)	N 1 N CON LOCAL PLANTS OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE P	4.0.4	5.46
phenyl]-N'-[3-(3,4-	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	484	546
dimethoxyphenoxy)-1,1-	( 04		
dimethylpropyl]oxalamide	٠٠رد ٢٠٠		
N-[3-[4-[(2-Hydroxyethyl)	1		
carbamoyl]phenoxy]-1,1-dimethyl-	ا ا	511	547
propyl]-N'-[3-methoxy-4-(5-	* * * * * * * * * * * * * * * * * * *		
oxazolyl)phenyl]oxalamide	<u>'</u>		
	CH.		
N-[3-(3-Chlorophenoxy)-1,1-	N TO OCH	150	5.40
dimethylpropyl]-N'-[3-methoxy-4-	0 NON 00 0	458	548
(5-oxazolyl)phenyl]oxalamide	0 0m		
	·		
N-[3-Methoxy-4-(5-oxazolyl)	0, 0 04, 1		
phenyl]-N'-[1,1-dimethyl-3-(3-	O N N SHOW	425	549
pyridyloxy)propyl]oxalamide	c		
	'4		
N-[3-Methoxy-4-(5-oxazolyl)	ું ૦ ફ ^{લ્મ}		
phenyl]-N'-[1,1-dimethyl-3-(2-	N 0	425	550
pyridyloxy)propyl]oxalamide	ON ON ON		
F //, F F /- 1	PHC OH		İ
2-[4-[3-[[[3-Methoxy-4-(5-	N. J. C. C. Co.		
oxazolyl)anilino]oxalyl]amino]-3-	, c 2. 0 se	482	551
methylbutoxy]phenyl]acetic acid		102	331
methyloutoxy/phenyl/acetic acid			
2 [2 [2 [[[2 Mathemy 4 (5			
2-[3-[3-[[[3-Methoxy-4-(5-	N c	100	₅₅₃
oxazolyl)anilino]oxalyl]amino]-3-	, , , , , , , , , , , , , , , , , , ,	482	552
methylbutoxy]phenyl]acetic acid	be no i		
	31		
4-[2-[[[3-Methoxy-4-(5-oxazolyl)	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		
anilino]oxalyl]amino]-2-	а	454	553
methylpropoxy]benzoic acid	, <u> </u>		
4-[3-[[[3-Methoxy-4-(5-oxazolyl)	N CH,		
anilino]oxalyl]amino]-3-	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	482	554
methylbutoxy]-2-methylbenzoic	7 24		
acid	сн. ан		T
acia			

3-[3-[3-[[[3-Methoxy-4-(5-	· 🚉		
oxazolyl)anilino]oxalyl]amino]-3-		496	555
methylbutoxy]phenyl]propionic	2		į.
acid			
3-[4-[3-[[[3-Methoxy-4-	5-50 - c		
(5oxazolyl)anilino]oxalyl]amino]-		496	556
3-methylbutoxy]phenyl]propionic			330
acid			
3-[2-[3-[[[3-Methoxy-4-(5-	0. ,044		
oxazolyl)anilino]oxalyl]amino]-3-	1	496	557
methylbutoxy]phenyl]propionic	Complete the second	420	337
acid	Č *+s,		
2-[3-[3-[[[3-Methoxy-4-(5-	<del></del>		
oxazolyl)anilino]oxalyl]amino]-3-	N 0	498	558
	N TOH	490	336
methylbutoxy]phenoxy]acetic acid	N 5 1 1 20 1 20 1 20 1 20 1 20 1 20 1 20		
1 [2 [[2 Mothors 4 (5 overal-1)	AN AN AN AN AN AN		- 1
4-[3-[[[3-Methoxy-4-(5-oxazolyl)	N	482	559
anilino]oxalyl]amino]-3-		402	339
methylbutoxy]-3-methylbenzoic	AND THE		
acid	.en	-	
N-[3-(4-Cyano-2-	(n. 2n. in	170	570
methoxyphenoxy)-1,1-	Section 1	479	560
dimethylpropyl]-N'-[3-methoxy-4-	12		
(5-oxazolyl)phenyl]oxalamide			
N-[3-(3-Cyanophenoxy)-1,1-	(4 ) (4 ) (5 ) (7 ) (7 ) (8 ) (8 ) (8 ) (8 ) (8 ) (8	140 5	F .: 1
dimethylpropyl]-N'-[3-methoxy-4-	N	449.6	561
(5-oxazolyl)phenyl]oxalamide	اسم ا		
N [2 [1 (4 Acetyl 1 pipergripyl)	3		
N-[3-[4-(4-Acetyl-1-piperazinyl)	***	550.4	562
phenoxy]-1,1-dimethylpropyl]-N'-	5-20-00	330.4	302
[3-methoxy-4-(5-oxazolyl)phenyl]			
oxalamide	~~		
N-[3-Methoxy-4-(5-	OH, CHECH	521.4	5.00
oxazolyl)phenyl]-N'-[1,1-dimethyl-	ا درمین	531.4	563
3-(2-morpholinophenoxy)propyl]	,	$(M + Na)^{\dagger}$	-
oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)	Cot de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de la constant de	190 €	EZA
phenyl]-N'-[1,1-dimethyl-3-[3-	0. 1.20 N	489.6	564
(dimethylamino)phenoxy]	N ⁻¹	$(M + Na)^+$	
propyl]oxalamide			
N-[3-(1,3-Benzodioxol-5-yloxy)-		160.1	E
1,1-dimethylpropyl]-N'-[3-	)	468.4	565
methoxy-4-(5-oxazolyl)phenyl]	N		
oxalamide (5			
N-[3-Methoxy-4-(5-oxazolyl)	)	5144	<b>5</b> / 1
phenyl]-N'-[3-(3,4,5-	Sur Sur Sur Sur Sur Sur Sur Sur Sur Sur	514.4	566
trimethoxyphenoxy)-1,1-	o. T		
dimethylpropyl]oxalamide	`N-'		

	⇒∩ <b>h</b>	1	
N-[3-Methoxy-4-(5-oxazolyl)	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	504	- · · ·
phenyl]-N'-[3-(3,5-	CH, CHO, CH,	506	567
dimethoxyphenoxy)-1,1-	\$7. · · ·	$(M + Na)^{\dagger}$	
dimethylpropyl]oxalamide N-[3-(5,6,7,8-Tetrahydro-5-oxo-2-	9		
	сч оно оч	492.4	560
naphthyloxy)-1,1-dimethylpropyl]-	C N	492.4	568
N'-[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	, Э.		
N-[3-(2-Acetamido-5-	દમ, ⊃મ ૦મ,	517.6	<i>=20</i>
methylphenoxy)-1,1- dimethylpropyl]-N'-[3-methoxy-4-	C , N,,,	$\left  \frac{317.0}{(M + Na)^+} \right $	569
	N	(NI + Na)	
(5-oxazolyl)phenyl]oxalamide N-[3-(3-Acetamidophenoxy)-1,1-			
dimethylpropyl]-N'-[3-methoxy-4-	CH	503.6	570
(5-oxazolyl)phenyl]oxalamide		$(M + Na)^{\dagger}$	370
(3-oxazoryr)phenyrjoxarannde	N-	(NI + Na)	
N-[3-(1H-Indol-4-yloxy)-1,1-	2. 0		
dimethylpropyl]-N'-[3-methoxy-4-	0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 -	485.2	571
(5-oxazolyl)phenyl]oxalamide		$(M + Na)^{+}$	3/1
(5 Oxazoryr) phenyrjoxaramide	N-	(141 + 144)	
N-[3-(2-Fluoro-6-	OH	<del> </del>	
methoxyphenoxy)-1,1-	OH, OH, CH,	472.2	572
dimethylpropyl]-N'-[3-methoxy-4-	СН		
(5-oxazolyl)phenyl]oxalamide	N-		
N-[3-Methoxy-4-(5-oxazolyl)	CH, TH, TH,		
phenyl]-N'-[1,1-dimethyl-3-(2-	OH, N N	492.4	573
oxo-2H-1-benzopyran-7-	a		
yloxy)propyl]oxalamide			
N-[3-(4-Acetyl-3-methylphenoxy)-	)-t		
1,1-dimethylpropyl]-N'-[3-	CH SHIT OH	480.2	574
methoxy-4-(5-oxazolyl)phenyl]	0 0		
oxalamide			
(E)-N-[3-Methoxy-4-(5-oxazolyl)	н,		
phenyl]-N'-[1,1-dimethyl-3-[4-(3-	a company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the comp	492.4	575
oxo-1-butenyl)phenoxy[propyl]			
oxalamide			
N-[3-(3-Acetylphenoxy)-1,1-	Çeq e ne e eq		
dimethylpropyl]-N'-[3-methoxy-4-	Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Charles No. 2 Ch	466.4	576
(5-oxazolyl)phenyl]oxalamide			
N-[3-(4-Acetylphenoxy)-1,1-	<b>&gt;</b>		
dimethylpropyl]-N'-[3-methoxy-4-	Cn	466.2	577
(5-oxazolyl)phenyl]oxalamide	0		
	ù-		
N-[3-(4-Acetamido-2-	он ин, и эн		
chlorophenoxy)-1,1-	O GI	515.6	578
dimethylpropyl]-N'-[3-methoxy-4-	O CI		
(5-oxazolyl)phenyl]oxalamide			

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-pyridyloxy)propyl]oxalamide	NEO OOL	425	579
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(1- oxido-4-pyridyloxy)propyl] oxalamide	Service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the service of the servic	441	580
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2,6- dimethyl-4-pyridyloxy)propyl] oxalamide		453	581
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2,6- dimethyl-1-oxido-4-pyridyloxy) propyl]oxalamide	1 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	469	582
N-[2-(4-Cyanophenoxy)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	C-1, N - 1, N - 20	435	583
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-(2-methoxy-4- pyridyloxy)-1,1-dimethylpropyl] oxalamide	Market State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State	455	584
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[4- (1H-tetrazol-5-yl)phenoxy]ethyl] oxalamide	CH	478	585
N-[3-(4-Cyanophenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		449	586
N-[2-(3-Cyanophenoxy)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	CH	476	587
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[3- (1H-tetrazol-5-yl)phenoxy]ethyl] oxalamide		478	588
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-[4- (1H-tetrazol-5-yl)phenoxy]propyl] oxalamide		492	589
Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclobutyl]ethoxy]benzoate		570.2	590

Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopentyl]ethoxy]benzoate		584.3	591
Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclohexyl]ethoxy]benzoate		598.3	592
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopentyl]ethoxy]benzoic acid	см	494.2	593
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclohexyl]ethoxy]benzoic acid	St. Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Committee Co	508.2	594
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl)amino]-1-cyclobutyl]ethoxy]benzoic acid	ς 	480.2	595
Benzyl 2-methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate		588	635
3-Chloro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N 2 C C C C C C C C C C C C C C C C C C	502	636
2-Methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		498	637
3-Methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N 2 N 3	498	638
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopropyl]ethoxy]benzoic acid	N	466	639
2-Chloro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N 20 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	502	640
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-quinolinecarboxylic acid	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	519	641

(cis/trans)-4-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]-1-cyclohexanecarboxylic acid	NS O NS N+O COH	474	642
(cis/trans)-4-[2-[[[3-Methoxy-4- (5-oxazolyl)anilino]oxalyl]amino]- 2-methylpropoxy -1- cyclohexanecarboxylic acid	OT NOT NOT OH	460	643
3-Fluoro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N ON TOH	486	644
3-Acetamido-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N O N O HN O HN	525	645
3-(Methanesulfonamido)-4-[3- [[[3-methoxy-4-(5- oxazolyl)anilino]oxalyl]amino]-3- methylbutoxy]benzoic acid	N O O O O O O O O O O O O O O O O O O O	561	646
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-3,5-dimethylbenzoic acid	N N N N N O N O N O N	496	647
3-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-pyridinecarboxylic acid	N O O O O O O O O O O O O O O O O O O O	469	648
8-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-quinolinecarboxylic acid	N O O O O O O O O O O O O O O O O O O O	519	649
5-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-indolecarboxylic acid	N N N N O O O O O O O O O O O O O O O O	507	650

## Examples 615-631 and 664-670

## 5 Example 615

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl] oxalamide.

(i) A mixture of 2g (17.7 mmol) of 2,4,4-trimethyl-2-oxazoline and 1.95 g (17.7 mmol) of thiophenol were heated at 120C for 18 hours. After cooling the resulting solid was triturated

with diethyl ether/petrol (1:2) and filtered off to give 2.55 g of N-[1,1-dimethyl-2-(phenylthio)ethyl]acetamide as a white solid.

10

15

20

(ii) A solution of 2.5 g (11.2 mmol) of N-[1,1-dimethyl-2-(phenylthio)ethyl]acetamide, 3.18 g (11.2 mmol) of titanium isopropoxide and 3.09 g (16.8 mmol) of diphenylsilane in 12 ml of tetrahydrofuran were stirred at room temperature for 18 hours. The resulting mixture was chromatographed on silica gel using 3%, 6% and 10% methanol in dichloromethane for the elution. There was obtained 2 g of 1,1-dimethyl-2-(phenylthio)ethylamine as a pale orange oil. The 1,1-dimethyl-2-(phenylthio)ethylamine was then coupled to N-[3-methoxy-4-(5-oxazolyl)phenyl oxalamic acid by a procedure analogous to that described in example 1 to afford N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl]oxalamide. MS: m/e 426 [M+H]⁺.

Example 616 was prepared by an analogous method to that described for example 615 but using 4-benzyloxythiophenol in place of the thiophenol and removing the protecting group using a mixture of hydrogen bromide in acetic acid.

The additional compounds in table 1f² were prepared in an analogous manner to that described for example 615 by reaction of the appropriate thiol with either 2,4,4-trimethyl-2-oxazoline or 2,4,4-trimethyl-5,6-dihydro-1,3(4H)oxazine and, where necessary, removal of any protecting groups by conventional methods.

table 1f²

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2- (phenylthio)ethyl]oxalamide	N N N N N N N N N N N N N N N N N N N	426	615
N-[2-(4-Hydroxyphenylthio)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		442	616
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2- (phenylthio)ethyl]oxalamide	N 0 0 0H,	440	617

	<del>,_</del>		
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(2-	N	427	618
pyridylthio)ethyl]oxalamide	N CHL CH		1
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2- pyridylthio)propyl]oxalamide	N O O OH	441	619
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2- thienylthio)propyl]oxalamide	N 0 C CH, S	446	620
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2- pyrimidylthio)propyl]oxalamide	N 0 0 CH	442	621
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- pyridylthio)propyl]oxalamide	N 10 0 CH 1 1 1 0 CH 1 N 1 N 5 1 1	441	622
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2- thiazolylthio)propyl]oxalamide	N 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	447	623
N-[3-(4-Hydroxyphenylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N 0 0 04 L 1, 0 N 54 K.	456	624
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(5-methyl-1,3,4-thiadiazol-2-ylthio) propyl]oxalamide	N C C C C C C C C C C C C C C C C C C C	462	625
N-[3-(2-Benzooxazolylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	Maria San San San San San San San San San Sa	481	626
N-[3-(2-Benzothiazolylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N	497	627
Methyl 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropylthio]benzoate	74. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	484	628
tert-Butyl 6-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutylthio]-3-pyridinecarboxylate	N TO THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF	541	629
6-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-3-pyridinecarboxylic acid trifluoroacetate (1:1)	N ON ON ON ON OH	485	630
timuoroacetate (1.1)	1		1

4-[3-[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]benzoic acid	N 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	484	631
N-[2-(4-Benzyloxyphenylthio)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N^O O O N N N S N S N S N S N S N S N S N	532	664
N-[2-(4-Benzyloxyphenylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N^O O'N NH~S	546	665
2-[3-[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-5-benzoxazolecarboxylic acid	NO SON SON SON SON SON SON SON SON SON S	525	666
N-[3-(1H-Imidazol-2-ylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		430	667
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-3-pyridinecarboxylic acid trifluoroacetate (1:1)	N N N N N N N N N N N N N N N N N N N	485	668
4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropylthio]benzoic acid		470	669
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-6-benzoxazolecarboxylic acid	(a) (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c	525	670

# Examples 632-634

The compounds in table 1f³ were prepared in an analogous manner to that described for example 398 in table 1f⁴ by replacing the 4-nitrophenol with the appropriate aniline and reaction with either 2,4,4-trimethyl-2-oxazoline or 2,4,4-trimethyl-5,6-dihydro-1,3(4H)oxazine and, where necessary, removal of any protecting groups by conventional methods.

table 1f3

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(N-methylanilino) ethyl] oxalamide	о нс сн,	423	632
N-(3-Anilino-1,1-dimethylpropyl)- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide hydrochloride (1:1)	NS O O N CH3	423	633
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylamino]benzoic acid	PACE CH CH	467	634

## Examples 407-414; 459-541 and 651-652

Typical methods used for the preparation of the compounds of table 1g are described below: <u>Example 408.</u>

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl] oxalamide.

- 10
- (i) A stirred solution of 3.23 g (16.8 mmol) of 1-(4-methoxyphenyl)piperazine, 2.00 g (16.8 mmol) of 2-methyl-2-nitropropan-1-ol and 5.34 g (50.4 mmol) of sodium carbonate in 40ml of n-butanol was refluxed for 16h. The reaction mixture was allowed to cool and diluted with 100ml of dichloromethane. The solution was filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using petroleum ether/ethyl acetate (10:1) for the elution to afford 1.86 g (6.34 mmol, 38%) of 1-(4-methoxyphenyl)-4-(2-methyl-2nitropropyl)piperazine as a white solid.
- (ii) A solution of 1.86 g (6.34 mmol) of 1-(4-methoxyphenyl)-4-(2-methyl-2-nitropropyl)piperazine and 0.5 g of palladium on activated charcoal in 50 ml of ethanol was stirred at room temperature under an atmosphere of hydrogen for 48h. The reaction mixture was filtered and the filtrate concentrated in vacuo to afford 1.59 g (6.04 g mmol, 95%) of 2-[4-(4-methoxyphenyl)-piperazin-1-yl)-1,1-dimethylethylamine as a clear oil. The 2-[4-(4-methoxyphenyl)-piperazin-1-yl)-1,1-dimethylethylamine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid by a procedure analogous to that described in example 1 to

afford N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl] oxalamide as a white solid. MS: m/e 508  $[M+H]^+$ .

Examples 407, 409, 410, 411, 412 and similar structures were prepared by an analogous procedure by replacing the 1-(4-methoxyphenyl)piperazine with the appropriately substituted piperazine.

Examples 413 and 414 were prepared by an analogous procedure by replacing the 1-(4-methoxyphenyl)piperazine with t-butyl-1-piperazinecarboxylate to give 4-(2-amino-2-methylpropyl)piperazine-1-carboxylic acid t-butyl ester which was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid. The resulting product could then be deprotected to give N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-piperazinyl)ethyl]oxalamide that could be used for the preparation of examples 413, 414 and a variety of additional N-acyl and N-sulfonyl derivatives, such as those shown in table 1g, by using the appropriate acylating or sulfonylating reagent.

### Example 489.

N-[2-[4-(Cyclohexylmethyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide.

20

30

15

10

A stirred solution of 48mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-piperazinyl)ethyl]oxalamide (1.2mmol) and 13mg of cyclohexanecarboxaldehyde (1.2mmol) in 1ml of a 5% acetic acid / dichloromethane mixture was treated with a solution of 38mg of sodium triacetoxyborohydride (1.8mmol) in 1ml of a 5% acetic acid / dichloromethane mixture. After stirring overnight at room temperature the reaction mixture was diluted with 10ml of dichloromethane and washed with 8ml of a sodium bicarbonate solution followed by 8ml of water. The organic layer was then evaporated and purified using flash chromatography on a silica gel column eluting with 5% methanol / dichloromethane to give after evaporation of the fractions 14.3mg (0.3 mmol, 25%) of N-[2-[4-(cyclohexylmethyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide in the form of a white solid. MS: m/e 498.2 [M+H][†].

Additional N-alkylated compounds shown in table 1g were prepared by analogous methods.

. 1	1		
tat	٦le	э I	σ
· ·	,,,		מי

table 1g			
Name	Structure	MS(ES) $(M+H)^{\dagger}$	Ex No
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-phenyl-1-piperazinyl)ethyl]oxalamide	or or or	478	407
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	408
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(3-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	409
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-phenyl-1-piperazinyl)propyl]oxalamide		492	410
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(2-methoxy-phenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	411
N-[2-(4-Benzyl-1-piperazinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		492	412
N-[2-[4-(Benzenesulfonyl)-1- piperazinyl]-1,1-dimethylethyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		452	413
N-[2-(4-Benzoyl-1-piperazinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		506	414
N-[2-[4-[4- (Trifluoromethyl)phenyl]-1- piperazinyl]-1,1-dimethylethyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	CH CH CH CH	546	459
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]oxalamide		492	460

			,
N-[2-[4-(2-Fluorophenyl)-1-	~		
piperazinyl]-1,1-dimethylethyl]-N'-	04 0 04 N	496	461
[3-methoxy-4-(5-	2, 1		
oxazolyl)phenyl]oxalamide			
N-[2-[4-(4-Fluorophenyl)-1-	S. 2		
piperazinyl]-1,1-dimethylethyl]-N'-	5.	496	462
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	1		
N-[3-Methoxy-4-(5-	O4,		
oxazolyl)phenyl]-N'-[2-[4-(2-		508	463
methoxyphenyl)-1-piperazinyl]-1,1-	P C N Hy My W.		
dimethylethyl]oxalamide	C.Y		
N-[3-Methoxy-4-(5-	,		+
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	CH, PHO IN I	548	464
[4-(2-thiophenesulfonyl)-1-	N N N	2.10	101
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	н, ДОЧ		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	CH. July St. N.S.	584.1	465
[4-(2,4,6-trimethylbenzenesulfonyl)-	Control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the contro	301.1	10,5
1-piperazinyl]ethyl]oxalamide	[ · ]		
N-[2-[4-(4-Fluorobenzenesulfonyl)-	,		
1-piperazinyl]-1,1-dimethylethyl]-N'-		560.1	466
[3-methoxy-4-(5-	and the second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second s	300.1	400
oxazolyl)phenyl]oxalamide			
N-[2-[4-(Trifluoromethanesulfonyl)-			
1-piperazinyl]-1,1-dimethylethyl]-N'-	The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s	534	467
	The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s	334	407
[3-methoxy-4-(5-			
oxazolyl)phenyl)]oxalamide			<del> </del>
N-[2-[4-(Isopropylsulfonyl)-1-	Sign Ciny Inc. No. 3 Mg	500 I	14:0
piperazinyl]-1,1-dimethylethyl]-N'-	A DESTRUCTION OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY	508.1	468
[3-methoxy-4-(5-			
oxazolyl)phenyl)]oxalamide			
(E)-N-[3-Methoxy-4-(5-	_ < ^ -	F ( 0 1	140
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	Crys Nagy N	568.1	469
[4-(styrylsulfonyl)-1-			
piperazinyl]ethyl]oxalamide			-
N-[2-[4-(Ethanesulfonyl)-1-	.н, : н: эн ( ° сң	40.4.1	1 .=-
piperazinyl]-1,1-dimethylethyl]-N'-	141 0 10H	494.1	470
[3-methoxy-4-(5-	0		
oxazolyl)phenyl]oxalamide	Ň		
N-[3-Methoxy-4-(5-	SH CHOTH N		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	CHI CHITTH NOTE	508.1	471
[4-(propanesulfonyl)-1-	0 0		
piperazinyl]ethyl]oxalamide	V-		
N-[2-[4-(3-Chloropropanesulfonyl)-	, , , , , , , , , , , , , , , , , , ,		
1-piperazinyl]-1,1-dimethylethyl]-N'-	CH, A NO	542.1	472
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	N-		<u> </u>

N-[3-Methoxy-4-(5-	27.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	CH CHC CH CH CH	556.1	473 i
[4-(o-toluenesulfonyl)-1-	2		
piperazinyl]ethyl]oxalamide	25		
N-[2-[4-(2-Fluorobenzenesulfonyl)-	**		<u> </u>
1-piperazinyl]-1,1-dimethylethyl]-N'-	on one h	560.1	474
[3-methoxy-4-(5-	5 .N. ~ N.	300.1	474
oxazolyl)phenyl]oxalamide			
N-[2-[4-(2-Cyanobenzenesulfonyl)-	್ಕಾರಿ		ļ
1-piperazinyl]-1,1-dimethylethyl]-N'-	9n. (H2 h / N / N / N / N / N / N / N / N / N /	567.1	<b>4</b> 75
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
N-[3-Methoxy-4-(5-	"		
oxazolyl)phenyl]-N'-[2-[4-(3,5-	SH, HIRE SHOWN IN	561.1	476
dimethyl-4-isoxazolylsulfonyl)-1-			-
piperazinyl]-1,1-dimethyl-			
ethyl]oxalamide			
N-[2-[4-(5-Fluoro-2-	*		
methylbenzenesulfonyl)-1-		574.1	477
	3, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	3/4.1	4//
piperazinyl]-1,1-dimethylethyl]-N'-	(~).		
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[2-[4-(2,5-	;		
Difluorobenzenesulfonyl)-1-		578.1	478
piperazinyl]-1,1-dimethylethyl]-N'-			
[3-methoxy-4-(5-	12		
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-	CH. CHE H. M.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	CH. THE HE THE	546.1	479
[4-(1-methyl-1H-imidazole-4-	°	2.0.1	
sulfonyl)-1-			
piperazinyl]ethyl]oxalamide			
	F		
N-[2-[4-(2,6-	on ne the ne	E 70 1	100
Difluorobenzenesulfonyl)-1-	8 N. 1 3 N. 1	578.1	480
piperazinyl]-1,1-dimethylethyl]-N'-	2. · · · · · · · · · · · · · · · · · · ·		
[3-methoxy-4-(5-	N		
oxazolyl)phenyl]oxalamide			
N-[2-[4-(3,4-			
Difluorobenzenesulfonyl)-1-		578.1	481
piperazinyl]-1,1-dimethylethyl]-N'-	0 1 2 1		
[3-methoxy-4-(5-	'-		
oxazolyl)phenyl]oxalamide			
N-[2-[4-	2		
(Cyclohexylmethanesulfonyl)-1-	O. A. H. H. N.	562.2	482
piperazinyl]-1,1-dimethylethyl]-N'-	0_ 1 1 3	002.2	102
[3-methoxy-4-(5-	***		
oxazolyl)phenyl]oxalamide			L

N-[3-Methoxy-4-(5-	or one or ore		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	OH, OH,COH,	570.1	483
[4-(2-phenylethanesulfonyl)-1-	.0		
piperazinyl]ethyl]oxalamide	· '		
N-[3-Methoxy-4-(5-	) ot		!
oxazolyl)phenyl]-N'-[2-[4-(2,4-	7 CO 2 N 2	538	484
dimethoxyphenyl)-1-piperazinyl]-	40.		
1,1-dimethylethyl]oxalamide	•		
N-[3-Methoxy-4-(5-	/ Va.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	.4.	492	485
[4-(4-methylphenyl)-1-	, , , , , , , , , , , , , , , , , , ,		
piperazinyl]ethyl]oxalamide	N .		
N-[3-Methoxy-4-(5-	;		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s	506	486
[4-(2,4-dimethylphenyl)-1-	A CONTRACTOR OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF TH		ľ
piperazinyl]ethyl]oxalamide	N		İ
N-[3-Methoxy-4-(5-	:		
oxazolyl)phenyl]-N'-[2-[4-(3,4-	) on on	538	487
dimethoxyphenyl)-1-piperazinyl]-			
1,1-dimethylethyl]oxalamide			
N-[2-(4-Cyclohexyl-1-piperazinyl)-	7-3-		
1,1-dimethylethyl]-N'-[3-methoxy-4-	ne many kathagas kan hara	484.4	488
(5-oxazolyl)phenyl]oxalamide	NC TO THE TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TOTAL TO	101.1	100
(5 Okaziotyt) prientyt jokalamiae			
N-[2-[4-(Cyclohexylmethyl)-1-	H. OHEOLO		
piperazinyl]-1,1-dimethylethyl]-N'-	H. HEIM N	498.2	489
[3-methoxy-4-(5-	3		
oxazolyl)phenyl]oxalamide	No.		1
N-[2-[4-(2-Methoxybenzyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-		522.1	490
[3-methoxy-4-(5-			İ
oxazolyl)phenyl]oxalamide	_		
N-[2-[4-(2-Hydroxybenzyl)-1-	٠.		
piperazinyl]-1,1-dimethylethyl]-N'-	1-13	508.1	491
[3-methoxy-4-(5-	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1		
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		506.1	492
[4-(2-methylbenzyl)-1-			1
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	, ~ s		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	H, 5 H,C OH, 1	498.1	493
[4-(2-thenyl)-1-	C N N N N N N N N N N N N N N N N N N N		1
piperazinyl]ethyl]oxalamide	N.		
N-[3-Methoxy-4-(5-			<u> </u>
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		520.2	494
[4-(2(RS)-phenylpropyl)-1-	H	220.2	
piperazinyl]ethyl]oxalamide	( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )		i
piperazinyijemyijoxaiainide	I ,		

			<del></del>
N-[3-methoxy-4-(5-	~~3.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	The same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the sa	486.1	495
(4-pivaloyl-1-	(T)		
piperazinyl)ethyl]oxalamide			
N-[2-[4-(2-Furoyl)-1-piperazinyl]-		İ	
1,1-dimethylethyl]-N'-[3-methoxy-4-	14. 0 145 25 mg/	496.1	496
(5-oxazolyl)phenyl]oxalamide	, I		İ
27 (2.24.1	N O		<u> </u>
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	3. 5. M. W. W.	512.1	497
[4-(2-thenoyl)-1-	G G		
piperazinyl]ethyl]oxalamide	N-3		
N-[3-Methoxy-4-(5-	-1 -5		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	The second second	512	498
[4-(3-thenoyl)-1-	2,7		:
piperazinyl]ethyl]oxalamide	w.1		
N-[2-[4-(2-Cyclopentylacetyl)-1-	1 E		
piperazinyl]-1,1-dimethyl-ethyl]-N'-	10000	512.1	499
[3-methoxy-4-(5-			ļ
oxazolyl)phenyl)]oxalamide		<u> </u>	
N-[2-[4-(Cyclohexylcarbonyl)-1-	3, -,		
piperazinyl]-1,1-dimethylethyl]-N'-	HIS OHOSE TO	512.1	500
[3-methoxy-4-(5-	9		
oxazolyl)phenyl]oxalamide	21,	:	į
N-[3-Methoxy-4-(5-	4.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		520.1	501
[4-(2-methylbenzoyl)-1-			
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	0		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	mg ones on	520.1	502
[4-(4-methylbenzoyl)-1-	0	320.1	302
piperazinyl]ethyl]oxalamide	- <del>"</del> J" - "		
N-[2-[4-(Cycloheptylcarbonyl)-1-	· - ,		
piperazinyl]-1,1-dimethylethyl]-N'-	HAT NO PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERT	526.2	503
[3-methoxy-4-(5-		320.2	303
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-	Q		
	- N - N - N	496.1	504
oxazolyl)phenyl]-N'-]1,1-dimethyl-2-	S. N. S. N.	490.1	304
[4-[(1H-pyrazol-4-yl)carbonyl]-1-	27		
piperazinyl]ethyl]oxalamide	Ş -		
N-[2-[4-(Cyclopentylcarbonyl)-1-	~~~	109.1	E05
piperazinyl]-1,1-dimethylethyl]-N'-	His OHENS W	498.1	505
[3-methoxy-4-(5-	o j		
oxazolyl)phenyl]oxalamide	g-		<del>                                     </del>
N-[3-Methoxy-4-(5-	- N - N	500.1	500
oxazolyl)phenyl]-N'-[1,1-Dimethyl-	The second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of th	509.1	506
2-[4-[(1-methyl-1H-pyrrol-2-	a 2 d = 1 d		
yl)carbonyl]-1-	4-9		
piperazinyl]ethyl]oxalamide			<u> </u>

N-[3-Methoxy-4-(5-			Ì
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	196 - W. T. W. W. W. W. W. W. W. W. W. W. W. W. W.	514.1	507
[4-[(1,2,3-thiadiazol-4-yl)carbonyl]-			
1-piperazinyl]-ethyl]oxalamide			
N-[2-[4-(3-Fluorobenzoyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-		524.1	508
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	QT .		
N-[2-[4-(4-Fluorobenzoyl)-1-	3		;
piperazinyl]-1,1-dimethylethyl]-N'-	HN OH OH N	524.1	509
[3-methoxy-4-(5-	"5	<i>52</i> 4.1	307
oxazolyl)phenyl]oxalamide	0.7		
	0		<u> </u>
N-[2-[4-(Cyclopropylcarbonyl)-1-	~~~~	470.1	510
piperazinyl]-1,1-dimethylethyl]-N'-	H ₁ JI OH, off N	470.1	510
[3-methoxy-4-(5-	of the second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second se		
oxazolyl)phenyl]oxalamide	4m²		
N-[2-[4-(2-Cyclohexylacetyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-	- 1-00 C	526.2	511
[3-methoxy-4-(5-	in the second		
oxazolyl)phenyl]oxalamide	C.S.		
N-[3-Methoxy-4-(5-	1		
oxazolyl)phenyl]-N'-[2-[4-(3,3-	H1 (1975)	500.2	512
dimethylbutyryl)-1-piperazinyl]-1,1-			
dimethylethyl]oxalamide	٠		
N-[2-[4-(3-Hydroxy-2,2-			
dimethylpropionyl)-1-piperazinyl]-	Hay CHI WE	502.1	513
1,1-dimethylethyl]-N'-[3-methoxy-4-			ĺ
(5-oxazolyl)phenyl]oxalamide	T.		
N-[3-Methoxy-4-(5-	·		1
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		510.1	514
[4-(3-methyl-2-furoyl)-1-			
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	<i>y</i>		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	,	510.1	515
	My SHEMIN )	310.1	515
[4-(2-methyl-3-furoyl)-1-			}
piperazinyl]ethyl]oxalamide	?		
N-[3-Methoxy-4-(5-	N-CH N N N	510.1	516
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	He CH CH N N	510.1	516
[4-[(5-methyl-1H-pyrazol-3-	0,000		
yl)carbonyl]-1-	~		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	م نبر آه		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	10 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC 20 HC	511.1	517
[4-[(5-methyl-4-	J. 7. *		
isoxazolyl)carbonyl]-1-	\ _J		
piperazinyl]ethyl]oxalamide			

N-[3-Methoxy-4-(5-	بعد ميد		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	MC SHOEN N	511.1	518
[4-[(5-methyl-3-	0. 7. 7.		
isoxazolyl)carbonyl]-1-	السمة ا		:
piperazinyl]ethyl]oxalamide			1
N-[2-[4-(4-Aminobenzoyl)-1-	- /-		-
piperazinyl]-1,1-dimethylethyl]-N'-	HC OHCON	521.1	519
[3-methoxy-4-(5-	3- 4	52111	
oxazolyl)phenyl]oxalamide			
N-[2-[4-(2-Hydroxybenzoyl)-1-	H		
piperazinyl]-1,1-dimethylethyl]-N'-	7	522.1	520
[3-methoxy-4-(5-		322.1	320
	\ \tau_{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\tin}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\ti}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\ti}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\ti}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\ti}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\tin}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\tin}\tint{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\ti}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\tex{\tex		
oxazolyl)phenyl]oxalamide	0		
N-[2-[4-(4-Hydroxybenzoyl)-1-	N ha	522.	53.
piperazinyl]-1,1-dimethylethyl]-N'-	He OHOM NO TON	522.1	521
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	ig-mg.		
N-[3-Methoxy-4-(5-	~:.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	H ACTUAL TO A	524.1	522
[4-[(2,5-dimethyl-2H-pyrazol-3-	2		
yl)carbonyl]-1-	~		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	2.3		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	3410	526.1	523
[4-(3-methyl-2-thenoyl)-1-			
piperazinyl]ethyl]oxalamide	7		
N-[3-Methoxy-4-(5-	8 - 00		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	HO ONCON	526.1	524
	HO N L W	J=0.1	324
[4-(4-methyl-2-thenoyl)-1-	in the second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second se		
piperazinyl]ethyl]oxalamide		1	
N-[3-Methoxy-4-(5-		526.2	525
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		526.2	525
[4-[(2,2,3,3-tetramethyl-1-			
cyclopropyl)carbonyl]-1-	فسية		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		528.1	526
[4-[(4-methyl-1,2,3-thiadiazol-5-			
yl)carbonyl]-1-	\!		
piperazinyl]ethyl]oxalamide			
N-[2-[4-(3-Cyanobenzoyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-	The second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second secon	531.1	527
[3-methoxy-4-(5-	The same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the sa		
oxazolyl)phenyl]oxalamide	, and a		
N-[2-[4-[(Bicyclo[4.2.0]octa-	į ,= ₁	+	
	-4.31	532.1	528
1(6),2,4-trien-7-yl)carbonyl]-1-	The second second	332.1	340
piperazinyl]-1,1-dimethylethyl]-N'-	27 27		
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide		<u> </u>	

N-[2-[4-(3-Hydroxybenzoyl)-1-	\$ ~ . ⁰⁴		
piperazinyl]-1,1-dimethylethyl]-N'-	н, онсон	522.1	529
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	N		
N-[2-[4-(2-Ethylbutyl)-1-	, -OH,		
piperazinyl]-1,1-dimethylethyl]-N'-	H ₂ , 0 H ₂ (34), 7H ₃	486.1	530
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	Ñ-		1
N-[3-Methoxy-4-(5-	·		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	~ ~ ~	506.2	531
[4-(2-phenylethyl)-1-	The same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the sa		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	C. S. CRK		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	N	490.1	532
[4-[3-(methylthio)propyl]-1-	Land Comment	470.1	332
piperazinyl]ethyl]oxalamide	Supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to the supplied to th		
N-[2-[4-(2,6-Difluorobenzyl)-1-			
		5201	E22
piperazinyl]-1,1-dimethylethyl]-N'-		528.1	533
[3-methoxy-4-(5-	1.5		
oxazolyl)phenyl]oxalamide			
N-[2-[4-(3-Furfuryl)-1-piperazinyl]-	O MCCON	400.1	504
1,1-dimethylethyl]-N'-[3-methoxy-4-	The second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second secon	482.1	534
(5-oxazolyl)phenyl]oxalamide			
N-[2-[4-[(2-Benzofuranyl)methyl]-			
1-piperazinyl]-1,1-dimethylethyl]-N'-	He Physical N	532.1	535
[3-methoxy-4-(5-	The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s	332.1	
oxazolyl)phenyl)]oxalamide	No.		
N-[2-[4-(2-Cyanobenzyl)-1-	· ·		
piperazinyl]-1,1-dimethylethyl]-N'-		517.1	536
[3-methoxy-4-(5-		317.1	330
	33400		
oxazolyl)phenyl]oxalamide	F2 19		
N-[3-Methoxy-4-(5-		106.3	527
oxazolyl)phenyl]-N'-[2-[4-(3,3-		486.2	537
dimethylbutyl)-1-piperazinyl]-1,1-	The second second		
dimethylethyl]oxalamide			
N-[3-Methoxy-4-(5-	- N - N - N - N - N - N - N - N - N - N	542.2	520
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	No. The Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market Market M	543.2	538
[4-[(2-quinolinyl)methyl]-1-	7		
piperazinyl]ethyl]oxalamide	N" OIL		
tert-Butyl 4-[2-[[[3-methoxy-4-(5-	o		
oxazolyl)anilino]oxalyl]amino]-2-	71 A. 2. F. A. 1	516	539
methylpropyl]-1-piperazineacetate			
4-[2-[[[3-Methoxy-4-(5-			
oxazolyl)anilino]oxalyl]amino]-2-		460	540
methylpropyl]-1-piperazineacetic	ا لا الله		1
acid trifluoroacetate (1:1)	, <u>;</u> ½, "		
(1.1)	1 -	l .	1

N-[2-[4-(Cyclopropylmethyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	O C OH N	456	541
tert-Butyl 4-[4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-1-piperazinyl]benzoate	NO NO NO NO NO NO NO NO NO NO NO NO NO N	578	651
4-[4-[2-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-2-methylpropyl]-1-piperazinyl]benzoic acid trifluoroacetate (1:1)	NO PLANT PERCH	522	652

## Examples 415-420:

In a manner analogous to that described in Example 4 starting with N-[3-(aminomethylphenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide and the appropriate carboxylic acid chloride compounds shown in table 1h were prepared.

table 1h

	table III		
Name	Structure	$ME(ES)$ $(M+H)^+$	Ex No
Phenyl [3-[[[4-(5-oxazolyl)anilino]oxalyl]amino]benzyl] carbamate		487	415
N-[3-[(3- Fluorobenzamido)methyl]phenyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	CH C N N N N N N N N N N N N N N N N N N	489	416
N-[3-[(3- Chlorobenzamido)methyl]phenyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	CH. CH. CH. CH. CH. CH. CH. CH. CH. CH.	505	417
N-[3-[(3- Methoxybenzamido)methyl]phenyl]- N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		501.2	418
N-[3-[(3,4- Dimethoxybenzamido)methyl]phenyl] -N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	CH, CH, CO, CH, CO, CH, CH, CH, CH, CH, CH, CH, CH, CH, CH	531.2	419

N-[3-[(3- Cyanobenzamido)methyl]phenyl]-N'-		496.1	420	1
[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	W-			İ

### Examples 421-427 and 598-614:

Typical methods used for the preparation of the compounds of table 1b are described below:

Examples 421 and 423 were prepared by reaction of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-piperidinyl)ethyl]oxalamide with the appropriate acylating reagent.

Example 424 was prepared in a manner analogous to that described in Example 1, starting with N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid, prepared as described in Example 1, parts (i) and (ii), and the appropriate amine.

### Example 422

5

15

20

25

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl] oxalamide.

- (i) A mixture of 2g (17.7 mmol) of 2,4,4-trimethyl-2-oxazoline and 1.95 g (17.7 mmol) of thiophenol were heated at 120C for 18 hours. After cooling the resulting solid was triturated with diethyl ether/petrol (1:2) and filtered off to give 2.55 g of N-[1,1-dimethyl-2-(phenylthio)ethyl]acetamide as a white solid.
- (ii) A solution of 2.5 g (11.2 mmol) of N-[1,1-dimethyl-2-(phenylthio)ethyl]acetamide, 3.18 g (11.2 mmol) of titanium isopropoxide and 3.09 g (16.8 mmol) of diphenylsilane in 12 ml of tetrahydrofuran were stirred at room temperature for 18 hours. The resulting mixture was chromatographed on silica gel using 3%, 6% and 10% methanol in dichloromethane for the elution. There was obtained 2 g of 1,1-dimethyl-2-(phenylthio)ethylamine as a pale orange oil. The 1,1-dimethyl-2-(phenylthio)ethylamine was then coupled to N-[3-methoxy-4-(5-oxazolyl)phenyl oxalamic acid by a procedure analogous to that described in example 1 to afford N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl]oxalamide. MS: m/e 426 [M+H][†].

Example 427 was prepared by an analogous method to that described for example 422 but using 4-benzyloxythiophenol in place of the thiophenol and removing the protecting group using a mixture of hydrogen bromide in acetic acid.

5

Example 607 was prepared starting from benzofuran-3-acetic ethyl ester by alkylation iodomethane using potassium tertiary butoxide as base followed by alkaline hydrolysis, Curtius reaction, hydrolysis in ethylene glycol and water at 180°C. The resulting amine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid as described in Example 1.

10

Example 426 was prepared in a manner analogous to that described for example 408 in table 1g using tetrahydro quinoline in place of 1-(4-methoxyphenyl)piperazine.

#### Example 610

15

N-[2-[1-(Methanesulfonyl)-4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide

20

14 mg (0.12 mmol) of methanesulphonyl chloride were added to a solution of 40 mg (0.1 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl-N'-[1,1-dimethyl-2-(4-piperidinyl)ethyl]oxalamide in 1 ml of dichloromethane followed by 17 mg (0.15 mmol) of N-ethylmorpholine and the mixture stirred at room temperature for 4 hours. The resulting solution was diluted with ethyl acetate, washed with 2M hydrochloric acid and saturated sodium bicarbonate solution, dried over magnesium sulphate, evaporated to dryness and the residue triturated with diethyl ether. There was obtained 23 mg of N-[2-[1-(methanesulfonyl)-4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as an offwhite solid. MS m/e 479  $[M+H]^+$ .

The starting material was prepared as follows:

3()

i) A solution of 4.65 g (31 mmol) of alpha, alpha-dimethyl-4-pyridineethylamine, 15.6 g (0.154 mol) of triethylamine and 13.5g (61.9 mmol) of di-tert-butyl dicarbonate in 100 ml of methanol was stirred at room temperature for 2 days then evaporated to dryness. The residue

was dissolved in ethyl acetate, washed with water, dried over magnesium sulphate, evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. There was obtained 2.12 g of tert-butyl [1,1-dimethyl-2-(4-pyridyl)ethyl]carbamate as a pale orange solid. ¹H NMR (400 MHz CDCl₃) δ: 1.29 (6H,s), 1.49 (9H,s), 3.04 (2H,s), 4.30 (1H, br.s), 7.10 (2H,d), 8.52 (2H,d).

- 2.1 g (8.4 mmol) of tert-butyl [1,1-dimethyl-2-(4-pyridyl)ethyl]carbamate, in 20 ml of methanol were hydrogenated with 400 mg of 10% palladium on carbon catalyst at 70°C and 7 Bar for 6 days. The resulting suspension was filtered, evaporated to dryness and the residue triturated with diethyl ether/petrol (1:9) to give 1.2 g of tert-butyl [1,1-dimethyl-2-(4-piperidinyl)ethyl]carbamate as a white solid. ¹H NMR (400 MHz DMSO) δ: 1.18 (6H,s), 1.28-1.41 (2H,m), 1.37 (9H,s), 1.52-1.69 (3H,m), 1.75-1.83 (2H,d), 2.74-2.84 (2H,t), 3.12-3.21 (2H,d), 6.40-6.48 (1H,br.s), 8.60-8.95 (1H,br.s).
- iii) A solution of 1.2 g (4.68 mmol) of tert-butyl [1,1-dimethyl-2-(4-piperidinyl)ethyl]carbamate, 945 mg (9.36 mmol) of triethylamine and 2.33 g (9.36 mmol) of N-(benzyloxycarbonyloxy)succinimide in 20 ml of dichloromethane was stirred at room temperature for 18 hours then washed with 10% citric acid solution and saturated sodium bicarbonate solution. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (1:2) for the elution. There was obtained 1.89 g of benzyl 4-[2-(tert-butoxyformamido)-2-methylpropyl]-1-piperidinecarboxylate. ¹H NMR (400 MHz CDCl₃) δ: 1.15-1.32 (2H,m), 1.29 (6H,s), 1.42 (9H,s), 1.49-1.78 (5H,m), 2.75-2.90 (2H,m), 4.05-4.16 (2H,m), 4.41 (1H,br.s), 5.12 (2H,s), 7.27-7.42 (5H,m).

25

30

iv) A solution of 1.79 g (4.6 mmol) of benzyl 4-[2-(tert-butoxyformamido)-2-methylpropyl]-1-piperidinecarboxylate in 6 ml of trifluoroacetic acid/dichloromethane (1:1) was stirred at room temperature for 5 minutes then evaporated to dryness. The residue was dissolved in 20 ml of dichloromethane along with 1.2 g (4.58 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 1.1 g (5.74 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 1.32g (11.5 mmol) of N-ethylmorpholine and 1.1 g (6.9mmol) of 1-hydroxy-7-azabenzotriazole. After stirring overnight the solution was diluted with ethyl acetate, washed with 10% citric acid solution and saturated sodium bicarbonate

solution, dried over magnesium sulphate evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (1:1) for the elution. There was obtained 1.14 g of benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]amino]-2-methylpropyl}-1-piperidinecarboxylate as a white foam. MS: m/e 535 [M+H]⁺.

v) A solution of 1.1 g (2.05 mmol) of benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]amino]-2-methylpropyl}-1-piperidinecarboxylate in 25 ml of methanol was hydrogenated with 100 mg of 10% palladium on carbon catalyst for 4 hours. The resulting suspension was filtered and evaporated to dryness to give 732 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-piperidinyl)ethyl]oxalamide as an off-white solid. MS: m/e 401  $[M+H]^{+}$ .

Example 616 was prepared starting from benzofuran-3-acetic ethyl ester by alkylation iodomethane using potassium tertiary butoxide as base followed by alkaline hydrolysis, Curtius reaction, hydrolysis in ethylene glycol and water at 180°C. The resulting amine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid as described in Example 1

Example 619

5

10

15

 $\underline{N-[2-[1-(Methanesulfonyl)-4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide }$ 

14 mg (0.12 mmol) of methanesulphonyl chloride were added to a solution of 40 mg (0.1 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl-N'-[1,1-dimethyl-2-(425 piperidinyl)ethyl]oxalamide in 1 ml of dichloromethane followed by 17 mg (0.15 mmol) of Nethylmorpholine and the mixture stirred at room temperature for 4 hours. The resulting solution was diluted with ethyl acetate, washed with 2M hydrochloric acid and saturated sodium bicarbonate solution, dried over magnesium sulphate, evaporated to dryness and the residue triturated with diethyl ether. There was obtained 23 mg of N-[2-[1-(methanesulfonyl)-4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as an offwhite solid. MS m/e 479 [M+H]⁺.

The starting material was prepared as follows:

- i) A solution of 4.65 g (31 mmol) of alpha, alpha-dimethyl-4-pyridineethylamine, 15.6 g (0.154 mol) of triethylamine and 13.5g (61.9 mmol) of di-tert-butyl dicarbonate in 100 ml of methanol was stirred at room temperature for 2 days then evaporated to dryness. The residue was dissolved in ethyl acetate, washed with water, dried over magnesium sulphate, evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. There was obtained 2.12 g of tert-butyl [1,1-dimethyl-2-(4-pyridyl)ethyl]carbamate as a pale orange solid. ¹H NMR (400 MHz CDCl₃) δ: 1.29 (6H,s), 1.49 (9H,s), 3.04 (2H,s), 4.30 (1H, br.s), 7.10 (2H,d), 8.52 (2H,d).
- ii) 2.1 g (8.4 mmol) of tert-butyl [1,1-dimethyl-2-(4-pyridyl)ethyl]carbamate, in 20 ml of methanol were hydrogenated with 400 mg of 10% palladium on carbon catalyst at 70°C and 7 Bar for 6 days. The resulting suspension was filtered, evaporated to dryness and the residue triturated with diethyl ether/petrol (1:9) to give 1.2 g of tert-butyl [1,1-dimethyl-2-(4-piperidinyl)ethyl]carbamate as a white solid. ¹H NMR (400 MHz DMSO) δ: 1.18 (6H,s), 1.28-1.41 (2H,m), 1.37 (9H,s), 1.52-1.69 (3H,m), 1.75-1.83 (2H,d), 2.74-2.84 (2H,t), 3.12-3.21 (2H,d), 6.40-6.48 (1H,br.s), 8.60-8.95 (1H,br.s).
  - iii) A solution of 1.2 g (4.68 mmol) of tert-butyl [1,1-dimethyl-2-(4-piperidinyl)ethyl]carbamate, 945 mg (9.36 mmol) of triethylamine and 2.33 g (9.36 mmol) of N-(benzyloxycarbonyloxy)succinimide in 20 ml of dichloromethane was stirred at room temperature for 18 hours then washed with 10% citric acid solution and saturated sodium bicarbonate solution. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (1:2) for the elution. There was obtained 1.89 g of benzyl 4-[2-(tert-butoxyformamido)-2-methylpropyl]-1-piperidinecarboxylate. ¹H NMR (400 MHz CDCl₃) δ: 1.15-1.32 (2H,m), 1.29 (6H,s), 1.42 (9H,s), 1.49-1.78 (5H,m), 2.75-2.90 (2H,m), 4.05-4.16 (2H,m), 4.41 (1H,br.s), 5.12 (2H,s), 7.27-7.42 (5H,m).
  - iv) A solution of 1.79 g (4.6 mmol) of benzyl 4-[2-(tert-butoxyformamido)-2-methylpropyl]-1-piperidinecarboxylate in 6 ml of trifluoroacetic acid/dichloromethane (1:1) was stirred at room temperature for 5 minutes then evaporated to dryness. The residue was dissolved in 20 ml of dichloromethane along with 1.2 g (4.58 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 1.1 g (5.74 mmol) of 1-(3-dimethylaminopropyl)-3-

ethylcarbodiimide hydrochloride, 1.32g (11.5 mmol) of N-ethylmorpholine and 1.1 g (6.9mmol) of 1-hydroxy-7-azabenzotriazole. After stirring overnight the solution was diluted with ethyl acetate, washed with 10% citric acid solution and saturated sodium bicarbonate solution, dried over magnesium sulphate evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (1:1) for the elution. There was obtained 1.14 g of benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]amino}-2-methylpropyl}-1-piperidinecarboxylate as a white foam. MS: m/e 535 [M+H].

v) A solution of 1.1 g (2.05 mmol) of benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]amino]-2-methylpropyl}-1-piperidinecarboxylate in 25 ml of methanol was hydrogenated with 100 mg of 10% palladium on carbon catalyst for 4 hours. The resulting suspension was filtered and evaporated to dryness to give 732 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-piperidinyl)ethyl]oxalamide as an off-white solid. MS: m/e 401 [M+H]⁺.

The remaining examples in table 1b were prepared by methods analogous to those described above, as appropriate to the structure, or by methods previously described for related structures.

20 table 1b

10

15

Name	Structure	$MS(ES)$ $(M+H)^+$	Ex No
Benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]a mino]-2-methylpropyl}-1-piperidinecarboxylate	Oran Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlotte Carlott	535	421
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2- (phenylthio)ethyl]oxalamide	N O C. CH,	426	422
N-[2-(1-Acetyl-4-piperidinyl)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide	, сн	443	423

N-(2-Cyclohexyl-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N 0 0 0 CH,	400	424
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(N-methylanilino)ethyl]oxalamide	о нс он (н, с он	423	425
N-[2-(1,2,3,4-Tetrahydro-1-quinolyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		449	426
N-[2-(4-Hydroxyphenylthio)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide		442	427
N-[3-(4-Hydroxyphenyl)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	OH,COH,	424	598
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[(1-oxido-4-pyridyl)carboxamido] ethyl]oxalamide		454	599
N-[2-(4-Acetylbenzamido)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	ON ON ON ON ON ON ON ON ON ON ON ON ON O	479.1	600
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-[(4- methylbenzamido)methyl]pheny l]oxalamide		485.1	601
N-[3-[(2-Methoxybenzamido) methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		501.1	602
N-[3-[(4-Chlorobenzmido) methyl]phenyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide		505.1	603
N-[3-[[(1,3-Benzodioxol-5-yl)carboxamido]methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	CH. J. J. J. J. J. J. J. J. J. J. J. J. J.	515.2	604

N-[2-(2,3-Dihydro-1-indolyl)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide	043 0 HC 0H3	435	605
N-[2-(3,4-Dihydro-6-methyl- 2H-quinol-1-yl)-1,1- dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	эл онс он	463	606
N-[1-(3-Benzofuranyl)-1- methylethyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	N ONC CH	420	607
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- phenoxypiperidino)propyl]oxala mide	No. on on	507	608
N-[2-(1-Butyryl-4-piperidinyl)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide		471	609
N-[2-[1-(Methanesulfonyl)-4- piperidinyl]-1,1-dimethylethyl]- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide	8 1 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	479	610
N-[2-[1-(Benzenesulfonyl)-4- piperidinyl]-1,1-dimethylethyl]- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide	A STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STA	541	611
N-[2-(1-Isobutyryl-4- piperidinyl)-1,1-dimethylethyl]- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide	A COM	471	612
tert-Butyl 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino] oxalyl] amino]-3-methylbutyl]-1-piperidinecarboxylate	No. 19 Sept. Col.	515	613
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- piperidinyl)propyl]oxalamide	OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O OH, O	415	614

#### Examples 428-432:

Examples 428, 431 and 432 of table 1i were prepared in a manner analogues to that described for example 408 in table 1g but using N-[3-methoxy-4-(4-oxazoyl)phenyl oxalamic acid or N-[3-methoxy-4-(2-methyl-4-oxazoyl)phenyl oxalamic acid in place of N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid for the coupling step.

Examples 429 and 430 of table 1i were prepared by analogues procedures to those described for the preparation of the compounds of table 1f.

10 table 1i

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-Methoxy-4-(4-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-phenyl-1-piperazinyl)ethyl]oxalamide		478	428
N-[2-(4-Benzyloxyphenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide		500	429
N-[2-(4-Hydroxyphenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide	CH, CH, CH,	410	430
N-[3-Methoxy-4-(4-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide	OH, OH, OH,	508	431
N-[3-Methoxy-4-(2-methyl-4-oxazolyl)-phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		522.4	432

The features disclosed in the foregoing description, or the following claims, or the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for attaining the disclosed result, as appropriate, may, separately, or in any combination of such features, be utilised for realising the invention in diverse forms thereof.